,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,737.1500244140625,2023-01-15,722.1300048828125,-0.02037579737338946,D3,[],"{""assetTurnoverTTM"": 0.4409, ""bookValue"": 22664, ""cashRatio"": 0.9888570518943012, ""currentRatio"": 5.057, ""ebitPerShare"": 10.0508, ""eps"": 10.4917, ""ev"": 78153.6, ""fcfMargin"": 0.4299, ""fcfPerShareTTM"": 30.8909, ""grossMargin"": 0.8417, ""inventoryTurnoverTTM"": 0.7169, ""longtermDebtTotalAsset"": 0.0678, ""longtermDebtTotalCapital"": 0.0781, ""longtermDebtTotalEquity"": 0.0874, ""netDebtToTotalCapital"": -0.016, ""netDebtToTotalEquity"": -0.0179, ""netMargin"": 0.3506, ""operatingMargin"": 0.3359, ""pb"": 3.4662, ""peTTM"": 18.1077, ""pfcfTTM"": 20.4665, ""pretaxMargin"": 0.388, ""psTTM"": 6.4536, ""ptbv"": 3.6122, ""quickRatio"": 4.1614, ""receivablesTurnoverTTM"": 2.142, ""roaTTM"": 0.1571, ""roeTTM"": 0.2049, ""roicTTM"": 0.1817, ""rotcTTM"": 0.1985, ""salesPerShare"": 29.9246, ""sgaToSale"": 0.1583, ""tangibleBookValue"": 21748, ""totalDebtToEquity"": 0.1192, ""totalDebtToTotalAsset"": 0.0925, ""totalDebtToTotalCapital"": 0.1065, ""totalRatio"": 4.4596, ""period"": ""2022-12-31""}"
1,2023-01-15,722.1300048828125,2023-01-22,722.0,-0.00018002974801412108,D1,[],"{""assetTurnoverTTM"": 0.4409, ""bookValue"": 22664, ""cashRatio"": 0.9888570518943012, ""currentRatio"": 5.057, ""ebitPerShare"": 10.0508, ""eps"": 10.4917, ""ev"": 78153.6, ""fcfMargin"": 0.4299, ""fcfPerShareTTM"": 30.8909, ""grossMargin"": 0.8417, ""inventoryTurnoverTTM"": 0.7169, ""longtermDebtTotalAsset"": 0.0678, ""longtermDebtTotalCapital"": 0.0781, ""longtermDebtTotalEquity"": 0.0874, ""netDebtToTotalCapital"": -0.016, ""netDebtToTotalEquity"": -0.0179, ""netMargin"": 0.3506, ""operatingMargin"": 0.3359, ""pb"": 3.4662, ""peTTM"": 18.1077, ""pfcfTTM"": 20.4665, ""pretaxMargin"": 0.388, ""psTTM"": 6.4536, ""ptbv"": 3.6122, ""quickRatio"": 4.1614, ""receivablesTurnoverTTM"": 2.142, ""roaTTM"": 0.1571, ""roeTTM"": 0.2049, ""roicTTM"": 0.1817, ""rotcTTM"": 0.1985, ""salesPerShare"": 29.9246, ""sgaToSale"": 0.1583, ""tangibleBookValue"": 21748, ""totalDebtToEquity"": 0.1192, ""totalDebtToTotalAsset"": 0.0925, ""totalDebtToTotalCapital"": 0.1065, ""totalRatio"": 4.4596, ""period"": ""2022-12-31""}"
2,2023-01-22,722.0,2023-01-29,742.8300170898438,0.02885043918260899,U3,[],{}
3,2023-01-29,742.8300170898438,2023-02-05,783.1300048828125,0.05425196460268311,U5+,"[{""date"": ""2023-01-30"", ""headline"": ""Sanofi and Regeneron's Dupixent wins new European Commission approval"", ""summary"": ""Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product had won approval from the European Commission to treat eosinophilic esophagitis (EoE), which is a condition that damages the esophagus.""}, {""date"": ""2023-01-31"", ""headline"": ""Cowen & Co. Upgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-01-31"", ""headline"": ""Regeneron Announces Investor Conference Presentations"", ""summary"": ""TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: SVB Securities Global Biopharma Conference at 9:20 a.m. ET on Tuesday, February 14, 2023Cowen 43rd Annual Health Care Conference at 12:50 p.m. ET on Monday, March 6, 2023Oppenheimer 33rd Annual Healthcare Conference at 9:20 a.m. ET on Monday, March 13, 2023Barclays Global Healthcare Conference at 9:00 a.m. ET on Wednesday, March 15, 2023 The sessions""}, {""date"": ""2023-02-01"", ""headline"": ""Time to Buy Cigna or Regeneron Stock Before Earnings?"", ""summary"": ""Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.""}, {""date"": ""2023-02-01"", ""headline"": ""The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023"", ""summary"": ""Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange\u2019s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv""}, {""date"": ""2023-02-01"", ""headline"": ""Top 25 Smartest Companies To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless [\u2026]""}, {""date"": ""2023-02-01"", ""headline"": ""How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings"", ""summary"": ""Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.""}, {""date"": ""2023-02-01"", ""headline"": ""Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 31%?"", ""summary"": ""Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN...""}, {""date"": ""2023-02-02"", ""headline"": ""The 7 Most Undervalued Stocks to Buy in February 2023"", ""summary"": ""As Feb. gets underway, I\u2019m finding under-appreciated, undervalued stocks to buy. When seeking value in the stock market the hope is that other investors will see what you see: The underappreciated value inherent in strong businesses that don\u2019t necessarily garner a lot of attention. In turn, they follow your lead, purchase en masse, and the price of your shares rises with demand. Short-term volatility will remain for those who take this approach now. But market cyclicality will do its magic and m""}, {""date"": ""2023-02-02"", ""headline"": ""The 7 Most Undervalued Biotech Stocks to Buy in February 2023"", ""summary"": ""You don\u2019t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science. At the same time, the established players tend to be pricey. By picking up underappreciated names, it\u2019s possible to secure significant upside down the line. However, anytime a discussion about the most undervalued biotech stocks to buy materializes, a question comes up: how doe""}, {""date"": ""2023-02-02"", ""headline"": ""Why Regeneron (REGN) Might Surprise This Earnings Season"", ""summary"": ""Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""2023-02-03"", ""headline"": ""Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern"", ""summary"": ""Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings. ADI is leader in the chip industry""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples"", ""summary"": ""Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.""}, {""date"": ""2023-02-03"", ""headline"": ""Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics"", ""summary"": ""While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.""}, {""date"": ""2023-02-03"", ""headline"": ""Health Care Edge Lower After Solid Earnings -- Health Care Roundup"", ""summary"": ""Health-care companies fell, but not by as much as the broad market, after a solid week of earnings. Regeneron Pharmaceuticals rallied after the biotech...""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline"", ""summary"": ""Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron\u2019s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment"", ""summary"": ""The pharmaceuticals company's total revenue dropped by 31% to $3.41 billion but beat the FactSet consensus of $3.13 billion.""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron profit beats estimates on Dupixent strength"", ""summary"": ""Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates"", ""summary"": ""Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor RelationsLeonard...""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Regeneron Pharmaceuticals, Inc.""}, {""date"": ""2023-02-03"", ""headline"": ""UPDATE 2-Regeneron profit beats estimates on Dupixent strength"", ""summary"": ""Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.  Eylea, which recorded total sales of $9.65 billion in 2022, has been a key growth driver for the company ever since its launch more than a decade ago.  Sales of Eylea, used to treat vision loss causing age-related macular degeneration, were impacted by temporary closing of a fund during the quarter that provides co-pay assistance to patients.""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron stock rallies after profit and revenue beat expectations by wide margins"", ""summary"": ""MARKET PULSE Shares of Regeneron Pharmaceuticals Inc. (REGN) rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company reported fourth-quarter profit and revenue that fell, as sales of its COVID-19 treatment dropped, but beat expectations by wide margins.""}, {""date"": ""2023-02-03"", ""headline"": ""CORRECTED-Regeneron quarterly profit drops 46%"", ""summary"": ""Regeneron Pharmaceuticals Inc reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales.""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results"", ""summary"": ""Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV\u00ae and RonapreveTM(a)(b), revenues increased 14%Full year 2022 revenues decreased 24% to $12.17 billion versus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues increased 17%Fourth quarter 2022 EYLEA\u00ae U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021; full year 2022 EYLEA U.S. net sales increased 8% to $6.26 billion versus 2021Fourth quarter 2022 Dupixen""}, {""date"": ""2023-02-03"", ""headline"": ""Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat"", ""summary"": ""By Scott Kanowsky""}, {""date"": ""2023-02-03"", ""headline"": ""Here's why 2seventy bio's chief executive thinks 2023 will be a 'special year'"", ""summary"": ""The chief executive of bluebird bio's oncology-focused spinout believes that this year, it will take off as a company in its own right.""}, {""date"": ""2023-02-03"", ""headline"": ""UPDATE 4-Sanofi forecasts moderate profit growth on Dupixent demand"", ""summary"": ""Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis pill Aubagio and product launch costs.  Aubagio, with 2 billion euros ($2.2 billion) in sales last year, will face competition from cheaper products over the next few months after losing patent protection, Sanofi said.  Sanofi shares were down 3% at 1107 GMT, having earlier fallen as much as 5.2% to their lowest since mid-November with JP Morgan analysts saying investors had expected a better 2023 outlook and a more benign view on foreign exchange headwinds.""}, {""date"": ""2023-02-04"", ""headline"": ""Stocks To Watch: Spotlight On Google, Disney, Regeneron Pharmaceuticals And Hesai Group IPO"", ""summary"": ""Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week""}]",{}
4,2023-02-05,783.1300048828125,2023-02-12,757.6099853515625,-0.03258720694154582,D4,"[{""date"": ""2023-02-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-05"", ""headline"": ""Tom Gayner`s Firm Buys Brookfield Asset Management, Dumps Texas Pacific Land"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Top 3 Healthcare Stocks for February 2023"", ""summary"": ""Many healthcare stocks are surging higher in 2023. Plenty of companies in the sector have seen large inflows recently. Chances are this theme can continue.""}, {""date"": ""2023-02-06"", ""headline"": ""Bayer seeks EU approval for retinal eye disease treatment aflibercept"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Regeneron price target lowered to $787 from $789 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript February 3, 2023 Operator: Welcome to the Regeneron Pharmaceuticals\u2019 Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today\u2019s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please [\u2026]""}, {""date"": ""2023-02-06"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Genmab (GMAB) and Immunovant (IMVT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Regeneron price target raised to $853 from $750 at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""BMO Capital Releases a Buy Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Top 5 4th Quarter Trades of Pacer Advisors, Inc."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-06"", ""headline"": ""Regeneron price target raised to $756 from $670 at Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-07"", ""headline"": ""Regeneron named `Catalyst Driven Idea` at Morgan Stanley ahead of COPD data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-07"", ""headline"": ""Regeneron will accelerate capital spending by at least 40%"", ""summary"": ""Regeneron anticipates spending will increase to somewhere between $825 million and $950 million this year.""}, {""date"": ""2023-02-07"", ""headline"": ""The 7 Best Biotech Stocks to Buy for February 2023"", ""summary"": ""While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn\u2019t mean that the best biotech stocks to buy are immune from""}, {""date"": ""2023-02-07"", ""headline"": ""Top 5 4th Quarter Trades of MCDONALD CAPITAL INVESTORS INC/CA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""EYLEA\u00ae\u00a0(aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA"", ""summary"": ""ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA\u00ae (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, EYLEA is now indicated to treat five retinal condi""}, {""date"": ""2023-02-08"", ""headline"": ""Should Investors Worry About Regeneron Pharmaceuticals Inc`s Insider Sells?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Freedom Day Solutions, LLC Buys 3, Sells 2 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""GLOBAL BROKER RATINGS: Bernstein cuts Deutsche Post; MS raises Amex"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Regeneron`s Eylea injection approved by FDA for treatment of preterm infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-08"", ""headline"": ""Government Contracts Trading Strategy"", ""summary"": ""As discussions about trillion-dollar debt ceiling question intensify on Capitol Hill, we bring you one of our budget-spending-oriented trading strategies. Click here to read more.""}, {""date"": ""2023-02-09"", ""headline"": ""Roche Vabysmo matches Eylea in 2 phase 3 trials for eye disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants"", ""summary"": ""Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).""}, {""date"": ""2023-02-09"", ""headline"": ""Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update"", ""summary"": ""Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.""}, {""date"": ""2023-02-09"", ""headline"": ""Regeneron wins FDA nod for Eylea to prevent infant blindness"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-09"", ""headline"": ""GLOBAL BROKER RATINGS: DZ Bank cuts Adyen; Kepler cuts Segro"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Performance Tethered To Its Attractive Financial Prospects?"", ""summary"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Given that the market rewards strong...""}, {""date"": ""2023-02-10"", ""headline"": ""Pfizer Gets FDA Nod for Cibinqo in Adolescents With Atopic Dermatitis >PFE"", ""summary"": ""By Colin Kellaher Pfizer Inc. on Friday said the U.S. Food and Drug Administration expanded its approval of Cibinqo to include adolescents with atopic...""}, {""date"": ""2023-02-11"", ""headline"": ""2 Biotech Stocks That Could Help Set You Up for Life"", ""summary"": ""Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are each up about 20% over the past year.  The biotech companies have shown increased revenue and earnings per share (EPS) over the past three years and have burgeoning pipelines that should continue to drive growth.""}, {""date"": ""2023-02-12"", ""headline"": ""LOOMIS SAYLES & CO L P Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
5,2023-02-12,757.6099853515625,2023-02-19,748.739990234375,-0.01170786458559081,D2,"[{""date"": ""2023-02-12"", ""headline"": ""Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""LOOMIS SAYLES & CO L P Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.84% higher to $763.97 Monday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-02-13"", ""headline"": ""New 52-Week Highs In 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""9 Healthcare Stocks Where the Doubters Are on the Run"", ""summary"": ""Cigna, Regeneron, Centene, and six other healthcare stocks have seen short interest drop by at least 40% recently. Fewer investors are betting against them.""}, {""date"": ""2023-02-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.28% to $754.21 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-02-14"", ""headline"": ""2 Top Healthcare Stocks Defying the Bear Market"", ""summary"": ""Among them are HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  With recession fears alive and well, HCA Healthcare might be an excellent stock to turn to\u00a0 now.  The company is a leading hospital chain operator in the U.S., a business that is sure to remain somewhat in high demand even if a recession hits.""}, {""date"": ""2023-02-14"", ""headline"": ""Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 136% gain"", ""summary"": ""When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...""}, {""date"": ""2023-02-14"", ""headline"": ""Regeneron: Waiting For A More Lucrative Price To Buy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Competition Coming For AbbVie's Blockbuster Humira"", ""summary"": ""It\u00e2\u0080\u0099s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper \u00e2\u0080\u009cbiosimilar\u00e2\u0080\u009d copycats. Read how price relief is on the way for Humira.""}, {""date"": ""2023-02-15"", ""headline"": ""5 Least-Hurt Biotech ETFs of the Last Week"", ""summary"": ""Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.""}, {""date"": ""2023-02-15"", ""headline"": ""Regeneron poised to benefit from bounce-back of eye drug"", ""summary"": ""Regeneron Pharmaceuticals Inc (NASDAQ:REGN) could benefit from a bounce-back in share for its drug to treat macular degeneration, according to analysts at Piper Sandler.  The analysts rate the stock overweight with an $800 price target.  Regeneron shares were down 0.2% on Wednesday but up 4.3% so far this year.""}, {""date"": ""2023-02-15"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.24% to $752.40 Wednesday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-02-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 2.14% to $736.33 Thursday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-02-16"", ""headline"": ""IDNA: Healthcare Dashboard For February"", ""summary"": ""Pharmaceuticals and biotechs still look attractive. We focus on iShares Genomics Immunology and Healthcare ETF. IDNA is an ETF in genomics and immunology. Click here for more.""}, {""date"": ""2023-02-16"", ""headline"": ""Competition Coming For AbbVie`s Blockbuster Humira"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""3 Super Profitable S&P 500 Stocks to Buy, Other Than ExxonMobil"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.69% to $748.74 Friday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2023-02-17"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Shockwave Medical (SWAV) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-18"", ""headline"": ""Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""2023-02-19"", ""headline"": ""The next big wave of patent cliffs is ahead; expect biopharma M&A to rise \ufffd\ufffd\ufffd report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
6,2023-02-19,748.739990234375,2023-02-26,756.989990234375,0.01101851124235731,U2,"[{""date"": ""2023-02-19"", ""headline"": ""The next big wave of patent cliffs is ahead; expect biopharma M&A to rise \ufffd\ufffd\ufffd report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-20"", ""headline"": ""25 Most Profitable NASDAQ Stocks Today"", ""summary"": ""In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as [\u2026]""}, {""date"": ""2023-02-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.30% to $746.52 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-02-21"", ""headline"": ""Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review"", ""summary"": ""Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.""}, {""date"": ""2023-02-21"", ""headline"": ""Three-Stock Lunch: Regeneron, General Mills and DocuSign"", ""summary"": ""Eva Ados, chief investment strategist at ERShares, joins \u2018Power Lunch\u2019 to discuss Regeneron, General Mills and DocuSign.""}, {""date"": ""2023-02-21"", ""headline"": ""Regeneron\u2019s pozelimab approved by US FDA for priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review"", ""summary"": ""If approved, pozelimab would be the first and only treatment for those living with CHAPLE CHAPLE is an ultra-rare hereditary immune disease that causes overactivation of the complement system, leading to potentially life-threatening abdominal and cardiovascular symptoms TARRYTOWN, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA""}, {""date"": ""2023-02-21"", ""headline"": ""Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN"", ""summary"": ""By Colin Kellaher Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking...""}, {""date"": ""2023-02-21"", ""headline"": ""Regeneron announces U.S. FDA accepted priority review for BLA for pozelimab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Regeneron price target raised to $860 from $800 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.21% higher to $748.08 Wednesday, on what proved to be an all-around dismal trading session for the stock...""}, {""date"": ""2023-02-23"", ""headline"": ""Notable Friday Option Activity: REGN, ORA, FSR"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.55% to $759.66 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-02-23"", ""headline"": ""Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review"", ""summary"": ""BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA\u00ae (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks If approved, aflibercept 8 mg will be second ophthalmology medicine developed by Regeneron TARRYTOWN, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics Lic""}, {""date"": ""2023-02-23"", ""headline"": ""Intellia, Novartis end gene editing partnership for sickle cell disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Regeneron`s high-dose Eylea application accepted for FDA priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Regeneron announces U.S. FDA accepted priority review for BLA for aflibercept"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Pharmas, medtechs dominate list of innovation leaders thanks to patents"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.35% to $756.99 Friday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-02-24"", ""headline"": ""Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y"", ""summary"": ""Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.""}, {""date"": ""2023-02-24"", ""headline"": ""NEW YORK MARKET CLOSE: US stocks tumble after strong inflation data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Libtayo\u00ae (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)"", ""summary"": ""Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo\u00ae (cemiplimab) in combination with platinum-based chemotherapy. Specifically, the CHMP recommended the Libtayo""}, {""date"": ""2023-02-24"", ""headline"": ""IN BRIEF: Regeneron's Libtayo combination wins EU positive opinion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Regeneron: CHMP Backs Libtayo/Chemotherapy Combo in Advanced Non-Small Cell Lung Cancer"", ""summary"": ""By Colin Kellaher Regeneron Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended...""}, {""date"": ""2023-02-24"", ""headline"": ""Regeneron wins EU nod for Libtayo in PD-L1 positive lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Regeneron says CHMP adopts positive opinion on Libtayo with chemotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-25"", ""headline"": ""FDA PDUFA Date for Regeneron Pharma Eylea-Aflibercept is February 28, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-25"", ""headline"": ""Regeneron: Innovation And Disruption Done Right"", ""summary"": ""Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.""}]",{}
7,2023-02-26,756.989990234375,2023-03-05,779.2999877929688,0.029471984895977688,U3,"[{""date"": ""2023-02-26"", ""headline"": ""Replimune ends selloff after FDA response to mid-stage cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""Bayer`s Q4 sales grow on back of crop products, pharma declines; FY23 EPS to see impact"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""FDA PDUFA Date for Regeneron Pharma Eylea-Aflibercept is February 28, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""Top 10 Drug Companies in USA and Their China Reliance"", ""summary"": ""In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China [\u2026]""}, {""date"": ""2023-02-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.11% higher to $757.79 Monday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-02-28"", ""headline"": ""Regeneron Pharmaceuticals Now #94 Largest Company, Surpassing Altria Group"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Kevzara\u00ae (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica"", ""summary"": ""Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara\u00ae (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adul""}, {""date"": ""2023-02-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.35% higher to $760.42 Tuesday, on what proved to be an all-around dismal trading session for the stock...""}, {""date"": ""2023-02-28"", ""headline"": ""A Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider lowered their holding by 26% earlier this year"", ""summary"": ""Insiders were net sellers of Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock during the past year. That is...""}, {""date"": ""2023-02-28"", ""headline"": ""Regeneron and Sanofi`s Kevzara approved by FDA for polymyalgia rheumatica"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles"", ""summary"": ""The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval covers adult patients who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. Kevzara is now approved to treat two chronic inflammatory disorders. PMR often initially presents with pain and stiffness around the neck, shoulder, and hip area, and symptoms include fa""}, {""date"": ""2023-03-01"", ""headline"": ""Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback"", ""summary"": ""Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.""}, {""date"": ""2023-03-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.32% to $770.44 Wednesday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2023-03-01"", ""headline"": ""Cantor Fitzgerald biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.20% to $768.90 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-03-02"", ""headline"": ""REGN April 14th Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.35% to $779.30 Friday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-03-04"", ""headline"": ""A Look At The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$923...""}, {""date"": ""2023-03-05"", ""headline"": ""Cantor biopharma/biotech analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Unity Biotechnology: One Last Chance With UBX1325"", ""summary"": ""Unity Biotechnology has spent its existence identifying the root causes of age-related diseases. Read more to see my full investment analysis on UBX stock.""}]",{}
8,2023-03-05,779.2999877929688,2023-03-12,747.0,-0.04144743782743354,D5,"[{""date"": ""2023-03-05"", ""headline"": ""What To Expect From Pfizer In The Post-COVID-19 Era"", ""summary"": ""In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.""}, {""date"": ""2023-03-05"", ""headline"": ""Unity Biotechnology: One Last Chance With UBX1325"", ""summary"": ""Unity Biotechnology has spent its existence identifying the root causes of age-related diseases. Read more to see my full investment analysis on UBX stock.""}, {""date"": ""2023-03-06"", ""headline"": ""Regeneron, Sanofi announces FDA acceptance for review of Dupixent sBLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.14% higher to $780.38 Monday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-03-06"", ""headline"": ""Merck's drug boosts exercise capacity in pulmonary hypertension patients"", ""summary"": ""Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.  A second experimental heart drug, MK-0616, helped reduce levels of low-density lipoprotein (LDL) cholesterol by between 41.2% at a low 6 mg dose to 60.9% at a higher 30 mg dose in a mid-stage study, the drugmaker said.  Sotatercept, which Merck gained through its $11.5 billion buyout of Acceleron Pharma, combined with background therapy helped extend the distance that patients with pulmonary arterial hypertension could walk in six minutes by 40.8 meters.""}, {""date"": ""2023-03-06"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ETCompany ParticipantsMarion McCourt - EVP of CommercialRyan Crowe -...""}, {""date"": ""2023-03-06"", ""headline"": ""Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.84% to $773.85 Tuesday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-03-07"", ""headline"": ""Dupixent\u00ae (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review"", ""summary"": ""More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistaminesTARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent\u00ae (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) that is not""}, {""date"": ""2023-03-07"", ""headline"": ""FDA accepts for review Regeneron/Sanofi`s Dupixent application for inflammatory skin condition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 3.70% to $745.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-03-08"", ""headline"": ""Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review"", ""summary"": ""Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA""}, {""date"": ""2023-03-08"", ""headline"": ""Roche: Ongoing Pipeline Issues Sap Growth And Increase M&A Likelihood"", ""summary"": ""Roche hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Find out our recommendation on RHHBY stock.""}, {""date"": ""2023-03-09"", ""headline"": ""Regeneron (REGN) Stock Moves -0.19%: What You Should Know"", ""summary"": ""Regeneron (REGN) closed the most recent trading day at $743.75, moving -0.19% from the previous trading session.""}, {""date"": ""2023-03-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 0.19% to $743.75 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-03-09"", ""headline"": ""2 Biotech Stocks You Can Buy and Hold for the Next Decade"", ""summary"": ""The U.S. market is highly likely to deliver attractive returns over periods of five years or more.  With that said, let's consider two biotech stocks that could deliver outsized returns in the next decade: Regeneron Pharmaceuticals (NASDAQ: REGN) and Sarepta Therapeutics (NASDAQ: SRPT).  One of the keys to success for biotech companies is the ability to develop newer medicines.""}, {""date"": ""2023-03-09"", ""headline"": ""Cantor biopharma/biotech analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""2seventy Bio: KarMMa-3 Finally Releases Positive Results"", ""summary"": ""2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Read more here.""}, {""date"": ""2023-03-09"", ""headline"": ""Regeneron price target raised to $806 from $787 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.44% higher to $747.00 Friday, on what proved to be an all-around rough trading session for the stock...""}, {""date"": ""2023-03-11"", ""headline"": ""Regeneron Borrows From Big Pharma Playbook to Keep Roche, Shorts at Bay"", ""summary"": ""Leonard Schleifer,  the longtime  Regeneron  boss, likes to point out that, unlike many giant drug companies gaming the healthcare system with all kinds of gimmicks, his biotech focuses on true innovation.  Roche is indeed grabbing market share, reporting Vabysmo revenue of 591 million Swiss francs, equivalent to about $640 million, last year\u2014an impressive figure for its first year on the market.""}]",{}
9,2023-03-12,747.0,2023-03-19,747.6500244140625,0.0008701799385040232,U1,"[{""date"": ""2023-03-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.71% higher to $752.33 Monday, on what proved to be an all-around poor trading session for the stock market,...""}, {""date"": ""2023-03-13"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare Conference"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 9:20 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor...""}, {""date"": ""2023-03-13"", ""headline"": ""Analysts` Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-14"", ""headline"": ""Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease"", ""summary"": ""Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Neel Moudgal, 17, of Saline, Mich., won the top $250,000 award in the 2023 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.""}, {""date"": ""2023-03-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.92% to $766.80 Tuesday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-03-14"", ""headline"": ""Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?"", ""summary"": ""It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...""}, {""date"": ""2023-03-14"", ""headline"": ""Regeneron price target raised to $1,025 from $1,001 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-15"", ""headline"": ""Regeneron (REGN) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Regeneron (REGN) closed at $760.30, marking a -0.85% move from the previous day.""}, {""date"": ""2023-03-15"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 0.85% to $760.30 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-03-15"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Barclays Global Healthcare Conference March 15, 2023 9:00 AM ETCompany ParticipantsRyan Crowe - Vice President of Investor...""}, {""date"": ""2023-03-15"", ""headline"": ""The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""2 Biotech Stocks To Watch In March 2023"", ""summary"": ""Check out these 2 biotech stocks in the stock market today.""}, {""date"": ""2023-03-16"", ""headline"": ""2 Biotech Stocks To Watch In March 2022"", ""summary"": ""Check out these 2 biotech stocks in the stock market today.""}, {""date"": ""2023-03-16"", ""headline"": ""Dow Jones Hits Session Highs; Tesla Faces New Lawsuit From Customers, Agrees To Open 7500 Charging Stations"", ""summary"": ""The Dow Jones Industrial Average rose throughout the session Thursday and closed near the day's highs. The blue chip index gained 1.2%, its best day since March 3. Intel was the Dow's clear leader, with a hefty 6% gain.""}, {""date"": ""2023-03-16"", ""headline"": ""Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme"", ""summary"": ""Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.""}, {""date"": ""2023-03-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.39% to $749.75 Thursday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-03-16"", ""headline"": ""Video: Nasdaq 100 Movers: REGN, INTC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""PBE: Healthcare Dashboard For March"", ""summary"": ""Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold.""}, {""date"": ""2023-03-17"", ""headline"": ""Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 0.28% to $747.65 Friday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-03-17"", ""headline"": ""Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?"", ""summary"": ""Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.""}, {""date"": ""2023-03-17"", ""headline"": ""Regeneron pressure from CMS draft a buying opportunity, says Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-18"", ""headline"": ""Easing COVID pandemic sees many pharmas seeking alternate revenue streams"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-18"", ""headline"": ""Regeneron, Sanofi present results from Dupixent clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-18"", ""headline"": ""Dupixent\u00ae (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis"", ""summary"": ""More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent\u00ae (dupilumab) in adults and adolescents with uncontrol""}, {""date"": ""2023-03-18"", ""headline"": ""Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 133% gain"", ""summary"": ""The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...""}]",{}
10,2023-03-19,747.6500244140625,2023-03-26,820.0,0.09676984313969439,U5+,"[{""date"": ""2023-03-18"", ""headline"": ""Easing COVID pandemic sees many pharmas seeking alternate revenue streams"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-18"", ""headline"": ""Regeneron, Sanofi present results from Dupixent clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-19"", ""headline"": ""IN BRIEF: Regeneron and Sanofi share positive data for Dupixent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""IN BRIEF: Sanofi, Regeneron's Dupixent wins another EU approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Regeneron price target lowered to $802 from $806 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""7 Value Stocks Worth Buying at These 52-Week Highs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""Regeneron (REGN) Gains But Lags Market: What You Should Know"", ""summary"": ""Regeneron (REGN) closed the most recent trading day at $759.76, moving +0.07% from the previous trading session.""}, {""date"": ""2023-03-21"", ""headline"": ""Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids"", ""summary"": ""Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.""}, {""date"": ""2023-03-21"", ""headline"": ""Sanofi/Regeneron say Dupixent skin treatment wins new regulatory approval in Europe"", ""summary"": ""Healthcare companies Sanofi and Regeneron announced on Tuesday that their Dupixent product, which treats the skin disease atopic dermatitis, had won a new regulatory approval from the European Commission.""}, {""date"": ""2023-03-21"", ""headline"": ""Dupixent\u00ae (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis"", ""summary"": ""Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo Patients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant improvements at 16 weeks sustained through one year Dupixent is now a treatment option for the approximately 80,000 infants and young children living with unc""}, {""date"": ""2023-03-21"", ""headline"": ""Regeneron, Sanofi announce EC approval of Dupixent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""IN BRIEF: Sanofi, Regeneron's Dupixent shows promise for COPD in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""Regeneron (REGN) Gets Label Extension for Cholesterol Drug"", ""summary"": ""Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.""}, {""date"": ""2023-03-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.11% to $751.30 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-03-22"", ""headline"": ""US FDA expands use of Regeneron's cholesterol drug in young children"", ""summary"": ""Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.""}, {""date"": ""2023-03-22"", ""headline"": ""UPDATE 3-US FDA expands use of Regeneron's cholesterol drug in young children"", ""summary"": ""Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.  The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies for patients aged 12 years and above with homozygous familial hypercholesterolemia (HoFH).  It causes elevated levels of low-density lipoprotein (LDL) cholesterol and types of premature cardiovascular diseases.""}, {""date"": ""2023-03-22"", ""headline"": ""Regeneron gets US FDA nod for expanded use of cholesterol drug in children"", ""summary"": ""Regeneron Pharmaceuticals Inc said on Wednesday the U.S. health regulator has approved expanded use of its drug to treat high cholesterol in children aged 5 to 11. (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)""}, {""date"": ""2023-03-22"", ""headline"": ""FDA Approves First-in-class Evkeeza\u00ae (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol"", ""summary"": ""Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other lipid-lowering therapies in the pivotal trial TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended""}, {""date"": ""2023-03-22"", ""headline"": ""Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN"", ""summary"": ""By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration extended the approval of its Evkeeza cholesterol...""}, {""date"": ""2023-03-22"", ""headline"": ""Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""Regeneron announces FDA approval of Evkeeza for young children"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""What You Missed On Wall Street On Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron May Win Big with New Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars"", ""summary"": ""Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with \""smoker's lung,\"" leading SNY and REGN stocks to rocket.""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron's Dupixent shows promise as COPD treatment"", ""summary"": ""CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.""}, {""date"": ""2023-03-23"", ""headline"": ""Options Action: Regeneron in reverse?"", ""summary"": ""Optimize Advisors' Mike Khouw looks at bearish options bets on Regeneron. With CNBC's Melissa Lee and the Fast Money traders, Karen Finerman, Tim Seymour, Guy Adami and Dan Nathan.""}, {""date"": ""2023-03-23"", ""headline"": ""ADRs End Mostly Higher, Tencent and Sanofi Trade Actively"", ""summary"": ""By Sabela Ojea International stocks trading in New York closed mostly higher on Thursday. The S&P/BNY Mellon index of American depositary receipts rose 0.5%...""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study"", ""summary"": ""Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.""}, {""date"": ""2023-03-23"", ""headline"": ""Health Care Down as Sanofi, Regeneron Rise -- Health Care Roundup"", ""summary"": ""Health-care companies fell, but not by as much as the broad market, amid optimism about drug developments. Regeneron shares rallied after the biotech concern...""}, {""date"": ""2023-03-23"", ""headline"": ""Pharma delivers, for others"", ""summary"": ""(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)""}, {""date"": ""2023-03-23"", ""headline"": ""KB Home, Worthington rise; MillerKnoll, Trupanion fall"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Why Shares of Regeneron Are Rising Thursday"", ""summary"": ""Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were up as much as 8.2% on Thursday morning after the biotech company announced positive news on Thursday for a phase 3 trial for Dupixent (dupilumab) to treat patients with chronic obstructive pulmonary disease (COPD).  Regeneron's shares are up more than 18% this year, and the stock has a 52-week low of $538.01 and a 52-week high of $812.69.  Regeneron partnered with Sanofi (NASDAQ: SNY) on the phase 3 trial and said it met all primary and secondary endpoints compared to a placebo on patients with uncontrolled COPD and evidence of type 2 inflammation.""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD"", ""summary"": ""Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say \""exceeded expectations.\""""}, {""date"": ""2023-03-23"", ""headline"": ""Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?"", ""summary"": ""The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...""}, {""date"": ""2023-03-23"", ""headline"": ""Stocks making the biggest moves midday: Netflix, Block, Snap, KB Home and more"", ""summary"": ""Block fell after Hindenburg Research unveiled its latest short position on the stock. KB Home popped on earnings. ""}, {""date"": ""2023-03-23"", ""headline"": ""Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today"", ""summary"": ""Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Phase 3 trial of Dupixent (dupilumab) for uncontrolled chronic obstructive pulmonary disease (COPD) met its primary and secondary endpoints. Dupixent exhibited a 30% reduction in moderate or severe acute exacerbations compared to the placebo. The Phase 3 trial involving 939 current or former smokers also showed impro""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi, Regeneron\u2019s Drug Succeeds in High-Stakes Lung Trial"", ""summary"": ""(Bloomberg) -- Sanofi\u2019s prescription drug Dupixent helped patients with a chronic lung disorder breathe better and regain lung function, opening a new avenue of growth for the blockbuster medicine. Most Read from BloombergJack Dorsey\u2019s Block Vows to Fight Back After Hindenburg Says It\u2019s Short the StockShort Seller Hindenburg Says \u2018Another Big One\u2019 Coming SoonUS Fears a War-Weary World May Embrace China\u2019s Ukraine Peace BidJPMorgan Sold $10 Million in Jewels Left in Bank Safe Deposit Box, Suit Cla""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron up 7% following Dupixent data, Raymond James upgrade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Why Are Stocks Up Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Raymond James ups Regeneron to Market Perform as few downside catalysts remain"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron upgraded to Market Perform from Underperform at Raymond James"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Early notable gainers among liquid option names on March 23rd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data"", ""summary"": ""Sanofi's asthma drug Dupixent met all targets in a trial to treat \""smoker's lung\"", potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi rises as analysts eye results from smoker's lung drug trial"", ""summary"": ""By Scott Kanowsky""}, {""date"": ""2023-03-23"", ""headline"": ""Coinbase\u2019s stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move"", ""summary"": ""Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday.""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron, Sanofi say Dupixent works in COPD"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied about 7% in premarket trading on Thursday after the company said a pivotal Phase 3 clinical trial showed...""}, {""date"": ""2023-03-23"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""S&P 500 Futures Rise in Premarket Trading; Coinbase Global, Apellis Pharmaceuticals Lag"", ""summary"": ""With U.S. stock markets set to open in two hours, (REGN) was up 6.7% in pre-market trading, and (DOOO) was up 5.0%. (ACN), (SMAR), and (FDS) were all posting...""}, {""date"": ""2023-03-23"", ""headline"": ""The Fed pivot is near, and yield curve inversion has likely peaked. That`s usually bad news for stocks, this Fidelity strategist says."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron Shares Rise Premarket on Dupixent COPD Study Success >REGN"", ""summary"": ""By Colin Kellaher Shares of Regeneron Pharmaceuticals Inc. rose sharply in premarket trading Thursday after the biotechnology company and partner Sanofi SA...""}, {""date"": ""2023-03-23"", ""headline"": ""UPDATE 3-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data"", ""summary"": ""Sanofi's asthma and eczema drug Dupixent met all targets in a trial to treat \""smoker's lung\"", giving a major boost to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.  In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline.  Sanofi and Regeneron said in a statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms.""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi Shares Rise After Dupixent Trial Hits Targets, Adding to Drug Potential"", ""summary"": ""By Adria Calatayud Shares in Sanofi SA rose Thursday after the French pharmaceutical company and Regeneron Pharmaceuticals Inc. said their jointly developed...""}, {""date"": ""2023-03-23"", ""headline"": ""Sanofi and Regeneron's Dupixent meets endpoints in clinical trial"", ""summary"": ""Healthcare firms Sanofi and Regeneron said their Dupixent product, which treats the skin disease atopic dermatitis, has met primary and all secondary endpoints in a trial to treat chronic obstructive pulmonary disease (COPD).  Dupixent showed a 30% reduction in moderate or severe acute exacerbations of COPD, a respiratory disease that damages the lungs and causes progressive lung function decline, in the Phase 3 trial, while also showing improvements in lung function, quality of life and COPD respiratory symptoms, the companies said on Thursday.""}, {""date"": ""2023-03-23"", ""headline"": ""Dupixent\u00ae (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial"", ""summary"": ""First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only biologic to demonstrate significant improvements in quality of life and respiratory symptoms COPD is the third leading cause of death worldwide with no new treatment approaches approved in more than a deca""}, {""date"": ""2023-03-23"", ""headline"": ""Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Jefferies Upgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-03-24"", ""headline"": ""Raymond James Upgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%"", ""summary"": ""Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.""}, {""date"": ""2023-03-24"", ""headline"": ""Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough"", ""summary"": ""Growth stock Regeneron Pharmaceuticals broke out in strong volume from a flat base and 800.58 entry this week.  News of the first breakthrough in a decade for a leading cause of death drove the biotech to new highs.  On Thursday, phase 3 clinical trials showed successful results for Regeneron's Dupixent in treating chronic obstructive pulmonary disease (COPD).""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 2.22% to $820.00 Friday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-03-24"", ""headline"": ""Wall Street Has High Hopes for These 2 Nasdaq Stocks"", ""summary"": ""The stock market started out on an uncertain note on Friday, initially falling but cutting its losses in the first hour of the trading day.  Two that they recently focused on were Regeneron Pharmaceuticals (NASDAQ: REGN) and Cracker Barrel Old Country Store (NASDAQ: CBRL).  Although the duo are in very different industries and don't necessarily have much in common other than being listed on the Nasdaq, positive assessments from stock analysts indicate optimism about the prospects for their respective businesses.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron\u2019s Asthma Drug Results Were \u2018Stellar.\u2019 Analyst Sees a Sales Bonanza."", ""summary"": ""The company and its partner Sanofi presented data from a trial of the drug as a treatment for chronic obstructive pulmonary disease.""}, {""date"": ""2023-03-24"", ""headline"": ""Stocks making the biggest moves midday: Block, Deutsche Bank, GameStop, Activision and more"", ""summary"": ""These are the stocks posting the largest moves in midday trading. ""}, {""date"": ""2023-03-24"", ""headline"": ""Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL"", ""summary"": ""Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951""}, {""date"": ""2023-03-24"", ""headline"": ""ETFs in Focus on Sanofi and Regeneron's COPD Drug Data"", ""summary"": ""Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.""}, {""date"": ""2023-03-24"", ""headline"": ""5 analyst picks of the day: Nike upped on Q3 beat | Pro Recap"", ""summary"": ""Barclays upgraded  Nike  (NYSE:NKE) to Overweight from Equalweight and raised its price target to $154.00 from $110.00 on its belief in a high probability of margin upside.  The company reported its Q3 earnings results on Tuesday, which, according to Barclays, demonstrated the company\u2019s \u201cbroad-based brand strength in spite of a weakening consumer macro backdrop.\u201d  Q3 EPS came in at $0.79, better than the consensus estimate of $0.55.""}, {""date"": ""2023-03-24"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""First Republic, Deutsche Bank, Chevon, Block fall premarket; Regeneron rises"", ""summary"": ""By Peter Nurse""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron price target raised to $1,040 from $1,025 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""GLOBAL BROKER RATINGS: Jefferies says 'buy' Regeneron and 'hold' UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron draws more bullish views from analysts after Dupixent COPD data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?"", ""summary"": ""Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron price target raised to $915 from $860 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron price target raised to $800 from $756 at Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Morgan Stanley Reaffirms Their Buy Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron price target raised to $915 from $815 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron upgraded to Buy on COPD opportunity at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron upgraded to Buy from Hold at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-25"", ""headline"": ""Regeneron and Sanofi Look for Billions From COPD Drug"", ""summary"": ""The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.""}, {""date"": ""2023-03-25"", ""headline"": ""Wall Street Breakfast: What Moved Markets"", ""summary"": ""Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.""}, {""date"": ""2023-03-25"", ""headline"": ""Regeneron Pharmaceuticals Boosted By COPD Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-26"", ""headline"": ""FDA PDUFA Date for Regeneron Evkeeza (evinacumab) March 30, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
11,2023-03-26,820.0,2023-04-02,821.6699829101562,0.002036564524580786,U1,"[{""date"": ""2023-03-27"", ""headline"": ""Amgen-Sanofi patent case divides makers of antibody drugs"", ""summary"": ""Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.  In the dispute with Sanofi and partner Regeneron, whose cholesterol-lowering monoclonal antibody drug Praluent works in a similar way as Repatha, Amgen wants the court to rule on how much information it and others need to disclose when describing inventions in patents.""}, {""date"": ""2023-03-27"", ""headline"": ""SVB Leerink Upgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-03-27"", ""headline"": ""UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug"", ""summary"": ""UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy. UBX1325 treatment generally maintained visual acuity for six months, with most patients not requiring anti-VEGF rescue. Patients in the every 8-week Rengeron Pharmaceuticals Inc (NASDAQ: REGN) Eylea (aflibercept) arm had an early and unexpected gain of 3""}, {""date"": ""2023-03-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.05% higher to $820.41 Monday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-03-27"", ""headline"": ""UPDATE 1-U.S. Supreme Court hears Amgen bid to revive cholesterol drug patents"", ""summary"": ""The U.S. Supreme Court on Monday began hearing a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a \""blatant attempt\"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc.""}, {""date"": ""2023-03-27"", ""headline"": ""Final Trades: Regeneron, Hess & Bank of America"", ""summary"": ""The \""Halftime Report\"" traders give their top picks to watch for the second half.""}, {""date"": ""2023-03-27"", ""headline"": ""Video: S&P 500 Analyst Moves: REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly"", ""summary"": ""Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.""}, {""date"": ""2023-03-27"", ""headline"": ""Regeneron Pharmaceuticals Takes Over #146 Spot From Arthur J. Gallagher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court"", ""summary"": ""The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a \""blatant attempt\"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc.""}, {""date"": ""2023-03-27"", ""headline"": ""Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""REGN Crosses Above Average Analyst Target"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""SVB Securities upgrades Regeneron to Outperform, sees positive drivers ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Regeneron upgraded to Outperform from Market Perform at SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Unity (UNX) Down on Disappointing Results From Wet AMD Study"", ""summary"": ""Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.""}, {""date"": ""2023-03-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.80% higher to $826.97 Tuesday, on what proved to be an all-around poor trading session for the stock...""}, {""date"": ""2023-03-28"", ""headline"": ""Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases"", ""summary"": ""Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone paymentTARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development""}, {""date"": ""2023-03-28"", ""headline"": ""Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases"", ""summary"": ""SOUTH SAN FRANCISCO, Calif. & TARRYTOWN, N.Y., March 28, 2023--Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases""}, {""date"": ""2023-03-28"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Regeneron resumed with a Buy at Erste Group"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Immuneering appoints Harold Brakewood as CBO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""FDA PDUFA Date for Regeneron Evkeeza (evinacumab) March 30, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.92% to $819.35 Wednesday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-03-29"", ""headline"": ""Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback"", ""summary"": ""Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.""}, {""date"": ""2023-03-29"", ""headline"": ""Regeneron Shares Rally on Heavy Demand and Strong Fundamentals"", ""summary"": ""Regeneron Pharmaceuticals (REGN) has been a bright spot in the market lately.""}, {""date"": ""2023-03-29"", ""headline"": ""Libtayo\u00ae (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)"", ""summary"": ""Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line indication in NSCLC and fifth indication for Libtayo in the European Union (EU) TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo\u00ae (cemipli""}, {""date"": ""2023-03-29"", ""headline"": ""Kodiak Q4 update had `a few nice surprises,` says Capital One"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""Regeneron Libtayo gets expanded approval in EU for lung cancer subtype"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""Regeneron announces EC approved Libtayo in combination with chemotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""Regeneron price target raised to $650 from $605 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Intra-Cellular Therapies (ITCI) and uniQure (QURE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""Amgen, AstraZeneca`s asthma therapy Tezspire gets UK`s NICE backing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.96% to $811.50 Thursday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-03-30"", ""headline"": ""Regeneron price target raised to $940 from $925 at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""Regeneron in research agreement with Xeris Biopharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-31"", ""headline"": ""Regeneron (REGN) Gains But Lags Market: What You Should Know"", ""summary"": ""Regeneron (REGN) closed at $821.67 in the latest trading session, marking a +1.25% move from the prior day.""}, {""date"": ""2023-03-31"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.25% to $821.67 Friday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-03-31"", ""headline"": ""Regeneron price target raised to $950 from $900 at JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4334, ""bookValue"": 23495, ""cashRatio"": 1.2632258064516129, ""currentRatio"": 5.4545, ""ebitPerShare"": 8.3044, ""eps"": 7.1737, ""ev"": 88615.51, ""fcfMargin"": 0.3442, ""fcfPerShareTTM"": 22.9691, ""grossMargin"": 0.8553, ""inventoryTurnoverTTM"": 0.7304, ""longtermDebtTotalAsset"": 0.0659, ""longtermDebtTotalCapital"": 0.0757, ""longtermDebtTotalEquity"": 0.0844, ""netDebtToTotalCapital"": -0.0463, ""netDebtToTotalEquity"": -0.0517, ""netMargin"": 0.2586, ""operatingMargin"": 0.2994, ""pb"": 3.8233, ""peTTM"": 21.4764, ""pfcfTTM"": 30.2762, ""pretaxMargin"": 0.2713, ""psTTM"": 7.2619, ""ptbv"": 3.9807, ""quickRatio"": 4.5413, ""receivablesTurnoverTTM"": 2.4844, ""roaTTM"": 0.1466, ""roeTTM"": 0.1895, ""roicTTM"": 0.1688, ""rotcTTM"": 0.1787, ""salesPerShare"": 27.7377, ""sgaToSale"": 0.1447, ""tangibleBookValue"": 22566, ""totalDebtToEquity"": 0.115, ""totalDebtToTotalAsset"": 0.0899, ""totalDebtToTotalCapital"": 0.1031, ""totalRatio"": 4.5788, ""period"": ""2023-03-31""}"
12,2023-04-02,821.6699829101562,2023-04-09,828.72998046875,0.008592254439658387,U1,"[{""date"": ""2023-04-03"", ""headline"": ""Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023"", ""summary"": ""TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 4, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the \u2018Investors and Media\u2019 page of Regeneron\u2019s website""}, {""date"": ""2023-04-03"", ""headline"": ""Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""Capital One remains bullish on RPT193 as Rapt initiates Phase 2a Asthma study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.50% to $822.09 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-04-04"", ""headline"": ""Why Investors Need to Take Advantage of These 2 Medical Stocks Now"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}, {""date"": ""2023-04-04"", ""headline"": ""One Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider reduced their stake by 26% in the previous year"", ""summary"": ""Looking at Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) insider transactions over the last year, we can see that...""}, {""date"": ""2023-04-04"", ""headline"": ""$6 billion in college scholarships are awarded each year. Here's what you need to know about applying"", ""summary"": ""Winning a scholarship can help students graduate with less student debt. Here's what you need to know about the awards. ""}, {""date"": ""2023-04-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $825.22 Wednesday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-04-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.43% higher to $828.73 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-04-06"", ""headline"": ""2 Top Growth Stocks That Could Soar This Spring"", ""summary"": ""Exciting news on the way for both of these companies could send their stock prices screaming higher.""}, {""date"": ""2023-04-07"", ""headline"": ""Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""2023-04-07"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-08"", ""headline"": ""A Look At The Intrinsic Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)"", ""summary"": ""Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,032 based on 2 Stage Free Cash Flow to...""}, {""date"": ""2023-04-09"", ""headline"": ""Investing $1,000 In These 2 Top Stocks Would Be a Great Move"", ""summary"": ""For those with $1,000 that isn't being saved for emergencies, here are two excellent stocks to buy today: HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  HCA Healthcare is a leading hospital chain in the U.S. It makes money based on occupancy rates in its 182 hospitals (among other facilities) and based on the services physicians order for their patients.  For instance, occupancy levels in HCA Healthcare's hospitals would soar along with the number of cases of COVID-19 and then drop back down, sometimes rendering year-over-year comparisons difficult.""}]","{""assetTurnoverTTM"": 0.4334, ""bookValue"": 23495, ""cashRatio"": 1.2632258064516129, ""currentRatio"": 5.4545, ""ebitPerShare"": 8.3044, ""eps"": 7.1737, ""ev"": 88615.51, ""fcfMargin"": 0.3442, ""fcfPerShareTTM"": 22.9691, ""grossMargin"": 0.8553, ""inventoryTurnoverTTM"": 0.7304, ""longtermDebtTotalAsset"": 0.0659, ""longtermDebtTotalCapital"": 0.0757, ""longtermDebtTotalEquity"": 0.0844, ""netDebtToTotalCapital"": -0.0463, ""netDebtToTotalEquity"": -0.0517, ""netMargin"": 0.2586, ""operatingMargin"": 0.2994, ""pb"": 3.8233, ""peTTM"": 21.4764, ""pfcfTTM"": 30.2762, ""pretaxMargin"": 0.2713, ""psTTM"": 7.2619, ""ptbv"": 3.9807, ""quickRatio"": 4.5413, ""receivablesTurnoverTTM"": 2.4844, ""roaTTM"": 0.1466, ""roeTTM"": 0.1895, ""roicTTM"": 0.1688, ""rotcTTM"": 0.1787, ""salesPerShare"": 27.7377, ""sgaToSale"": 0.1447, ""tangibleBookValue"": 22566, ""totalDebtToEquity"": 0.115, ""totalDebtToTotalAsset"": 0.0899, ""totalDebtToTotalCapital"": 0.1031, ""totalRatio"": 4.5788, ""period"": ""2023-03-31""}"
13,2023-04-09,828.72998046875,2023-04-16,829.3300170898438,0.0007240435790127897,U1,"[{""date"": ""2023-04-09"", ""headline"": ""Investing $1,000 In These 2 Top Stocks Would Be a Great Move"", ""summary"": ""For those with $1,000 that isn't being saved for emergencies, here are two excellent stocks to buy today: HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  HCA Healthcare is a leading hospital chain in the U.S. It makes money based on occupancy rates in its 182 hospitals (among other facilities) and based on the services physicians order for their patients.  For instance, occupancy levels in HCA Healthcare's hospitals would soar along with the number of cases of COVID-19 and then drop back down, sometimes rendering year-over-year comparisons difficult.""}, {""date"": ""2023-04-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.60% to $823.76 Monday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-04-10"", ""headline"": ""U.S. launches $5B program to speed up development of next-gen COVID vaccines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market"", ""summary"": ""GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""Why Healthcare Stocks Are A Prescription For Investors In Q2 2023"", ""summary"": ""The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.""}, {""date"": ""2023-04-11"", ""headline"": ""Regeneron Announces Investor Conference Presentations"", ""summary"": ""TARRYTOWN, N.Y., April 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2023 Health Care Conference at 1:40 p.m. PT (4:40 p.m. ET) on Tuesday, May 9, 20232023 RBC Capital Markets Global Healthcare Conference at 9:30 a.m. ET on Tuesday, May 16, 2023 The sessions may be accessed from the \""Investors & Media\"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of t""}, {""date"": ""2023-04-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.50% to $819.64 Tuesday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2023-04-11"", ""headline"": ""12 Best Covid Treatment Stocks to Buy Today"", ""summary"": ""In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there\u2019s one thing that can be said for sure, it\u2019s that the coronavirus pandemic has changed the world. The deadly disease, [\u2026]""}, {""date"": ""2023-04-11"", ""headline"": ""IN BRIEF: Regeneron expects USD56 million hit in first quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.10% higher to $820.43 Wednesday, on what proved to be an all-around poor trading session for the stock...""}, {""date"": ""2023-04-12"", ""headline"": ""Regeneron price target lowered to $880 from $883 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""S&P 500 will see 11% upside from the current levels - Piper Sandler`s Craig Johnson"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.21% to $830.35 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-04-13"", ""headline"": ""Intellia up 12% as Canaccord starts with Buy citing gene editing approach"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Regeneron: New Highs Following Dupixent's COPD Data"", ""summary"": ""Regeneron shares jumped to new all-time highs following the successful phase 3 results of Dupixent in COPD. See why I think REGN stock is well-positioned to grow.""}, {""date"": ""2023-04-13"", ""headline"": ""Regeneron: New Highs Following Dupixent`s COPD Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.12% to $829.33 Friday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-04-14"", ""headline"": ""Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?"", ""summary"": ""Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 15...""}, {""date"": ""2023-04-14"", ""headline"": ""Ghana 1st in world to approve new malaria vaccine by Oxford"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4334, ""bookValue"": 23495, ""cashRatio"": 1.2632258064516129, ""currentRatio"": 5.4545, ""ebitPerShare"": 8.3044, ""eps"": 7.1737, ""ev"": 88615.51, ""fcfMargin"": 0.3442, ""fcfPerShareTTM"": 22.9691, ""grossMargin"": 0.8553, ""inventoryTurnoverTTM"": 0.7304, ""longtermDebtTotalAsset"": 0.0659, ""longtermDebtTotalCapital"": 0.0757, ""longtermDebtTotalEquity"": 0.0844, ""netDebtToTotalCapital"": -0.0463, ""netDebtToTotalEquity"": -0.0517, ""netMargin"": 0.2586, ""operatingMargin"": 0.2994, ""pb"": 3.8233, ""peTTM"": 21.4764, ""pfcfTTM"": 30.2762, ""pretaxMargin"": 0.2713, ""psTTM"": 7.2619, ""ptbv"": 3.9807, ""quickRatio"": 4.5413, ""receivablesTurnoverTTM"": 2.4844, ""roaTTM"": 0.1466, ""roeTTM"": 0.1895, ""roicTTM"": 0.1688, ""rotcTTM"": 0.1787, ""salesPerShare"": 27.7377, ""sgaToSale"": 0.1447, ""tangibleBookValue"": 22566, ""totalDebtToEquity"": 0.115, ""totalDebtToTotalAsset"": 0.0899, ""totalDebtToTotalCapital"": 0.1031, ""totalRatio"": 4.5788, ""period"": ""2023-03-31""}"
14,2023-04-16,829.3300170898438,2023-04-23,800.72998046875,-0.03448571260142319,D4,"[{""date"": ""2023-04-16"", ""headline"": ""Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.16% to $819.74 Monday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron Set to Reach New Heights: $1,000 in Sight?"", ""summary"": ""Biotechnology company Regeneron Pharmaceuticals has posted strong stock gains since June but further gains look likely in the weeks and months ahead. Let's check out the charts. In the daily bar chart of REGN, below, I see a positive-looking picture.""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary"", ""summary"": ""Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent DirectorTARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company\u2019s Board of Directors and will not stand for reelection at the Company\u2019s 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 a""}, {""date"": ""2023-04-17"", ""headline"": ""Aflibercept 8 mg and EYLEA\u00ae (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases"", ""summary"": ""New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema 18 presentations reinforce Regeneron\u2019s commitment to patients with serious retinal diseases TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced th""}, {""date"": ""2023-04-17"", ""headline"": ""IN BRIEF: Regeneron Chair to retire; CEO and CSO to become co-chairs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire"", ""summary"": ""By Colin Kellaher Regeneron Pharmaceuticals Inc. on Monday said its longtime chairman, P. Roy Vagelos, plans to retire in June. The Tarrytown, N.Y.,...""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron announces retirement of board chair"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron aflibercept, EYLEA Injection to be featured at ARVO 2023 meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), UnitedHealth (UNH) and Sarepta Therapeutics (SRPT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Healthcare Shares Fall; J&J Boosts Earnings Outlook -- Healthcare Roundup"", ""summary"": ""Healthcare companies sank as investors rotated into stocks with more to gain from a strong economy. Johnson &amp; Johnson raised its full-year sales and...""}, {""date"": ""2023-04-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.43% to $808.01 Tuesday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2023-04-18"", ""headline"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their splendid 159% return over the last five years"", ""summary"": ""The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...""}, {""date"": ""2023-04-18"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-20"", ""headline"": ""TD Cowen Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""2023-04-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.33% to $798.10 Thursday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-04-20"", ""headline"": ""The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio"", ""summary"": ""While the debate will certainly rage over which ideas legitimately rank as the greatest blue-chip stocks to buy of all time, for right now, certain enterprises stand out for a combination of their relevance and resilience. As well, a select few large-capitalization companies may be too undervalued and beaten down for their own good. Therefore, speculators may enjoy significant upside. To generate this list, I turned to the investment resource Gurufocus, specifically its screener function. Here,""}, {""date"": ""2023-04-20"", ""headline"": ""Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-20"", ""headline"": ""Sensei gains FDA IND clearance for solid tumors candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-20"", ""headline"": ""Regeneron price target raised to $885 from $875 at TD Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day.""}, {""date"": ""2023-04-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.33% higher to $800.73 Friday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-04-21"", ""headline"": ""Intellia Therapeutics: Signs Of Possible Life"", ""summary"": """"}, {""date"": ""2023-04-21"", ""headline"": ""Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}]",{}
15,2023-04-23,800.72998046875,2023-04-30,801.7899780273438,0.001323789023077726,U1,"[{""date"": ""2023-04-24"", ""headline"": ""Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea"", ""summary"": ""UNITY Biotechnology Inc (NASDAQ: UBX) announced results from the long-term follow-up of the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). Patients taking UBX1325 saw a mean change in best-corrected visual acuity of +6.2 ETDRS letters from baseline, a statistically significant result (p=0.0037). At 48 weeks, Unity also noted a difference of +5.6 ETDRS letters compared to sham-treated patients, but that part of the result was not statistically significant (p=0.1198""}, {""date"": ""2023-04-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.46% to $797.04 Monday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-04-24"", ""headline"": ""4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates"", ""summary"": ""We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.""}, {""date"": ""2023-04-24"", ""headline"": ""Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?"", ""summary"": ""Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...""}, {""date"": ""2023-04-25"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.94% to $789.58 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-04-25"", ""headline"": ""3 Biotech Stocks To Watch Today"", ""summary"": ""Biotech stocks for your late-April 2023 watchlist.""}, {""date"": ""2023-04-26"", ""headline"": ""Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy"", ""summary"": ""CAMBRIDGE, Mass. & TARRYTOWN, N.Y., April 26, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer\u2019s disease and cerebral amyloid angiopathy (CAA).""}, {""date"": ""2023-04-26"", ""headline"": ""Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy"", ""summary"": ""- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPP\u03b1 and sAPP\u03b2 in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform - TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,""}, {""date"": ""2023-04-26"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.47% to $778.00 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-04-26"", ""headline"": ""Democratic senators introduce bill to enhance CMS drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akebia Therapeutics (AKBA) and Panbela Therapeutics (PBLA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer`s candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Regeneron (REGN) Gains But Lags Market: What You Should Know"", ""summary"": ""In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.""}, {""date"": ""2023-04-27"", ""headline"": ""Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says"", ""summary"": ""Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP. ALN-APP is an investigational RNAi therapeutic targeting amyloid precursor protein (APP, a brain protein) in development for Alzheimer's disease and cerebral amyloid angiopathy (CAA). Patients treated with single-dose ALN-APP experienced dose-dependent, rapid and sustained reduction in cerebrospinal""}, {""date"": ""2023-04-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.84% to $792.29 Thursday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-04-27"", ""headline"": ""Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?"", ""summary"": ""Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-04-27"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Sanofi Q1 profit climbs on Dupixent as drug on track for \ufffd\ufffd\ufffd10B this year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.20% to $801.79 Friday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-04-28"", ""headline"": ""Stock Charts Strategy, May 1-5: Fed Policy, April Payrolls, Apple Earnings"", ""summary"": ""Fed policy and April payrolls may influence the stock market, but earnings will have Apple, Vertex and Albemarle stock charts in focus.""}]",{}
16,2023-04-30,801.7899780273438,2023-05-07,762.0999755859375,-0.04950174425858522,D5,"[{""date"": ""2023-05-01"", ""headline"": ""EF Hutton Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-05-01"", ""headline"": ""Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?"", ""summary"": ""Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.""}, {""date"": ""2023-05-01"", ""headline"": ""Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), PTC Therapeutics (PTCT) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""Regeneron looks to strong Dupixent, Eylea sales in Q1 report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.03% to $798.45 Tuesday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-05-02"", ""headline"": ""LGND vs. REGN: Which Stock Is the Better Value Option?"", ""summary"": ""LGND vs. REGN: Which Stock Is the Better Value Option?""}, {""date"": ""2023-05-02"", ""headline"": ""These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}, {""date"": ""2023-05-02"", ""headline"": ""Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research"", ""summary"": ""Oral presentations include interim results from pivotal trial of linvoseltamab (BCMAxCD3) in relapsed/refractory multiple myeloma and three cohorts of fianlimab (LAG-3 inhibitor) combined with Libtayo\u00ae (cemiplimab-rwlc) in advanced melanoma Ten total presentations to cover clinical research across six solid tumors and blood cancers TARRYTOWN, N.Y., May 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new and updated data from its div""}, {""date"": ""2023-05-02"", ""headline"": ""Regeneron to highlight new, updates data at ASCO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""GLOBAL BRIEFING: China's manufacturing weakens; Fed enacts 25bp hike"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.59% higher to $803.17 Wednesday, on what proved to be an all-around dismal trading session for the stock...""}, {""date"": ""2023-05-03"", ""headline"": ""Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More"", ""summary"": ""Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.""}, {""date"": ""2023-05-03"", ""headline"": ""Regeneron Pharmaceuticals Q1 2023 Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Why Earnings Season Could Be Great for Regeneron (REGN)"", ""summary"": ""Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""2023-05-03"", ""headline"": ""Regeneron price target raised to $1,050 from $856 at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call"", ""summary"": ""Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker"", ""summary"": ""The struggles continued for Regeneron's blockbuster eye disease treatment, Eylea, in the first quarter \u2014 leading REGN stock to dive Thursday.""}, {""date"": ""2023-05-04"", ""headline"": ""Why Regeneron Pharmaceuticals Shares Are Trading Lower Today"", ""summary"": ""Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating the $9.60 Street estimate. Revenues decreased 6% Y/Y to $3.16 billion, down from $3.41 billion in Q4 FY22, beating the consensus of $3.00 billion. Revenues from REGEN-COV, covid-19 antibody cocktail, reached $613.2 million, down 4% Y/Y. In the first quarter of 2023, Dupixent global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus the first quarter of 2022. Eylea U.S. net sales de""}, {""date"": ""2023-05-04"", ""headline"": ""Why Regeneron Pharmaceuticals Stock Is Tanking Today"", ""summary"": ""Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today.  Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of 12:19 p.m. ET Thursday afternoon.  Regeneron's shares are moving southward in response to lower-than-expected sales of its flagship eye-care treatment, Eylea, during the first quarter of 2023.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 6.14% to $753.88 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline"", ""summary"": ""Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron Pharmaceuticals Inc. (REGN) Q1 2023 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Investor RelationsLeonard Schleifer - Chief...""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron's Eylea drug sales hit by competition from 'new kid in town'"", ""summary"": ""Regeneron Pharmaceuticals Inc's first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company's shares more than 5% lower in early trade.""}, {""date"": ""2023-05-04"", ""headline"": ""Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings"", ""summary"": ""While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.""}, {""date"": ""2023-05-04"", ""headline"": ""Intellia jumps 13% after Q1 updates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron (REGN) Q1 Earnings and Revenues Top Estimates"", ""summary"": ""Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-05-04"", ""headline"": ""CORRECTED-Regeneron beats quarterly profit estimates "", ""summary"": ""Regeneron Pharmaceuticals Inc beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.""}, {""date"": ""2023-05-04"", ""headline"": ""Goldman Sachs Keeps Their Buy Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron Reports First Quarter 2023 Financial and Operating Results"", ""summary"": ""First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent\u00ae global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022First quarter 2023 EYLEA\u00ae U.S. net sales were $1.43 billionFirst quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS(a) of $10.09; includes unfavorable $0.42 impact from acquired IPR&D chargeEuropean Commission approved Dupixent for atopic dermatitis in children aged 6 months to 5""}, {""date"": ""2023-05-04"", ""headline"": ""Truist Securities Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower"", ""summary"": ""Regeneron Pharmaceuticals Inc. \u2018s stock slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance...""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work"", ""summary"": ""By Will Feuer Regeneron Pharmaceuticals posted higher first-quarter sales, lifted by its collaboration with Sanofi. The Tarrytown, N.Y.-based company...""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron: Q1 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron stock dips amid decline in Eylea sales despite Q1 beat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-05-05"", ""headline"": ""RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-05-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.09% to $762.10 Friday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-05-05"", ""headline"": ""Regeneron Pharmaceuticals Insider Lowered Holding By 26% During Last Year \\"", ""summary"": ""From what we can see, insiders were net sellers in Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) during the past 12...""}, {""date"": ""2023-05-05"", ""headline"": ""Regeneron price target raised to $927 from $880 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Regeneron price target lowered to $895 from $976 at SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Ultragenyx Pharmaceutical (RARE) and Surface Oncology (SURF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
17,2023-05-07,762.0999755859375,2023-05-14,744.3499755859375,-0.023290907451286813,D3,"[{""date"": ""2023-05-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.31% to $752.12 Monday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-05-08"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Karuna Therapeutics (KRTX) and Pennant Group (PNTG)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""Regeneron price target lowered to $935 from $960 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""Q1 2023 Xeris Biopharma Holdings Inc Earnings Call"", ""summary"": ""Q1 2023 Xeris Biopharma Holdings Inc Earnings Call""}, {""date"": ""2023-05-09"", ""headline"": ""Notable Wednesday Option Activity: REGN, YETI, RNG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""15 Biggest Immunotherapy Companies in the World"", ""summary"": ""In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power [\u2026]""}, {""date"": ""2023-05-09"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript May 4, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.09, expectations were $9.56. Operator: Welcome to the Regeneron Pharmaceuticals First Quarter 2023 Earnings Conference Call. My name is Josh, and I will be your operator for today\u2019s call. At this time, all participants [\u2026]""}, {""date"": ""2023-05-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.37% higher to $754.88 Tuesday, on what proved to be an all-around dismal trading session for the stock...""}, {""date"": ""2023-05-09"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 29% Discount?"", ""summary"": ""Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,053 based on 2 Stage Free Cash Flow to...""}, {""date"": ""2023-05-09"", ""headline"": ""Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-05-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.70% to $749.59 Wednesday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2023-05-10"", ""headline"": ""2 Cathie Wood Stocks That Can Get You Through Any Recession"", ""summary"": ""Economists at the U.S. Federal Reserve recently uttered the dreaded \""R\"" word. They are now predicting a recession will come later this year.\u00a0Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise.""}, {""date"": ""2023-05-10"", ""headline"": ""Alvotech, Polifarma ink pact to sell potential Eylea biosimilar in Turkey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.54% to $745.57 Thursday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-05-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.16% to $744.35 Friday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-05-13"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ETCompany ParticipantsRyan Crowe - VP, IRRobert Landry - EVP,...""}]",{}
18,2023-05-14,744.3499755859375,2023-05-21,759.0499877929688,0.019748791145535627,U2,"[{""date"": ""2023-05-15"", ""headline"": ""CEO Pay Packages Fell Sharply in 2022 as the Stock Market Sank"", ""summary"": ""The annual WSJ analysis of compensation for CEOs in the S&P 500 reveals that the median pay held steady. But in a first, companies are also disclosing how much those pay packages rose or fell in the year.""}, {""date"": ""2023-05-15"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.89% higher to $750.96 Monday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-05-16"", ""headline"": ""Regeneron CEO backs regulators attempt to block Amgen deal, FT reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.16% to $742.28 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-05-16"", ""headline"": ""RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-05-16"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 9:30 AM ETCompany ParticipantsAris Baras \u00e2\u0080\u0093 Senior Vice President,...""}, {""date"": ""2023-05-16"", ""headline"": ""Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""Regeneron Pharmaceuticals (NASDAQ:REGN) has had a rough month with its share price down 9.4%. However, stock prices are...""}, {""date"": ""2023-05-16"", ""headline"": ""What To Expect From GSK In 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Viking Therapeutics (VKTX) and UpHealth (UPH)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""The 7 Growth Stocks You Need to Own Now for Maximum Returns"", ""summary"": ""Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially represent growth stocks to buy now. Using Gurufocus, all the companies below feature (on a per-share basis) five-year and ten-year growth rates of 20% and 15%, respectively. However, companies that rank among the growth stocks to own may have already run their course; that is to say, there might not b""}, {""date"": ""2023-05-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.99% higher to $749.63 Wednesday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-05-17"", ""headline"": ""Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Regeneron boss backs attempt to block $28bn Amgen acquisition"", ""summary"": ""The Regeneron chief executive has backed an attempt by US regulators to block Amgen\u2019s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition.  Leonard Schleifer said he supported the US Federal Trade Commission\u2019s decision to tackle a \u201cnew area\u201d after the agency made its first attempt to block a pharma deal in over a decade by filing a novel lawsuit against the Amgen transaction.  Drugmakers pay rebates to ensure their treatment is placed on the lists of drugs covered by insurance companies.""}, {""date"": ""2023-05-18"", ""headline"": ""Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Amgen (NASDAQ:AMGN) Loses Patent Battle to Sanofi, Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Regeneron Announces Investor Conference Presentations"", ""summary"": ""TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 4th Annual Oncology Innovation Summit at 12:30 p.m. ET on Tuesday, May 30, 2023Jefferies Healthcare Conference at 8:30 a.m. ET on Wednesday, June 7, 2023 Goldman Sachs 44th Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Wednesday, June 14, 2023 The sessions may be accessed from the \""Investors & Media\"" page of Regeneron""}, {""date"": ""2023-05-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.29% to $747.48 Thursday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-05-18"", ""headline"": ""Sanofi Wins Supreme Court Patent Dispute With Amgen"", ""summary"": ""The court said Amgen patents relating to its cholesterol drug Repatha shouldn\u2019t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi.""}, {""date"": ""2023-05-18"", ""headline"": ""Regeneron Applauds Supreme Court\u2019s Unanimous Opinion Striking Down Amgen\u2019s PCSK9 Patent Claims and Supporting Scientific Innovation"", ""summary"": ""Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent\u00ae (alirocumab) TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) applauds the United States Supreme Court\u2019s unanimous opinion1 ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent\u00ae (alirocumab). The decision affirms the United States Court of Appeals for the Federal Circuit\u2019s opinion, which held that Amgen\u2019s asserte""}, {""date"": ""2023-05-18"", ""headline"": ""UPDATE 1-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents"", ""summary"": ""The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha over a legal challenge by French rival Sanofi SA.  The nine justices unanimously upheld a lower court's ruling that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating the full scope of its claimed innovation.  Amgen has waged a years-long court battle to restore two of its patents on Repatha, a drug that can reduce the risk of heart attack and stroke in people with heart disease, stemming from a legal fight with Sanofi and its partner Regeneron Pharmaceuticals Inc.""}, {""date"": ""2023-05-18"", ""headline"": ""Ocular Therapeutix: I Still Don't See The Need"", ""summary"": ""Ocular Therapeutix is up since my last article. I am neutral to bearish because I don't see the molecule making a space for itself. Click here for more on OCUL.""}, {""date"": ""2023-05-18"", ""headline"": ""Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen"", ""summary"": ""By Denny Jacob Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court opinion affirms a lower court opinion that held Amgen's asserted U.S. PCSK9...""}, {""date"": ""2023-05-18"", ""headline"": ""Ocular Therapeutix: I Still Don`t See The Need"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Sanofi `pleased` with Supreme Court`s ruling on Amgen`s asserted patent claims"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Regeneron `applauds` Supreme Court`s striking down Amgen`s patent claims"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC"", ""summary"": ""Much of what the FTC attacks isn\u00e2\u0080\u0099t anticompetitive, it\u00e2\u0080\u0099s competitive. Click here to find out more on HZNP and LQDA.""}, {""date"": ""2023-05-19"", ""headline"": ""High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023"", ""summary"": ""Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San Jos\u00e9, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global pre-college science and engineering competition, for a project that explored planets that orbit very close around their suns. Other top prizes went to projects in the fields of computational biology, animal sciences and neurobiology.""}, {""date"": ""2023-05-19"", ""headline"": ""Regeneron (REGN) Faces Challenges as Eylea Sales Decline"", ""summary"": ""Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.""}, {""date"": ""2023-05-19"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.55% to $759.05 Friday, on what proved to be an all-around grim trading session for the stock market, with the...""}, {""date"": ""2023-05-19"", ""headline"": ""High School Scientists and Engineers Win Nearly $9 Million at the\u00a0Regeneron International Science and Engineering Fair 2023"", ""summary"": ""$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teensTARRYTOWN, N.Y. and WASHINGTON, D.C., May 19, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San Jos\u00e9, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world\u2019s large""}, {""date"": ""2023-05-19"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-19"", ""headline"": ""Regeneron Q1 Eylea miss `not about share, says Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-20"", ""headline"": ""Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-20"", ""headline"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years"", ""summary"": ""When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...""}, {""date"": ""2023-05-21"", ""headline"": ""Dupixent\u00ae (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine"", ""summary"": ""Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respira""}]",{}
19,2023-05-21,759.0499877929688,2023-05-28,725.0499877929688,-0.04479283386705424,D5,"[{""date"": ""2023-05-20"", ""headline"": ""Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-21"", ""headline"": ""Dupixent\u00ae (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine"", ""summary"": ""Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respira""}, {""date"": ""2023-05-22"", ""headline"": ""Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained"", ""summary"": ""Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented results from a Phase 3 study of Dupixent (dupilumab) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. Dupixent demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo, meeting the primary endpoint. Dupixent significantly improved lung""}, {""date"": ""2023-05-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.99% to $751.50 Monday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-05-22"", ""headline"": ""A Good Week For The Market But A Pause In The Biotech Rally"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""Sanofi: smoker's lung drug benefit was swift and sustained in trial"", ""summary"": ""The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat \""smoker's lung\"" and lasted for the duration of the 1-year study, French drugmaker Sanofi said late on Sunday.""}, {""date"": ""2023-05-22"", ""headline"": ""Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-23"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.39% to $748.56 Tuesday, on what proved to be an all-around rough trading session for the stock market,...""}, {""date"": ""2023-05-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.49% to $737.40 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-05-25"", ""headline"": ""Brandywine Global Investment Management, LLC Buys 1, Sells 4 in 1st Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""Notable Friday Option Activity: REGN, URI, KSS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma"", ""summary"": ""71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also observed across prespecified subgroups, including patients with high disease burden and aggressive disease Data from this trial to form the basis of planned regulatory submissions, starting with the FDA in 2023 TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R""}, {""date"": ""2023-05-25"", ""headline"": ""Fianlimab (LAG-3 inhibitor) Combined with Libtayo\u00ae (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations"", ""summary"": ""Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients \u2013 about double the rate historically seen with anti-PD-1 alone in similar settings \u2013 per trial results to be presented in an oral session at ASCO Clinically meaningful responses observed in post hoc analyses of populations of interest, including patients with poor prognosis factors, prior anti-PD-1 therapy in the adjuvant setting and varying tumor PD-L1 expression levels Pivot""}, {""date"": ""2023-05-25"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.68% to $725.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-05-25"", ""headline"": ""Biopharmaceutical Sector Revisited: Investor Interest Subdued, Valuations Attractive"", ""summary"": ""The dramatic correction seems to have bottomed in June 2022, and the Biopharma ETFs have rallied since then. See if it is a good time to enter into this sector.""}, {""date"": ""2023-05-25"", ""headline"": ""Regeneron Pharmaceuticals (REGN) Shares Cross Below 200 DMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""14 Best Biotech Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, [\u2026]""}, {""date"": ""2023-05-25"", ""headline"": ""Regeneron says updated Linvoseltamab data demonstrates durable responses"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study"", ""summary"": ""A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.""}, {""date"": ""2023-05-26"", ""headline"": ""TD Cowen pharma/biotech analysts hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
20,2023-05-28,725.0499877929688,2023-06-04,739.9500122070312,0.02055034089362273,U3,"[{""date"": ""2023-05-29"", ""headline"": ""Regeneron Pharmaceuticals Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) TD Cowen 4th Annual Oncology Innovation Summit May 30, 2023 12:30 PM ETCompany ParticipantsIzzy Lowy - SVP, Solid Organ Oncology...""}, {""date"": ""2023-05-31"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.96% higher to $735.56 Wednesday, on what proved to be an all-around dismal trading session for the stock...""}, {""date"": ""2023-06-01"", ""headline"": ""Cantor Fitzgerald biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.60% to $731.17 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-06-01"", ""headline"": ""Thursday\u2019s Top Analyst Upgrades and Downgrades: Chevron, Coty, Twilio, Viking Therapeutics, Xylem and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Roche to divest biologics production plant in California \u2013 Reuters"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.20% to $739.95 Friday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-06-02"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""Oppenheimer biotech analyst to hold a reception"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}]",{}
21,2023-06-04,739.9500122070312,2023-06-11,746.52001953125,0.0088789880611293,U1,"[{""date"": ""2023-06-04"", ""headline"": ""Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Regeneron Pharmaceuticals Unusual Options Activity For June 05"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}, {""date"": ""2023-06-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.39% to $750.27 Monday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-06-05"", ""headline"": ""Noteworthy Monday Option Activity: REGN, GNRC, ORCL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Global company events calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.28% to $748.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-06-06"", ""headline"": ""3 Biotech Stocks to Sell in June Before They Crash and Burn"", ""summary"": ""The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline. This means there\u2019s more than a couple biotech stocks to sell. The iShares US Pharmaceuticals ETF (NYSEARCA:IHE) that tracks the industry is down 10% over the last 12 months and major players such as Pfizer (NYSE:PFE) have seen their share price decline 25% so far in 2023. The""}, {""date"": ""2023-06-06"", ""headline"": ""26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold \\"", ""summary"": ""Insiders were net sellers of Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock during the past year. That is...""}, {""date"": ""2023-06-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.27% to $738.63 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-06-07"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Jefferies Global Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies Global Healthcare Conference Call June 7, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor...""}, {""date"": ""2023-06-08"", ""headline"": ""18 Analysts Have This to Say About Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""GLOBAL BRIEFING: Chinese CPI stays near zero, producer prices plunge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day.""}, {""date"": ""2023-06-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.56% to $750.12 Thursday, on what proved to be an all-around great trading session for the stock market,...""}, {""date"": ""2023-06-09"", ""headline"": ""RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-06-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.48% to $746.52 Friday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-06-09"", ""headline"": ""Kiniksa Pharmaceuticals: A Somewhat Complicated Story"", ""summary"": ""Kiniksa Pharmaceuticals is a commercial stage biopharma firm. KNSA sees growth in its primary drug asset and has an intriguing pipeline. Read more here.""}, {""date"": ""2023-06-09"", ""headline"": ""Cantor Fitzgerald biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""AbbVie, Amgen among firms targeted for Medicare inflation penalties"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""Regeneron price target raised to $816 from $811 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca in pact with Quell Therapeutics for Treg cell therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-11"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 29% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,045 based on 2 Stage Free Cash Flow to...""}]",{}
22,2023-06-11,746.52001953125,2023-06-18,783.0499877929688,0.048933675328166615,U5,"[{""date"": ""2023-06-11"", ""headline"": ""Ocular falls after 12-month data for wet AMD candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-11"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 29% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,045 based on 2 Stage Free Cash Flow to...""}, {""date"": ""2023-06-12"", ""headline"": ""Notable Tuesday Option Activity: REGN, TPC, TTD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""Regeneron: Solid Investment Based On Continued EYLEA Expansion"", ""summary"": ""Regeneron Pharmaceuticals has potential to receive FDA approval of higher dosing of 8 mg of EYLEA with FDA target action date of June 27, 2023. Click here for more on REGN.""}, {""date"": ""2023-06-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rose 1.77% to $767.35 Tuesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-06-13"", ""headline"": ""SVB Securities Remains a Buy on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""15 Most Profitable Drugs In The World"", ""summary"": ""In this article, we will be taking a look at the 15 most profitable drugs in the world. If you wish to see the top ones, feel free to skip our detailed analysis of the pharma industry and head straight to the 5 Most Profitable Drugs In The World. The pharmaceutical industry has long been [\u2026]""}, {""date"": ""2023-06-13"", ""headline"": ""Regeneron named 'Catalyst Driven Idea' at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-14"", ""headline"": ""Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day.""}, {""date"": ""2023-06-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.49% higher to $771.11 Wednesday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-06-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. (REGN) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 11:40 AM ETCompany ParticipantsRyan Crowe - VP, IRBob Landry - EVP...""}, {""date"": ""2023-06-14"", ""headline"": ""2 Stocks to Buy No Matter What Happens in June and Beyond"", ""summary"": ""The first half of the year is almost over -- and so far, 2023 has been pretty kind to investors.  Buying shares of the right companies can help investors' portfolios do the same.  With that said, let's consider two stocks worth investing in regardless of what lies ahead: Regeneron Pharmaceuticals (NASDAQ: REGN) and Microsoft (NASDAQ: MSFT).""}, {""date"": ""2023-06-15"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.55% to $783.07 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-06-15"", ""headline"": ""Video: S&P 500 Analyst Moves: REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-15"", ""headline"": ""Regeneron Pharmaceuticals Achieves #131 Analyst Rank, Surpassing PulteGroup"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-15"", ""headline"": ""Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""2023-06-15"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and BioMarin Pharmaceutical (BMRN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-15"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Healthequity (HQY) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.00% to $783.05 Friday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-06-18"", ""headline"": ""How to Retire Rich: Biotech Stocks Edition"", ""summary"": ""Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector \u2013 which falls under the broad healthcare industry \u2013 is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement""}]",{}
23,2023-06-18,783.0499877929688,2023-06-25,779.72998046875,-0.004239840847933829,D1,"[{""date"": ""2023-06-18"", ""headline"": ""How to Retire Rich: Biotech Stocks Edition"", ""summary"": ""Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector \u2013 which falls under the broad healthcare industry \u2013 is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement""}, {""date"": ""2023-06-19"", ""headline"": ""PBE: Healthcare Dashboard For June"", ""summary"": ""Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.""}, {""date"": ""2023-06-20"", ""headline"": ""Agree To Buy Regeneron Pharmaceuticals At $560, Earn 5.6% Using Options"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Biotech And Healthcare Stocks Lagging"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.23% to $781.21 Tuesday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-06-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.31% to $778.77 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-06-21"", ""headline"": ""2 Biotech Stocks You Can Buy and Hold for the Next Decade"", ""summary"": ""Biotech companies use living organisms to develop their therapies, and much like some living things, biotech stocks can be notoriously volatile.  Part of that is due to the complexities of making biotech therapies.  The success rate for biotech start-ups is low, but Gilead Sciences (NASDAQ: GILD), founded 36 years ago and Regeneron Pharmaceuticals (NASDAQ: REGN), founded 35 years ago, have already stood the test of time.""}, {""date"": ""2023-06-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.13% higher to $779.81 Thursday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-06-22"", ""headline"": ""$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.01% to $779.73 Friday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-06-23"", ""headline"": ""Friday\u2019s Top Analyst Upgrades and Downgrades: Alcoa, Caterpillar, Dow, Kellogg, PagSeguro, Tesla, Tripadvisor, Walmart and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Kezar Life Sciences (KZR)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
24,2023-06-25,779.72998046875,2023-07-02,718.5399780273438,-0.0784758877741506,D5+,"[{""date"": ""2023-06-26"", ""headline"": ""REGN Makes Notable Cross Below Critical Moving Average"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Morgan Stanley says Regeneron likely to come under pressure after surprising CRL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron falls as FDA rejects high-dose Eylea (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron resumes, down 9% after CRL issued for aflibercept 8 mg BLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron trading resumes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron high-dose Eylea version rejected by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Roche turns positive after Regeneron issued CRL for aflibercept 8 mg BLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron to resume trading at 3:15 pm ET"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron announces top-line, two-year data for aflibercept 8 mg PHOTON trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""FDA issues CRL to Regeneron for Aflibercept 8 mg Biologics License Application"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Regeneron trading halted, news pending"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Where Regeneron Pharmaceuticals Stands With Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-06-27"", ""headline"": ""Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender"", ""summary"": ""The Food and Drug Administration rejected a high-dose version of Regeneron's eye drug Eylea on Tuesday, leading REGN stock to crumble.""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release"", ""summary"": ""The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea.""}, {""date"": ""2023-06-27"", ""headline"": ""Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema"", ""summary"": ""89% of all aflibercept 8 mg patients maintained \u226512-week dosing intervals through two years Of those assigned to a 16-week dosing regimen at baseline, 83% maintained \u226516-week dosing intervals through two years Many patients met the extension criteria for even longer dosing intervals, including 43% for \u226520-week intervals and 27% for 24-week intervals Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA\u00ae (aflibercept) 2 mg Injection TARRYTOWN, NY, J""}, {""date"": ""2023-06-27"", ""headline"": ""FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler"", ""summary"": ""No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the CRL No additional clinical data or trials have been requested TARRYTOWN, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for aflibercept 8 mg for the treatment of patients with wet age-r""}, {""date"": ""2023-06-27"", ""headline"": ""10 Martin Shkreli Stock Picks and Their Performance"", ""summary"": ""In this article, we will take a look at the 10 Martin Shkreli stock picks and their performance. To see more such companies, go directly to 5 Martin Shkreli Stock Picks and Their Performance. Martin Shkreli a.k.a. \u201cPharma Bro\u201d is known for a variety of reasons, many of which are tinged with notoriety. He cofounded [\u2026]""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron shares fall after FDA rejects high-dose eye disease treatment"", ""summary"": ""Regeneron said the rejection was \""solely due to an ongoing review of inspection findings at a third-party filler.\"" ""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron Pharmaceuticals shares fall on US FDA Eylea blow"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 8.71% to $716.09 Tuesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler"", ""summary"": ""By Stephen Nakrosis Regeneron Pharmaceuticals said it received a complete response letter from the Food and Drug Administration for its aflibercept 8 mg...""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron\u2019s high-dose Eylea not approved by FDA"", ""summary"": ""Regeneron Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the biologics license...""}, {""date"": ""2023-06-27"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Regeneron's two-year Eylea data should look 'consistent', says RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Edwards Lifesciences (EW) and Tonix Pharma (TNXP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Why Catalent Stock Flopped Today"", ""summary"": ""It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA).  According to a media report from a leading financial news agency, this is what likely happened.  The party applying for it was biotech Regeneron Pharmaceuticals (NASDAQ: REGN), and the drug is a stronger formulation of its previously approved Eylea.""}, {""date"": ""2023-06-28"", ""headline"": ""INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm"", ""summary"": ""The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (\u201cRegeneron\u201d or \u201cthe Company\u201d) (NASDAQ: REGN) for violations o...""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 2.24% to $700.03 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-06-28"", ""headline"": ""Catalent Is Linked to Regeneron\u2019s Eye-Drug Rejection in Latest Misstep"", ""summary"": ""(Bloomberg) -- Problems at a Catalent Inc. production facility led US regulators to deny a key drug application from Regeneron Pharmaceuticals Inc., the latest headache for one of the main manufacturing partners to the drug industry. Most Read from BloombergPutin Claims He\u2019s Back in Control. Russia\u2019s Elite Isn\u2019t SureUBS Preparing to Cut Over Half of Credit Suisse WorkforceQatar Group Now Confident of Winning Manchester United RaceBiden Can Cancel Student Debt Even If Supreme Court Blocks Order,""}, {""date"": ""2023-06-28"", ""headline"": ""Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).""}, {""date"": ""2023-06-28"", ""headline"": ""Three-Stock Lunch: REGN, PINS & GNRC"", ""summary"": ""Lee Munson, Portfolio Wealth Advisors president and CIO, joins 'Power Lunch' to discuss three stocks: Regeneron, Pinterest and Generac Holdings.""}, {""date"": ""2023-06-28"", ""headline"": ""General Mills, Nvidia fall; AeroVironment, Circor rise, Wednesday, 6/28/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year total shareholder returns outpace the underlying earnings growth"", ""summary"": ""While Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders are probably generally happy, the stock hasn't had...""}, {""date"": ""2023-06-28"", ""headline"": ""Catalent confirms being Regeneron's Eylea 8 mg third party filler, says Stephens"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall"", ""summary"": ""Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.""}, {""date"": ""2023-06-28"", ""headline"": ""Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Catalent confirmed as manufacturer of Regeneron\u2019s high-dose Eylea rejected by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Catalent says FDA made three observations in Eylea inspection, Bloomberg reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Uber downgraded, Pinterest upgraded: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Check Out What Whales Are Doing With REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""SVB Securities Sticks to Its Buy Rating for Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron price target lowered to $1,045 from $1,050 at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron cut to Neutral at Cannacord on FDA snub for high-dose Eylea"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Radnet (RDNT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""GLOBAL BROKER RATINGS: Exane raises BHP Group; HSBC likes Prosus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron price target lowered to $789 from $816 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""BMO Capital Sticks to Its Buy Rating for Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron price target lowered to $760 from $800 at Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron price target lowered to $875 from $915 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron price target lowered to $888 from $915 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Regeneron downgraded to Hold from Buy at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""These Stocks Are Moving the Most Today: Nvidia, Micron, Joby Aviation, Carnival, and More"", ""summary"": ""Nvidia slumps after a report says the U.S. is considering new restrictions on exports of AI chips to China, and Joby Aviation surges after getting a special...""}, {""date"": ""2023-06-28"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Paycor HCM (PYCR), Regeneron (REGN) and Pharvaris (PHVS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Paycor HCM (PYCR), Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023"", ""summary"": ""TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the \u2019Investors and Media\u2019 page of Regeneron\u2019s webs""}, {""date"": ""2023-06-29"", ""headline"": ""Why Regeneron Pharmaceuticals Stock Dipped This Week"", ""summary"": ""Shares of biotech heavyweight Regeneron Pharmaceuticals (NASDAQ: REGN) lost 10% of their value over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence.  The double-digit decline came after the company announced that the Food and Drug Administration (FDA) issued a Complete Response Letter (i.e., a rejection) for its high-dose formulation of Eylea.  Eylea, a biologic therapy for various eye disorders like wet age-related macular degeneration (wet AMD), generated approximately $6.3 billion in net U.S. sales for the drugmaker in 2022.""}, {""date"": ""2023-06-29"", ""headline"": ""Canaccord Genuity Downgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-06-29"", ""headline"": ""RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-06-29"", ""headline"": ""Baird Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation"", ""summary"": """"}, {""date"": ""2023-06-29"", ""headline"": ""Truist Securities Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-06-29"", ""headline"": ""Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-06-29"", ""headline"": ""Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL"", ""summary"": ""Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.""}, {""date"": ""2023-06-29"", ""headline"": ""INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm"", ""summary"": ""The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (\u201cRegeneron\u201d or \u201cthe Company\u201d) (NASDAQ: REGN) for violations o...""}, {""date"": ""2023-06-29"", ""headline"": ""The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks"", ""summary"": ""Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.""}, {""date"": ""2023-06-29"", ""headline"": ""Thursday\u2019s Top Analyst Upgrades and Downgrades: Amazon, Bristol-Myers Squibb, Deere, GoDaddy, Pinterest, Salesforce, Uber, Vale, Walgreens and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.43% to $718.54 Friday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-07-01"", ""headline"": ""Wall Street Breakfast: What Moved Markets"", ""summary"": ""Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.""}]","{""assetTurnoverTTM"": 0.4309, ""bookValue"": 24018, ""cashRatio"": 0.6240335051546392, ""currentRatio"": 5.452, ""ebitPerShare"": 8.9245, ""eps"": 8.5022, ""ev"": 79596.2, ""fcfMargin"": 0.2813, ""fcfPerShareTTM"": 27.5624, ""grossMargin"": 0.8718, ""inventoryTurnoverTTM"": 0.7281, ""longtermDebtTotalAsset"": 0.0646, ""longtermDebtTotalCapital"": 0.0742, ""longtermDebtTotalEquity"": 0.0825, ""netDebtToTotalCapital"": 0.0286, ""netDebtToTotalEquity"": 0.0319, ""netMargin"": 0.3066, ""operatingMargin"": 0.3219, ""pb"": 3.2822, ""peTTM"": 18.3371, ""pfcfTTM"": 22.8848, ""pretaxMargin"": 0.3429, ""psTTM"": 6.2215, ""ptbv"": 3.4178, ""quickRatio"": 4.5277, ""receivablesTurnoverTTM"": 2.4647, ""roaTTM"": 0.1462, ""roeTTM"": 0.1877, ""roicTTM"": 0.1679, ""rotcTTM"": 0.1692, ""salesPerShare"": 27.727, ""sgaToSale"": 0.1282, ""tangibleBookValue"": 23065, ""totalDebtToEquity"": 0.1125, ""totalDebtToTotalAsset"": 0.0881, ""totalDebtToTotalCapital"": 0.1011, ""totalRatio"": 4.6172, ""period"": ""2023-06-30""}"
25,2023-07-02,718.5399780273438,2023-07-09,692.4500122070312,-0.0363096927354537,D4,"[{""date"": ""2023-07-02"", ""headline"": ""Check Out What Whales Are Doing With REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""Looking Into Regeneron Pharmaceuticals's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""Biotech Blues: Stay Balanced Through July Earnings Season"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Regeneron (REGN) and Blueprint Medicines (BPMC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""The 3 Best Biotech Stocks to Buy In July"", ""summary"": ""Although it\u2019s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B""}, {""date"": ""2023-07-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.04% to $717.83 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-07-05"", ""headline"": ""Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?"", ""summary"": ""Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.""}, {""date"": ""2023-07-05"", ""headline"": ""Regeneron gets FDA orphan drug designation for cemdisiran"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation"", ""summary"": """"}, {""date"": ""2023-07-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.81% to $704.83 Thursday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-07-06"", ""headline"": ""Is Regeneron's Stock in Trouble After This FDA Rejection?"", ""summary"": ""The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue.""}, {""date"": ""2023-07-06"", ""headline"": ""Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""INVESTIGATION ALERT : The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ"", ""summary"": ""NEW YORK, July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:\nThe investigation focuses on whether the Company issued...""}, {""date"": ""2023-07-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.76% to $692.45 Friday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-07-07"", ""headline"": ""Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-07"", ""headline"": ""Is Regeneron Stock a Buy After a Regulatory Blow?"", ""summary"": ""Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year.  Regeneron suffered this blow following a regulatory obstacle, as is often the case in the biotech industry (more on that below).  Do these developments represent an excellent opportunity to buy Regeneron's shares on the dip?""}, {""date"": ""2023-07-07"", ""headline"": ""4D Molecular Therapeutics: A Complicated Story"", ""summary"": ""Shares of 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. Read more about FDMT stock here.""}, {""date"": ""2023-07-07"", ""headline"": ""REGN FRAUD ALERT : Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws"", ""summary"": ""NEW YORK, July 7, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron...""}, {""date"": ""2023-07-07"", ""headline"": ""Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check"", ""summary"": ""Regeneron's stock price has suffered a setback due to concerns over the future of Eylea, its flagship drug, as competition and potential drug pricing regulations loom. Read more here.""}, {""date"": ""2023-07-08"", ""headline"": ""26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold"", ""summary"": ""Looking at Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) insider transactions over the last year, we can see that...""}]","{""assetTurnoverTTM"": 0.4309, ""bookValue"": 24018, ""cashRatio"": 0.6240335051546392, ""currentRatio"": 5.452, ""ebitPerShare"": 8.9245, ""eps"": 8.5022, ""ev"": 79596.2, ""fcfMargin"": 0.2813, ""fcfPerShareTTM"": 27.5624, ""grossMargin"": 0.8718, ""inventoryTurnoverTTM"": 0.7281, ""longtermDebtTotalAsset"": 0.0646, ""longtermDebtTotalCapital"": 0.0742, ""longtermDebtTotalEquity"": 0.0825, ""netDebtToTotalCapital"": 0.0286, ""netDebtToTotalEquity"": 0.0319, ""netMargin"": 0.3066, ""operatingMargin"": 0.3219, ""pb"": 3.2822, ""peTTM"": 18.3371, ""pfcfTTM"": 22.8848, ""pretaxMargin"": 0.3429, ""psTTM"": 6.2215, ""ptbv"": 3.4178, ""quickRatio"": 4.5277, ""receivablesTurnoverTTM"": 2.4647, ""roaTTM"": 0.1462, ""roeTTM"": 0.1877, ""roicTTM"": 0.1679, ""rotcTTM"": 0.1692, ""salesPerShare"": 27.727, ""sgaToSale"": 0.1282, ""tangibleBookValue"": 23065, ""totalDebtToEquity"": 0.1125, ""totalDebtToTotalAsset"": 0.0881, ""totalDebtToTotalCapital"": 0.1011, ""totalRatio"": 4.6172, ""period"": ""2023-06-30""}"
26,2023-07-09,692.4500122070312,2023-07-16,718.52001953125,0.03764893763396193,U4,"[{""date"": ""2023-07-10"", ""headline"": ""$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.58% to $703.36 Monday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-07-10"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Pacira Pharmaceuticals (PCRX), Regeneron (REGN) and Thermo Fisher (TMO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""REGN ALERT : The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws"", ""summary"": ""NEW YORK, July 10, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc.   shareholders:\nThe Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and...""}, {""date"": ""2023-07-11"", ""headline"": ""Why These 7 Stocks Are the Best Ways to Play Biotech Right Now"", ""summary"": ""Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors. You must conduct your own due diligence. However, as a narrative, the biotechnology industry stands at the forefront of humanitarian innovation. The space has never been more important than it is right now. From the strictly financial view of investing in biotech stocks, the underlyi""}, {""date"": ""2023-07-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.92% to $716.83 Tuesday, on what proved to be an all-around great trading session for the stock market,...""}, {""date"": ""2023-07-11"", ""headline"": ""Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-07-11"", ""headline"": ""Regeneron 483 issues might not require reinspection, says Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""REGN NEWS : The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc."", ""summary"": ""NEW YORK, July 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Regeneron Pharmaceuticals, Inc.   violated federal securities laws.\nCURRENT...""}, {""date"": ""2023-07-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.22% higher to $718.42 Wednesday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-07-12"", ""headline"": ""Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"", ""summary"": ""NEW YORK, July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of\u00a0Regeneron Pharmaceuticals, Inc.\u00a0\u00a0. Such investors are advised to contact Robert S....""}, {""date"": ""2023-07-12"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 33% Discount?"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$1,073...""}, {""date"": ""2023-07-12"", ""headline"": ""INVESTIGATION ALERT : The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ"", ""summary"": ""NEW YORK, July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:\nThe investigation focuses on whether the Company issued...""}, {""date"": ""2023-07-13"", ""headline"": ""3 Pharma Stocks That AI is Loving in July"", ""summary"": ""When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes. And in 2023, many companies are closer than ever to a solution. So, although I know that\u2019s not how it works, it was interesting that when ChatGPT gave me a list of pharmaceutical stocks, it included several which have partnerships with gene editing companies. It\u2019s importan""}, {""date"": ""2023-07-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.36% higher to $720.98 Thursday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-07-13"", ""headline"": ""How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}, {""date"": ""2023-07-13"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""REGN Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc."", ""summary"": ""NEW YORK, July 13, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc.   concerning possible violations of federal...""}, {""date"": ""2023-07-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.34% to $718.52 Friday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-07-14"", ""headline"": ""Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""2023-07-14"", ""headline"": ""REGN FRAUD ALERT : Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws"", ""summary"": ""NEW YORK, July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron...""}, {""date"": ""2023-07-15"", ""headline"": ""Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""Eli Lilly, Merck among top pharma picks in Barclays Q2 preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4309, ""bookValue"": 24018, ""cashRatio"": 0.6240335051546392, ""currentRatio"": 5.452, ""ebitPerShare"": 8.9245, ""eps"": 8.5022, ""ev"": 79596.2, ""fcfMargin"": 0.2813, ""fcfPerShareTTM"": 27.5624, ""grossMargin"": 0.8718, ""inventoryTurnoverTTM"": 0.7281, ""longtermDebtTotalAsset"": 0.0646, ""longtermDebtTotalCapital"": 0.0742, ""longtermDebtTotalEquity"": 0.0825, ""netDebtToTotalCapital"": 0.0286, ""netDebtToTotalEquity"": 0.0319, ""netMargin"": 0.3066, ""operatingMargin"": 0.3219, ""pb"": 3.2822, ""peTTM"": 18.3371, ""pfcfTTM"": 22.8848, ""pretaxMargin"": 0.3429, ""psTTM"": 6.2215, ""ptbv"": 3.4178, ""quickRatio"": 4.5277, ""receivablesTurnoverTTM"": 2.4647, ""roaTTM"": 0.1462, ""roeTTM"": 0.1877, ""roicTTM"": 0.1679, ""rotcTTM"": 0.1692, ""salesPerShare"": 27.727, ""sgaToSale"": 0.1282, ""tangibleBookValue"": 23065, ""totalDebtToEquity"": 0.1125, ""totalDebtToTotalAsset"": 0.0881, ""totalDebtToTotalCapital"": 0.1011, ""totalRatio"": 4.6172, ""period"": ""2023-06-30""}"
27,2023-07-16,718.52001953125,2023-07-23,734.6300048828125,0.02242106679514988,U3,"[{""date"": ""2023-07-16"", ""headline"": ""This Is What Whales Are Betting On Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""Eli Lilly, Merck among top pharma picks in Barclays Q2 preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.43% higher to $721.61 Monday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-07-17"", ""headline"": ""Regeneron price target lowered to $900 from $935 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""REGN ALERT : The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws"", ""summary"": ""NEW YORK, July 17, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc.   shareholders:\nThe Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and...""}, {""date"": ""2023-07-17"", ""headline"": ""Alnylam announces updated interim results from ALN-APP study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?"", ""summary"": ""Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...""}, {""date"": ""2023-07-18"", ""headline"": ""Regeneron price target lowered to $960 from $1,040 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-07-19"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-22"", ""headline"": ""Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?"", ""summary"": ""It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...""}]",{}
28,2023-07-23,734.6300048828125,2023-07-30,746.0999755859375,0.01561326195076207,U2,"[{""date"": ""2023-07-23"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-23"", ""headline"": ""Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape"", ""summary"": ""Kodiak Sciences shows improved financial performance in Q1 2023, and it's developing treatments for prevalent retinal diseases. See why KOD stock is a Hold.""}, {""date"": ""2023-07-24"", ""headline"": ""Kodiak Sciences Plumb New Lows After Tarcocimab Failure >KOD"", ""summary"": ""By Colin Kellaher Kodiak Sciences shares lost more than half of their value and hit a new all-time low Monday after the biopharmaceutical company said it was...""}, {""date"": ""2023-07-24"", ""headline"": ""Kodiak drops eye disease candidate after Phase 3 setback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Weight loss drugs excluded from WHO\u2019s 'essential' medicines list"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $729.88 Tuesday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-07-26"", ""headline"": ""Intellia Therapeutics: The Future Is Here"", ""summary"": ""Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. Read why NTLA stock is a Buy.""}, {""date"": ""2023-07-26"", ""headline"": ""If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names"", ""summary"": ""The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns. In this article, I\u2019m going to introduce you to three companies that are making waves in this field and are pioneering stocks in biotech. They are making a difference and deserve to be on your radar! Best Biotech Stocks: Regeneron (REGN) Sou""}, {""date"": ""2023-07-26"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.15% higher to $730.96 Wednesday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-07-26"", ""headline"": ""Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.87% to $744.66 Thursday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-07-27"", ""headline"": ""Kiniksa Pharmaceuticals: Arcalyst's Growth Picks Up"", ""summary"": ""Kiniksa delivered excellent Q2 results that put it in an even better position to deliver long-term growth. Read why I'm bullish on KNSA stock.""}, {""date"": ""2023-07-27"", ""headline"": ""Roche's 1H Earnings Decline On Lower COVID-19 Sales, CFO Says Late-Stage Pipeline Has Gaps That Needs To Be Filled"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.19% higher to $746.10 Friday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-07-28"", ""headline"": ""Regeneron (REGN) to Report Q2 Earnings: What's in Store?"", ""summary"": ""Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.""}, {""date"": ""2023-07-28"", ""headline"": ""Those who invested in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago are up 88%"", ""summary"": ""Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...""}, {""date"": ""2023-07-28"", ""headline"": ""P/E Ratio Insights for Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""BMO Capital Remains a Buy on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), HCA Healthcare (HCA) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-29"", ""headline"": ""Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS"", ""summary"": ""89% and 84% of patients were maintained on \u226512- and \u226516-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements At two years, 44% of patients met the criteria for \u226520-week dosing intervals, including 27% who were eligible for 24-week dosing intervals TARRYTOWN, N.Y., July 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results fro""}, {""date"": ""2023-07-30"", ""headline"": ""Regeneron presents aflibercept 8 mg two-year results from pivotal PHOTON trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
29,2023-07-30,746.0999755859375,2023-08-06,766.4400024414062,0.027261798044551755,U3,"[{""date"": ""2023-07-30"", ""headline"": ""Regeneron presents aflibercept 8 mg two-year results from pivotal PHOTON trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.56% to $741.91 Monday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-07-31"", ""headline"": ""REGENERON PHARMACEUTICALS, INC. - AFLIBERCEPT 8 MG TWO-YEAR RESULTS FROM PIVOTAL PHOTON TRIAL IN DIABETIC MACULAR EDEMA PRESENTED AT ASRS"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc.  today announced the first presentation of positive two-year  results from the pivotal PHOTON trial investigating aflibercept 8 mg with 12- and 16-week...""}, {""date"": ""2023-07-31"", ""headline"": ""Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points"", ""summary"": ""The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo""}, {""date"": ""2023-08-01"", ""headline"": ""If You Invested $1000 In This Stock 20 Years Ago, You Would Have $58,000 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation"", ""summary"": ""TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research. Each year, Regeneron invites the nation\u2019s top research universities to nominate up-and-coming postdoctoral fellows and graduate students to pitch their \""dream projects\"" within the field of biomedical science. Applicants out""}, {""date"": ""2023-08-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""GLOBAL BRIEFING: China's services see strong growth in July"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""NEW YORK MARKET CLOSE: Fitch downgrade sparks retreat on Wall Street"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Regeneron Pharmaceuticals Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Regeneron Pharmaceuticals Q2 2023 Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Regeneron (REGN) and Addus Homecare (ADUS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening"", ""summary"": ""Regeneron's shares decline as the company faces market delay for Eylea, allowing Roche's Vabysmo to gain ground. Click here to read my analysis of REGN stock.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Zimmer Biomet Holdings (ZBH) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""S&P 500 Gains and Losses Today: Stocks Fall After Weaker-Than-Expected Earnings Reports"", ""summary"": ""The S&P 500 fell 0.3% on Thursday, Aug. 3, 2023 after weaker-than-expected earnings reports from ecommerce, travel, and chip companies weighed on the index.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon"", ""summary"": ""Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration.""}, {""date"": ""2023-08-03"", ""headline"": ""The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line"", ""summary"": ""Regeneron guided to a faster-than-expected approval timeline for a high dose of its eye drug Eylea on Thursday, and REGN stock jumped.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline"", ""summary"": ""Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.""}, {""date"": ""2023-08-03"", ""headline"": ""Is Regeneron Pharmaceuticals (REGN) Modestly Overvalued?"", ""summary"": ""Regeneron Pharmaceuticals Inc (NASDAQ:REGN) witnessed a 6.4% gain, with an Earnings Per Share (EPS) of 36.8.  This article provides a comprehensive valuation analysis of Regeneron Pharmaceuticals (NASDAQ:REGN).  Regeneron Pharmaceuticals discovers, develops, and commercializes products that combat eye disease, cardiovascular disease, cancer, and inflammation.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say"", ""summary"": ""Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. (REGN) Q2 2023 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor RelationsLeonard...""}, {""date"": ""2023-08-03"", ""headline"": ""Replimmune down 8% on skin cancer cancer candidate data delay"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates"", ""summary"": ""Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron expects FDA decision on higher-dose Eylea this year"", ""summary"": ""(Reuters) -Regeneron Pharmaceuticals expects a U.S. decision on a higher-dose version of its blockbuster eye disease drug Eylea in the third quarter, much earlier than market expectations, sending its shares up 5% on Thursday.  The U.S. Food and Drug Administration declined to approve the higher-dose version in June following an inspection at third-party manufacturer Catalent.  Regeneron said it has been submitting manufacturing data required by the FDA on a rolling basis, and expects to finish the submissions by mid-August.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Reports Second Quarter 2023 Financial and Operating Results"", ""summary"": ""Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022Second quarter 2023 Dupixent\u00ae global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022Second quarter 2023 EYLEA\u00ae U.S. net sales were $1.50 billionSecond quarter 2023 GAAP diluted EPS of $8.50 and non-GAAP diluted EPS(a) of $10.24Two-year results reported for aflibercept 8 mg from pivotal PHOTON trial demonstrated durable vision gains at extended dosing intervals in diabeti""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharmaceuticals : August 2023 Corporate Presentation"", ""summary"": ""Regeneron Corporate Presentation\n        \n      \n      \n        \n          A u g u s t 2 0 2 3\n        \n      \n      \n        \n          This non-promotional presentation...""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron\u2019s stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported...""}, {""date"": ""2023-08-03"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharmaceuticals quarterly profit boosted by Dupixent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron gains after Q2 beat; FDA action on high-dose Eylea expected in Q3"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharma beats quarterly profit estimates"", ""summary"": ""Regeneron Pharmaceuticals Inc\nbeat Wall Street estimates for quarterly profit on Thursday,\ndriven by strong demand for eczema treatment Dupixent.\n              The company reported adjusted profit of...""}, {""date"": ""2023-08-03"", ""headline"": ""Earnings Scheduled For August 3, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Humana (HUM) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Regeneron reports Q2 adjusted EPS $10.24, consensus $9.84"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript August 3, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.24, expectations were $9.92. Operator: Welcome to the Regeneron Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Shannon and I will be your operator for today\u2019s call. At this time, all participants [\u2026]""}, {""date"": ""2023-08-04"", ""headline"": ""Oppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""2023-08-04"", ""headline"": ""(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Regeneron halts enrollment in prostate cancer trial following two deaths"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""BMO Capital Gives a Buy Rating to Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""Regeneron price target raised to $950 from $900 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-05"", ""headline"": ""Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-08-05"", ""headline"": ""RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-08-06"", ""headline"": ""2 Top Stocks to Buy in August and Hold Forever"", ""summary"": ""Technological progress sometimes renders products or entire industries completely obsolete.  With that said, let's look at two healthcare stocks with solid track records of innovation and are worth buying and holding onto for good: Regeneron (NASDAQ: REGN) and Abbott Laboratories (NYSE: ABT).  Biotech giant Regeneron has outperformed the market over the past year, partly thanks to the company's excellent financial results and prospects.""}]",{}
30,2023-08-06,766.4400024414062,2023-08-13,806.9500122070312,0.052854769631784704,U5+,"[{""date"": ""2023-08-06"", ""headline"": ""2 Top Stocks to Buy in August and Hold Forever"", ""summary"": ""Technological progress sometimes renders products or entire industries completely obsolete.  With that said, let's look at two healthcare stocks with solid track records of innovation and are worth buying and holding onto for good: Regeneron (NASDAQ: REGN) and Abbott Laboratories (NYSE: ABT).  Biotech giant Regeneron has outperformed the market over the past year, partly thanks to the company's excellent financial results and prospects.""}, {""date"": ""2023-08-07"", ""headline"": ""3 AI Stocks You\u2019ll Regret Not Buying Soon"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-08-07"", ""headline"": ""GLOBAL BROKER RATINGS: Stifel likes ConvaTec; JPMorgan ups Rolls-Royce"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Cantor biotech/biopharma analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Stryker (SYK) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron to buy Boston-based hearing loss biotech for $213M"", ""summary"": ""The Tarrytown, New York-based drugmaker has its sights set on Decibel Therapeutics, which develops gene therapies designed to treat various forms of hearing loss.""}, {""date"": ""2023-08-09"", ""headline"": ""Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals"", ""summary"": ""Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"", ""summary"": ""Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel\u2019s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biot""}, {""date"": ""2023-08-09"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Decibel Therapeutics Shares Surge on Regeneron Acquisition"", ""summary"": ""By Dean Seal Shares of Decibel Therapeutics were markedly higher after the company signed a deal to be acquired by Regeneron Pharmaceuticals at a 43% premium...""}, {""date"": ""2023-08-09"", ""headline"": ""Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron to acquire Decibel Therapeutics for USD109 million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Decibel Therapeutics stock rallies as Regeneron moves to buy the biotech company"", ""summary"": ""Decibel Therapeutics Inc. stock was up 85% in premarket trades on Wednesday after Regeneron Pharmaceuticals Inc. said it would pay $4 a share for the...""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron To Acquire Decibel Therapeutics"", ""summary"": ""By Dean Seal Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% premium from yesterday's closing price. The...""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron to acquire gene therapy developer Decibel for $4 per share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron buying small cap Decibel Therapeutics for $4 a share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Regeneron to acquire Decibel Therapeutics for $4.00 per share plus CVR"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""The 7 Best Value Stocks to Buy in August"", ""summary"": ""While several market ideas have blossomed this year, many are overpriced, which naturally draws eyes to the best value stocks to buy. Here, we\u2019re talking about publicly traded securities that trade at a lower price relative to fundamental metrics, most commonly sales or earnings. Obviously, value investing opportunities entice market participants due to their underlying discount. As humans, we\u2019re geared to respond positively toward bargain offers. Essentially, by targeting must-buy value stocks,""}, {""date"": ""2023-08-10"", ""headline"": ""Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies"", ""summary"": ""Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.""}, {""date"": ""2023-08-10"", ""headline"": ""IN BRIEF: Regeneron reports positive trial results for aflibercept"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Baird downgrades Decibel to neutral to reflect Regeneron takeover"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Bayer: eye drug shows vision gains in 70% of patients at higher dose"", ""summary"": ""Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron, has been shown to achieve vision gains in more than 70% of patients when given at a higher dose at a longer interval between injections.  Eylea, which is normally given in doses of 2 milligrams every eight weeks, was given at 8 mg at intervals of up to 24 weeks, resulting in vision gains in more than 70% patients with wet age-related macular degeneration, the company said.""}, {""date"": ""2023-08-10"", ""headline"": ""Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration"", ""summary"": ""88% of all aflibercept 8 mg patients were on a \u226512-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained \u226512-week dosing intervals throughout the two-year study period 71% met the extension criteria for even longer dosing intervals, including 47% for \u226520-week intervals and 28% for 24-week intervals Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA\u00ae (aflibercept) 2 mg Injection TARRYTOWN, N.Y., Aug. 10, 202""}, {""date"": ""2023-08-10"", ""headline"": ""This Is What Whales Are Betting On Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""3 Top Biotech Stocks Defying the Bear Market"", ""summary"": ""If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming.  The iShares Biotechnology ETF is down more than 3% so far in 2023, and the SPDR S&P Biotech EFT is down more than 5%.  The two ETFs reflect negative market sentiment toward biotech stocks, in general, this year.""}, {""date"": ""2023-08-10"", ""headline"": ""Regeneron announces PULSAR trial met its primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News"", ""summary"": ""Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.""}, {""date"": ""2023-08-11"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Alcon (ALC) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-12"", ""headline"": ""Pharma under threat from bill to expand drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-12"", ""headline"": ""4 big deal reports: Michael Kors parent rockets on huge buyout deal with Tapestry"", ""summary"": ""Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: Deals at Capri-Tapestry, Decibel-Regeneron, Amazon in talks to potentially anchor Arm's IPO, and  Digital World Acquisition  and Trump Media & Technology Group reaffirm commitment to the merger.  Capri (NYSE:CPRI) shares rocketed more than 55% on Thursday after Tapestry (NYSE:TPR) said it agreed to buy Capri, the parent company of Michael Kors, for $57 per share in cash, as reported in real time on InvestingPro.""}]",{}
31,2023-08-13,806.9500122070312,2023-08-20,812.4000244140625,0.006753841160650476,U1,"[{""date"": ""2023-08-12"", ""headline"": ""Pharma under threat from bill to expand drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Regeneron could see share price bounce with potential approvals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""This Is What Whales Are Betting On Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Second Half Outlook For Biotech Stocks"", ""summary"": ""Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts.""}, {""date"": ""2023-08-15"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""18 Analysts Have This to Say About Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-08-16"", ""headline"": ""Cantor biotech/biopharma analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Catalyst watch: Nvidia earnings, Twilio event, AMC drama and Jackson Hole jitters"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""RBC says Regeneron news intimates high-dose Eylea approval likely"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Regeneron wins approval for rare immune disease therapy pozelimab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 73% Above Its Share Price"", ""summary"": ""Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,376 based on 2 Stage Free Cash Flow to Equity...""}, {""date"": ""2023-08-17"", ""headline"": ""Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma"", ""summary"": ""TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for""}, {""date"": ""2023-08-17"", ""headline"": ""Bronte Capital Amalthea Fund June 2023 Letter"", ""summary"": ""The Amalthea fund shed 1.35% in June whereas the globally diverse MSCI ACWI (in $A) was up 2.57%. For the financial year the fund gained 14.75%, outpaced by the ACWI\u00e2\u0080\u0099s 20.78%.""}, {""date"": ""2023-08-17"", ""headline"": ""EMA accepts Regeneron's filing for odronextamab for lymphoma form"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Regeneron lymphoma therapy accepted for EU review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Thursday\u2019s Top Wall Street Analyst Upgrades and Downgrades: Chevron, GE Healthcare, Keurig Dr Pepper, News Corp, Visa and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Regeneron receives EMA filing acceptance for treatment of R/R FL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""With two approvals in one day, Regeneron could be headed higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Hold Recommendation"", ""summary"": """"}, {""date"": ""2023-08-18"", ""headline"": ""UPDATE 2-US FDA approves higher dose of Regeneron's eye disease drug Eylea"", ""summary"": ""The U.S. Food and Drug Administration approved a higher dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is a leading cause of blindness among the elderly, the company said in a statement on Friday.  The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), Regeneron said.  Eylea, which is jointly developed with Bayer, is normally given in doses of 2 milligrams every eight weeks.""}, {""date"": ""2023-08-18"", ""headline"": ""Is Regeneron Pharmaceuticals Inc (REGN) Modestly Overvalued?"", ""summary"": ""A Comprehensive Analysis of Regeneron Pharmaceuticals' Valuation""}, {""date"": ""2023-08-18"", ""headline"": ""EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)"", ""summary"": ""Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA\u00ae HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and DME for immediate dosing at 8-week and up to 16-week intervals following three initial monthly doses TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administ""}, {""date"": ""2023-08-18"", ""headline"": ""US FDA approves higher dose of Regeneron's eye disease drug Eylea"", ""summary"": ""The U.S. Food and Drug Administrationapproved a higher dose version of Regeneron Pharmaceuticals'drug Eylea for treatment of a disease that is a leadingcause of blindness among the elderly, the...""}, {""date"": ""2023-08-18"", ""headline"": ""US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea"", ""summary"": ""The U.S. Food and Drug Administrationapproved the 8-mg dose of Regeneron Pharmaceuticals'eye disease drug Eylea, the company said in a statement onFriday.(Reporting by Jahnavi Nidumolu in...""}, {""date"": ""2023-08-18"", ""headline"": ""Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment"", ""summary"": ""By Will Feuer Regeneron Pharmaceuticals said the Food and Drug Administration has approved an eight-milligram injection of its Eylea treatment for various...""}, {""date"": ""2023-08-18"", ""headline"": ""UPDATE 2-US FDA approves Regeneron's ultra-rare blood disease drug"", ""summary"": ""Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease.  The drug pozelimab, branded as Veopoz, has been approved to treat adult and pediatric patients 1 year of age and older suffering from the CHAPLE disease.  Veopoz \u2014 the first treatment to be approved by the U.S. Food and Drug Administration (FDA) for the life-threatening disease \u2014 will be sold in the United States at a list price of $34,615.38 per single-use vial, the company told Reuters in an emailed response.""}, {""date"": ""2023-08-18"", ""headline"": ""Veopoz\u2122 (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease"", ""summary"": ""CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by Regeneron With the approval of Veopoz, the pre-approval inspection issues related to the aflibercept 8 mg biologics license application (BLA) have been addressed FDA action on the aflibercept 8 mg BLA is expected in the next few weeks TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutica""}, {""date"": ""2023-08-18"", ""headline"": ""Regeneron's (REGN) Application for Blood Cancer Drug Accepted"", ""summary"": ""Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.""}, {""date"": ""2023-08-18"", ""headline"": ""Regeneron Pharmaceuticals' Veopoz Gets FDA Approval for Adults, Children"", ""summary"": ""By Denny Jacob Regeneron Pharmaceuticals said the Food and Drug Administration approved Veopoz to treat patients aged 1 year old and up who have CHAPLE disease. The biotechnology company...""}, {""date"": ""2023-08-18"", ""headline"": ""Regeneron gets FDA green light on first treatment for life-threatening immune disease"", ""summary"": ""Regeneron Pharmaceuticals Inc. said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and...""}, {""date"": ""2023-08-18"", ""headline"": ""US FDA approves Regeneron's ultra-rare blood disease drug"", ""summary"": ""The U.S. health regulator on Fridayapproved Regeneron Pharmaceuticals' drug to treat arare blood disease, the company said. The drug, Veopoz, is the first treatment to be approved...""}, {""date"": ""2023-08-18"", ""headline"": ""Regeneron announces FDA approval of Veopoz for Chaple disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""AARP, Public Citizen file briefs in Medicare drug price negotiations case"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""REGENERON PHARMACEUTICALS, INC. - ODRONEXTAMAB RECEIVES EMA FILING ACCEPTANCE FOR TREATMENT OF RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for odronextamab to treat adult...""}, {""date"": ""2023-08-18"", ""headline"": ""Regeneron high-dose Eylea gains FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-19"", ""headline"": ""Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade)"", ""summary"": ""Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. Read more about REGN stock here.""}]",{}
32,2023-08-20,812.4000244140625,2023-08-27,830.3499755859375,0.022094966312711906,U3,"[{""date"": ""2023-08-20"", ""headline"": ""Regeneron celebrates as Eylea HD and Veopoz gain FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-20"", ""headline"": ""Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Oppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""Wells Fargo Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""BMO Capital Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""Canaccord Genuity Upgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-08-21"", ""headline"": ""Canaccord ups Regeneron to buy, sees high-dose Eylea re-igniting sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron, J&J receive millions to develop new COVID therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron confirms $326M BARDA funding for Covid antibody therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron awarded $326M from U.S. for next-generation COVID antibody"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'"", ""summary"": ""Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 3.94% to $844.37 Monday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-08-21"", ""headline"": ""FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder"", ""summary"": ""The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE. CHAPLE is an ultra-rare and life-threatening hereditary immune disease driven by an overactivation of the complement system. In healthy individuals, the complement system is a mechanism for destroying micro""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron Hits The High End Of Its Buy Zone On The Approval That 'Could Not Come Soon Enough'"", ""summary"": ""Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron Pharmaceuticals Inc: A Deep Dive into Its Financial Metrics and Competitive Strengths"", ""summary"": ""Unpacking the Growth and Competitive Edges of Regeneron Pharmaceuticals Inc""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea"", ""summary"": ""Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.""}, {""date"": ""2023-08-21"", ""headline"": ""Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?"", ""summary"": ""On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Read more about MRK stock here.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron Stock-Price Targets Rise as FDA Approves Higher Dose of Eye Drug"", ""summary"": ""The Food and Drug Administration approved 8-milligram doses of Eylea, a treatment for wet age-related macular degeneration.""}, {""date"": ""2023-08-21"", ""headline"": ""Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Palo Alto, Earthstone Energy rise; Napco Security, Nikola fall, Monday, 8/21/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher"", ""summary"": ""\""I think it's going to be worth more,\"" Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment.""}, {""date"": ""2023-08-21"", ""headline"": ""Cramer\u2019s Stop Trading: Regeneron"", ""summary"": ""CNBC\u2019s Jim Cramer explains why he is keeping an eye on shares of Regeneron""}, {""date"": ""2023-08-21"", ""headline"": ""Is Regeneron Pharmaceuticals Modestly Overvalued?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Is Regeneron Pharmaceuticals Still a Top Growth Stock?"", ""summary"": ""Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence.  The biotech has partnered with Bayer to create a dominant eye-disease franchise, led by Eylea (aflibercept), the best-selling anti-VEGF drug in the market.  The biotech has also collaborated with Sanofi to develop cutting-edge therapies for cancer, inflammatory diseases, and lung disorders.""}, {""date"": ""2023-08-21"", ""headline"": ""REGENERON PHARMACEUTICALS, INC. - VEOPOZ RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has approved Veopoz for the treatment of adult and pediatric patients 1 year of age and older with...""}, {""date"": ""2023-08-21"", ""headline"": ""REGENERON PHARMACEUTICALS, INC. - EYLEA HD INJECTION 8 MG APPROVED BY FDA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION, DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA HD Injection 8 mg for the treatment of patients with wet age-related...""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron upgraded to Buy at Canaccord after high dose EYLEA approved"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron upgraded to Buy from Hold at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron shares climb after FDA approval of macular degeneration treatment"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had...""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron price target raised to $830 from $820 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron price target raised to $985 from $960 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron price target raised to $980 from $875 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Nemaura Medical (NMRD), Kineta (KA) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron price target raised to $1,050 from $950 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Palo Alto Networks shares surge after earnings, Tesla climbs and more stocks on the move"", ""summary"": ""Palo Alto Networks, Napco Security, Tesla and Jet.AI were among the biggest moving stocks on Monday.""}, {""date"": ""2023-08-21"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron price target raised to $925 from $900 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Regeneron announces FDA approval of Eylea HD for three indications"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Regeneron VP Stahl sells $9.8M in company shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""UPDATE 1-US govt awards $1.4 bln for development of new COVID therapies, vaccines"", ""summary"": ""The U.S. government said on Tuesday it had awarded $1.4 billion for the development of new therapies and vaccines against COVID-19, including a $326 million contract with Regeneron Pharmaceuticals for a next-generation antibody therapy for prevention of infections.  The funding to Regeneron is a part of a $5 billion initiative dubbed \""Project NextGen\"" by the U.S. Department of Health and Human Services (HHS).""}, {""date"": ""2023-08-22"", ""headline"": ""Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention"", ""summary"": ""Program is part of U.S. Government\u2019s \u2018Project NextGen\u2019 and provides partial funding for clinical development of a novel monoclonal antibody therapyTARRYTOWN, N.Y., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has entered into an agreement with Regeneron to support clinical development, clinical manufacturing and the regulatory licensure process of a next-generation COVID-19""}, {""date"": ""2023-08-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.44% to $840.63 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-08-22"", ""headline"": ""US govt awards $1.4 bln for development of new COVID therapies, vaccines"", ""summary"": ""The U.S. government said on Tuesdayit had awarded $1.4 billion for the development of new therapiesand vaccines against COVID-19, including a $326 million contractwith Regeneron Pharmaceuticals for...""}, {""date"": ""2023-08-22"", ""headline"": ""Regeneron Pharmaceuticals inks new Covid contract with BARDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Regeneron gets federal funding for next-generation COVID treatment"", ""summary"": ""Regeneron Pharmaceuticals Inc. said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development,...""}, {""date"": ""2023-08-22"", ""headline"": ""Regeneron enters $326 mln pact with US to develop new COVID therapy"", ""summary"": ""Regeneron Pharmaceuticals onTuesday said it had entered into a contract worth $326 millionwith a U.S. government agency for the development ofnext-generation antibody therapy for COVID-19...""}, {""date"": ""2023-08-22"", ""headline"": ""Peering Into Regeneron Pharmaceuticals's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing"", ""summary"": ""Apogee Therapeutics has the ability to capture large target market indications if it can ultimately achieve a specific outcome. Find out why APGE stock is a Hold.""}, {""date"": ""2023-08-22"", ""headline"": ""GLOBAL BROKER RATINGS: Metzler reinitiates SAP at 'buy'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Regeneron Announces Investor Conference Presentations"", ""summary"": ""TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: \u2022 2023 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 6, 2023 \u2022 Morgan Stanley 21st Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, September 11, 2023 The sessions may be accessed from the \""Investors & Media\"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of th""}, {""date"": ""2023-08-23"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.02% higher to $840.81 Wednesday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-08-23"", ""headline"": ""Health Care Roundup: Market Talk"", ""summary"": ""Find insight on Roche, Regeneron and Emergent BioSolutions in the latest Market Talks covering the Health Care sector.""}, {""date"": ""2023-08-23"", ""headline"": ""Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy"", ""summary"": ""Adverum is expecting two data readouts of Ixo-vec for the treatment of patients with Wet age-related macular degeneration in 2023. Read why ADVM is a strong buy.""}, {""date"": ""2023-08-23"", ""headline"": ""Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent"", ""summary"": ""On August 18, Samsung Bioepis Co., Ltd. , filed a petition for Inter Partes Review, IPR2023-01312, challenging the validity of claims 1-18 of U.S. Patent No. 10,464,992, assigned to Regeneron...""}, {""date"": ""2023-08-23"", ""headline"": ""Are Robust Financials Driving The Recent Rally In Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock?"", ""summary"": ""Most readers would already be aware that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased significantly by 14...""}, {""date"": ""2023-08-23"", ""headline"": ""GLOBAL BROKER RATINGS: Redburn cuts Adyen; Morgan Stanley lifts SocGen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Top 5 Health Care Stocks That May Fall Off A Cliff"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Check Out What Whales Are Doing With REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.14% to $831.21 Thursday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-08-24"", ""headline"": ""Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More"", ""summary"": ""Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.""}, {""date"": ""2023-08-24"", ""headline"": ""Agilent receives European IVDR certification for companion diagnostic assay"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""These Are the ONLY 7 Penny Stocks to Consider in August 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.10% to $830.35 Friday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-08-25"", ""headline"": ""Is Regeneron Stock a Buy Now?"", ""summary"": ""There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors.  The company could soon face biosimilar competition from one of its key growth drivers, Eylea, while it recently received an important regulatory approval from the U.S. Food and Drug Administration (FDA).  With that said, let's dig deeper into what's happening with Regeneron and figure out whether it is worth investing in the drugmaker.""}, {""date"": ""2023-08-25"", ""headline"": ""The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics"", ""summary"": ""Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-27"", ""headline"": ""Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly"", ""summary"": ""The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...""}]",{}
33,2023-08-27,830.3499755859375,2023-09-03,831.6300048828125,0.0015415539646059795,U1,"[{""date"": ""2023-08-27"", ""headline"": ""Regeneron treatment of myasthenia gravis granted FDA orphan status"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-27"", ""headline"": ""Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly"", ""summary"": ""The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...""}, {""date"": ""2023-08-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.07% higher to $830.89 Monday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-08-29"", ""headline"": ""Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.08% to $830.19 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-08-29"", ""headline"": ""Celularity enters Research Collaboration Services Agreement with Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Tuesday\u2019s Top Wall Street Analyst Upgrades and Downgrades: Boston Scientific, Ciena, CrowdStrike, Emerson Electric, Kimco Realty, Nike and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-30"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.57% higher to $834.95 Wednesday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-08-31"", ""headline"": ""Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD"", ""summary"": ""Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.""}, {""date"": ""2023-08-31"", ""headline"": ""It\u2019s Still Tech\u2019s Year. These Stocks Led the Market in August."", ""summary"": ""For much of Thursday, it looked drug stocks would be August's biggest gainers in the Dow, S&P 500 and Nasdaq 100, but tech firms took the top spots.""}, {""date"": ""2023-08-31"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.01% to $826.49 Thursday, on what proved to be an all-around rough trading session for the stock market, with...""}, {""date"": ""2023-09-01"", ""headline"": ""Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.62% higher to $831.63 Friday, on what proved to be an all-around positive trading session for the stock...""}]",{}
34,2023-09-03,831.6300048828125,2023-09-10,830.6900024414062,-0.0011303132834158403,D1,"[{""date"": ""2023-09-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.05% to $822.91 Tuesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-09-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.55% to $818.39 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-09-06"", ""headline"": ""12 Best Healthcare ETFs To Buy"", ""summary"": ""In this article, we discuss 12 best healthcare ETFs. If you want to skip our discussion on the healthcare market, head directly to 5 Best Healthcare ETFs To Buy. In December 2022, BlackRock highlighted concerns about the performance for the healthcare sector in 2023. The previous year was rather challenging for equity and fixed income [\u2026]""}, {""date"": ""2023-09-06"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2023 Wells Fargo Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) 2023 Wells Fargo Healthcare Conference Transcript September 6, 2023 8:45 AM ETExecutivesMarion McCourt - Head, CommercialRyan Crowe -...""}, {""date"": ""2023-09-07"", ""headline"": ""Regeneron CFO Robert Landry to retire, Christopher Fenimore to succeed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Check Out What Whales Are Doing With REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?"", ""summary"": ""Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""2023-09-08"", ""headline"": ""Regeneron Provides Update on Planned Chief Financial Officer Transition"", ""summary"": ""Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO roleTARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024. Christopher Fenimore, current Senior Vice President, Head of Accounting and Controller at Re""}, {""date"": ""2023-09-08"", ""headline"": ""Regeneron Announces Updates to Board of Directors"", ""summary"": ""Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron\u2019s Board of DirectorsTARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron\u2019s Board of Directors effective September 8, 2023. \u201cToday\u2019s announcement demonstrates our strong commitment to strategic refreshment of the Board, a focus on the recruitment of new directors to complement the overall""}, {""date"": ""2023-09-08"", ""headline"": ""Regeneron says CFO Landry to retire in February"", ""summary"": ""Regeneron Pharmaceuticals IncChief Financial Officer Robert Landry will retire inFebruary and will be succeeded by insider Christopher Fenimore,the company said on Friday. Fenimore...""}, {""date"": ""2023-09-08"", ""headline"": ""Regeneron Finance Chief Robert Landry to Retire"", ""summary"": ""By Ben Glickman Regeneron Pharmaceuticals said Friday that Financial Chief Robert Landry would retire in February. The Tarrytown, N.Y.-based pharmaceutical company said that Landry would...""}, {""date"": ""2023-09-08"", ""headline"": ""IN BRIEF: Regeneron CFO Robert Landry to retire in 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Regeneron CFO Landry to retire, top accountant Fenimore to become CFO"", ""summary"": ""Regeneron Pharmaceuticals Inc. said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma...""}, {""date"": ""2023-09-08"", ""headline"": ""U.S. health agency, Regeneron extend partnership to develop monoclonal antibodies"", ""summary"": ""The U.S. Department of Health andHuman Services said on Friday that it is extending its contractwith Regeneron Pharmaceuticals to develop monoclonalantibodies as part of a project to enhance...""}, {""date"": ""2023-09-08"", ""headline"": ""2 Top Biotech Stocks to Buy in September"", ""summary"": ""With that said, let's look at two biotech stocks to buy this month (or any month) that have excellent long-term prospects: Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals\u00a0(NASDAQ: REGN).  Vertex defied last year's bear market and has outperformed broader indexes over the trailing-12-month period thanks to solid financial results, a strong economic moat, and an exciting pipeline that should yield plenty of new approvals in the next five years.  Over the past five years, Vertex has continued to grow its revenue consistently, with practically no disruptions even during the early days of the pandemic.""}, {""date"": ""2023-09-08"", ""headline"": ""Regeneron CFO Robert Landry to retire"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-09"", ""headline"": ""3 Unstoppable Growth Stocks to Buy Right Now"", ""summary"": ""With this in mind, we asked three Motley Fool contributors to identify unstoppable growth stocks to buy right now.  Here's why they chose Eli Lilly (NYSE: LLY), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski\u00a0(Eli Lilly):\u00a0\u00a0If you're looking for a top growth stock to buy, it's hard to find one that's more promising right now than Eli Lilly.""}]",{}
35,2023-09-10,830.6900024414062,2023-09-17,823.4000244140625,-0.008775810477938184,D1,"[{""date"": ""2023-09-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 9:20 AM ETCompany ParticipantsRyan Crowe - VP, IRMarion...""}, {""date"": ""2023-09-11"", ""headline"": ""AI Integration In Biotech & Pharma: Companies Positioned To Benefit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""REGENERON ANNOUNCES UPDATES TO BOARD OF DIRECTORS"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron's Board of Directors effective September 8,...""}, {""date"": ""2023-09-11"", ""headline"": ""REGENERON PROVIDES UPDATE ON PLANNED CHIEF FINANCIAL OFFICER TRANSITION"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February...""}, {""date"": ""2023-09-11"", ""headline"": ""Morgan Stanley says it\u2019s a lonely bull, recommending government bonds"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Notable Friday Option Activity: REGN, CVX, FIVN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Peering Into Regeneron Pharmaceuticals's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""White House imposes price limits on Covid drug in Regeneron deal, STATNews says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""Argus Research Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-09-15"", ""headline"": ""Decibel Therapeutics' CVR Appears Around Fair Value"", ""summary"": ""Regeneron acquires Decibel Therapeutics for $4/share and a CVR linked to their promising gene therapy for hearing loss, DB-OTO. Read why I rate DBTX stock a Hold.""}, {""date"": ""2023-09-15"", ""headline"": ""WestPark Capital Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation"", ""summary"": """"}, {""date"": ""2023-09-15"", ""headline"": ""Shake Shack upgraded, DoorDash downgraded: Wall Street's top analyst calls"", ""summary"": ""Shake Shack upgraded, DoorDash downgraded: Wall Street's top analyst calls""}, {""date"": ""2023-09-15"", ""headline"": ""Regeneron\u2019s pricing deal with federal government may have \u2018far-reaching consequences,\u2019 analysts say"", ""summary"": ""Regeneron Pharmaceuticals Inc.\u2019s agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a...""}, {""date"": ""2023-09-15"", ""headline"": ""Regeneron price target raised to $920 from $825 at Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""Regeneron initiated with a Hold at WestPark Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
36,2023-09-17,823.4000244140625,2023-09-24,824.8400268554688,0.0017488491604442657,U1,"[{""date"": ""2023-09-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""3 Stocks to Buy to Ride Europe\u2019s Coming Market Surge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare"", ""summary"": ""Regeneron Pharmaceuticals Q2 2023 revenue exceeded expectations despite competition and falling Eylea sales. Click here to read an analysis on REGN stock now.""}, {""date"": ""2023-09-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost"", ""summary"": ""Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years.  From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last year.  There have been concerns, however, that its growth rate could continue to slow down, especially as competition wrestles away market share from its top-selling eye medication, Eylea.""}, {""date"": ""2023-09-20"", ""headline"": ""Regeneron\u2019s Eylea HD Gets FDA Approval, Boosting Company\u2019s Growth Outlook"", ""summary"": ""Regeneron (NASDAQ:REGN) Pharmaceuticals has recently experienced a boost in its future growth prospects, following a period of declining growth rate. The company's revenue had surged from $2 billion in 2013 to over $12 billion in the previous year but faced challenges due to a drop in COVID-19 treatment revenue and increased competition for its top-selling eye medication, Eylea.""}, {""date"": ""2023-09-20"", ""headline"": ""AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""AbCellera expands its multi-target collaboration with Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""AbCellera expands its multi-tagret collaboration with Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""AbCellera expands multi-target antibody discovery pact with Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Analyst Expectations for Regeneron Pharmaceuticals's Future"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Regeneron management to meet with Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Top Stock Reports for Amazon.com, Boeing, Regeneron & Others"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).""}, {""date"": ""2023-09-23"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 40% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,376 based on 2 Stage Free Cash Flow to Equity...""}]",{}
37,2023-09-24,824.8400268554688,2023-10-01,822.9600219726562,-0.0022792357567559263,D1,"[{""date"": ""2023-09-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""Three Of Our Top Picks For Your Healthcare Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""Ultragenyx Launches Evkeeza\u00ae (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)"", ""summary"": ""Evkeeza is a first-in-class medicine approved by Health Canada, the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultrarare, inherited form of high cholesterolTORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza\u00ae (evinacumab) in Canada. Evkeeza\u00ae was""}, {""date"": ""2023-09-25"", ""headline"": ""Ultragenyx Says the Cholesterol Drug Evkeeza Gets Canadian Approval"", ""summary"": ""By Stephen Nakrosis Ultragenyx Pharmaceutical said Evkeeza was approved by Health Canada to help treat certain patients with high cholesterol. Evkeeza was...""}, {""date"": ""2023-09-25"", ""headline"": ""GLOBAL BUSINESS: Broadcom wins legal case against Netflix over patent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management"", ""summary"": ""Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-09-25"", ""headline"": ""Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss"", ""summary"": ""TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company\u2019s gene therapy and auditory programs. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss. The most advanced clinical-stage candidate is""}, {""date"": ""2023-09-25"", ""headline"": ""Regeneron finalizes acquisition of Decibel Therapeutics, enhancing gene therapy portfolio"", ""summary"": ""Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that it has successfully completed the acquisition of Decibel Therapeutics, Inc., a move that strengthens Regeneron's gene therapy and auditory programs. The acquisition builds on previous collaborations between the two companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss.""}, {""date"": ""2023-09-25"", ""headline"": ""Regeneron completes Decibel acquisition, any guidance update to be in Q3"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Dow Jones Futures Rise After Market Correction Worsens; Meta AI News Due"", ""summary"": ""The market correction hit new lows Tuesday. Investors need to be patient. Meta is set to unveil VR hardware and AI tools at its Meta Connect event.""}, {""date"": ""2023-09-26"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.27% to $832.41 Tuesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-09-26"", ""headline"": ""FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE"", ""summary"": ""If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.""}, {""date"": ""2023-09-26"", ""headline"": ""Regeneron management to meet with Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Correction: Repligen to acquire Metenova"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Regeneron, Sanofi label expansion for Dupixent under FDA priority  review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Regeneron to acquire Metenova AB, terms not disclosed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Dupixent\u00ae (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review"", ""summary"": ""If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, about 9,000 do not satisfactorily respond to the unapproved therapies they have been treated with and potentially require advanced alternative therapy options TARRYTOWN, N.Y. and PARIS, Sept. 26, 2023 (GLOBE""}, {""date"": ""2023-09-26"", ""headline"": ""Sanofi, Regeneron say Dupixent accepted for US FDA priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Regeneron, Sanofi announce FDA acceptance for Priority Review of Dupixent sBLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Regeneron Pharmaceuticals Stock Earns 85 RS Rating"", ""summary"": ""A Relative Strength Rating upgrade for Regeneron Pharmaceuticals shows improving technical performance.""}, {""date"": ""2023-09-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.02% higher to $832.56 Wednesday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-09-27"", ""headline"": ""Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?"", ""summary"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 19% over the past three months. Given the...""}, {""date"": ""2023-09-27"", ""headline"": ""Sensei Biotherapeutics initiates Phase 1/2 study of SNS-101"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Regeneron to Report Third Quarter 2023 Financial and\u00a0Operating Results and Host Conference Call and Webcast\u00a0on November 2, 2023"", ""summary"": ""TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the \u2019Investors and Media\u2019 page of Regeneron\u2019s we""}, {""date"": ""2023-09-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.24% higher to $834.57 Thursday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-09-28"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Thursday\u2019s Top Analyst Upgrades and Downgrades: Etsy, Johnson Controls, Kosmos Energy, Levi Strauss, Snowflake, Tesla and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.39% to $822.96 Friday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-09-29"", ""headline"": ""Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review"", ""summary"": ""If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL \u2013 the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextam""}, {""date"": ""2023-09-29"", ""headline"": ""Regeneron nabs FDA priority review for lymphoma therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""Regeneron Gets FDA Priority Review of Odronextamab in Follicular, Diffuse Large B-cell Lymphoma"", ""summary"": ""By Colin Kellaher Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review of its application seeking approval of odronextamab for...""}, {""date"": ""2023-09-29"", ""headline"": ""Regeneron announces FDA accepted priority review the BLA for odronextamab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), Regeneron (REGN) and Mirati Therapeutics (MRTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""Regeneron price target raised to $680 from $665 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-30"", ""headline"": ""Stock Split Watch: Is Regeneron Pharmaceuticals Next?"", ""summary"": ""Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors.  A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's holdings, but it does bring down the price of each individual share.  Of course, it's impossible to predict which company may perform a stock split with 100% accuracy, but a top performer that has been setting new share price highs could make a good candidate.""}, {""date"": ""2023-10-01"", ""headline"": ""Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}]","{""assetTurnoverTTM"": 0.4291, ""bookValue"": 24904, ""cashRatio"": 0.5979438732981384, ""currentRatio"": 5.1778, ""ebitPerShare"": 9.7972, ""eps"": 8.8871, ""ev"": 89355.29, ""fcfMargin"": 0.2719, ""fcfPerShareTTM"": 39.9917, ""grossMargin"": 0.8702, ""inventoryTurnoverTTM"": 0.7396, ""longtermDebtTotalAsset"": 0.0617, ""longtermDebtTotalCapital"": 0.0718, ""longtermDebtTotalEquity"": 0.0796, ""netDebtToTotalCapital"": 0.02, ""netDebtToTotalEquity"": 0.0221, ""netMargin"": 0.2997, ""operatingMargin"": 0.3304, ""pb"": 3.5659, ""peTTM"": 22.2506, ""pfcfTTM"": 20.3722, ""pretaxMargin"": 0.3303, ""psTTM"": 6.7804, ""ptbv"": 3.7177, ""quickRatio"": 4.3062, ""receivablesTurnoverTTM"": 2.3529, ""roaTTM"": 0.1308, ""roeTTM"": 0.1679, ""roicTTM"": 0.1508, ""rotcTTM"": 0.1594, ""salesPerShare"": 29.6534, ""sgaToSale"": 0.1298, ""tangibleBookValue"": 23887, ""totalDebtToEquity"": 0.1085, ""totalDebtToTotalAsset"": 0.084, ""totalDebtToTotalCapital"": 0.0979, ""totalRatio"": 4.4308, ""period"": ""2023-09-30""}"
38,2023-10-01,822.9600219726562,2023-10-08,836.5700073242188,0.016537845081391778,U2,"[{""date"": ""2023-10-01"", ""headline"": ""Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""2023-10-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.60% to $818.03 Monday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-10-02"", ""headline"": ""Eli Lilly's lebrikizumab CRL impact 'likely limited,' says Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.19% to $808.31 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-10-03"", ""headline"": ""MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron Pharmaceuticals Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases"", ""summary"": ""Collaboration combines Intellia\u2019s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron\u2019s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron expands research collaboration with Intellia on gene-editing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""MAIA shares fall 17% pre-market after rallying in prior session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron and Intellia expand gene editing partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Regeneron, Intellia expand collaboration for CRISPR-based therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Intellia Therapeutics, Regeneron announce expanded research collaboration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""Regeneron says Q3 results to be impacted by $100M IPR&D expense"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies"", ""summary"": ""Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.""}, {""date"": ""2023-10-04"", ""headline"": ""$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""P/E Ratio Insights for Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Biotech Sector: On The Verge Of Triumph Or Turmoil?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.98% to $831.12 Thursday, on what proved to be an all-around poor trading session for the stock market,...""}, {""date"": ""2023-10-05"", ""headline"": ""Decoding Regeneron Pharmaceuticals (REGN)'s Valuation: Is It Truly Worth the Price?"", ""summary"": ""A Comprehensive Analysis of Regeneron Pharmaceuticals' Market Value""}, {""date"": ""2023-10-05"", ""headline"": ""Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More"", ""summary"": ""Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.""}, {""date"": ""2023-10-05"", ""headline"": ""EYLEA\u00ae HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA"", ""summary"": ""First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two yearsTARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA\u00ae HD (aflibercept) Injection 8 mg with 12- and 16-week dosing regimens, compared to EYLEA\u00ae (aflibercept) Injection, in patients with wet""}, {""date"": ""2023-10-05"", ""headline"": ""This Market-Beating Stock Just Gave Investors More Reasons to Invest"", ""summary"": ""Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years.  Despite its doing so, one could argue that the drugmaker, which isn't that far off from its 52-week high, is still worth buying at current levels, given the company's prospects and upside potential.  Let's discuss recent developments with Regeneron and determine why the company's shares are still worth buying.""}, {""date"": ""2023-10-05"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)"", ""summary"": ""The overall stock market has performed well since 2020, despite the COVID-19 pandemic.  As things stand now, only six big pharma stocks are beating the S&P 500.  Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) have more than doubled.""}, {""date"": ""2023-10-05"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Regeneron (REGN) and Alnylam Pharma (ALNY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Regeneron presents two-year resuts from PULSAR trial of EYLEA HD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.66% higher to $836.57 Friday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-10-06"", ""headline"": ""Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""2023-10-06"", ""headline"": ""The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna"", ""summary"": ""Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.""}, {""date"": ""2023-10-07"", ""headline"": ""Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 118% gain"", ""summary"": ""The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...""}]","{""assetTurnoverTTM"": 0.4291, ""bookValue"": 24904, ""cashRatio"": 0.5979438732981384, ""currentRatio"": 5.1778, ""ebitPerShare"": 9.7972, ""eps"": 8.8871, ""ev"": 89355.29, ""fcfMargin"": 0.2719, ""fcfPerShareTTM"": 39.9917, ""grossMargin"": 0.8702, ""inventoryTurnoverTTM"": 0.7396, ""longtermDebtTotalAsset"": 0.0617, ""longtermDebtTotalCapital"": 0.0718, ""longtermDebtTotalEquity"": 0.0796, ""netDebtToTotalCapital"": 0.02, ""netDebtToTotalEquity"": 0.0221, ""netMargin"": 0.2997, ""operatingMargin"": 0.3304, ""pb"": 3.5659, ""peTTM"": 22.2506, ""pfcfTTM"": 20.3722, ""pretaxMargin"": 0.3303, ""psTTM"": 6.7804, ""ptbv"": 3.7177, ""quickRatio"": 4.3062, ""receivablesTurnoverTTM"": 2.3529, ""roaTTM"": 0.1308, ""roeTTM"": 0.1679, ""roicTTM"": 0.1508, ""rotcTTM"": 0.1594, ""salesPerShare"": 29.6534, ""sgaToSale"": 0.1298, ""tangibleBookValue"": 23887, ""totalDebtToEquity"": 0.1085, ""totalDebtToTotalAsset"": 0.084, ""totalDebtToTotalCapital"": 0.0979, ""totalRatio"": 4.4308, ""period"": ""2023-09-30""}"
39,2023-10-08,836.5700073242188,2023-10-15,839.6300048828125,0.003657790181100573,U1,"[{""date"": ""2023-10-09"", ""headline"": ""Merck: Right On Time"", ""summary"": ""Merck is slowly executing a pivot into adjacent areas of oncology, immunology, and beyond. Read more to see why MRK stock is a Hold.""}, {""date"": ""2023-10-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.57% to $831.82 Monday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-10-09"", ""headline"": ""14 Best Cancer Stocks To Buy Now"", ""summary"": ""In this article, we discuss 14 best cancer stocks to buy. If you want to skip our detailed discussion on the oncology industry, head directly to 5 Best Cancer Stocks To Buy Now. The global oncology landscape continues to evolve, with ongoing efforts to discover, develop, and provide innovative treatments aimed at improving outcomes for [\u2026]""}, {""date"": ""2023-10-09"", ""headline"": ""Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Down 45%, Is Intellia a Buy?"", ""summary"": ""Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron Pharmaceuticals.  The gene editing company doesn't yet have a product on the market, but its trial data in diseases of great need have been positive, and Intellia even plans on starting a phase 3 study as early as next year for one candidate.  This doesn't mean a product launch is right around the corner, but the company clearly is progressing, and rewards could be significant.""}, {""date"": ""2023-10-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $834.96 Tuesday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-10-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.13% higher to $836.07 Wednesday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-10-11"", ""headline"": ""Commit To Buy Regeneron Pharmaceuticals At $470, Earn 2.7% Using Options"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-11"", ""headline"": ""The Latest Analyst Ratings for Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Noteworthy Friday Option Activity: REGN, PLAY, GNRC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.29% higher to $838.49 Thursday, on what proved to be an all-around poor trading session for the stock...""}, {""date"": ""2023-10-12"", ""headline"": ""Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-10-13"", ""headline"": ""Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?"", ""summary"": ""With Regeneron earnings due Nov. 2, the big debate is whether the company will get its mojo back in its core eye disease treatment business?""}, {""date"": ""2023-10-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.14% higher to $839.63 Friday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-10-13"", ""headline"": ""RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation"", ""summary"": """"}, {""date"": ""2023-10-13"", ""headline"": ""Sanofi reaps rewards of immunology investment with eczema results"", ""summary"": ""Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment.""}, {""date"": ""2023-10-13"", ""headline"": ""Regeneron (REGN) Receives a Hold from RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Regeneron (REGN) and HashiCorp (HCP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-14"", ""headline"": ""AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points"", ""summary"": ""AI stocks Broadcom and Arista lead five names near buy points all sporting a flat base, showing resilience in a tough market.""}, {""date"": ""2023-10-15"", ""headline"": ""Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO"", ""summary"": ""Event-free survival of investigational use of Libtayo\u00ae (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presented Additional presentations on outcomes of Libtayo-based therapy in advanced non-small cell lung cancer, including PD-L1 expression and histology specific subgroups TARRYTOWN, N.Y., Oct. 15,""}]","{""assetTurnoverTTM"": 0.4291, ""bookValue"": 24904, ""cashRatio"": 0.5979438732981384, ""currentRatio"": 5.1778, ""ebitPerShare"": 9.7972, ""eps"": 8.8871, ""ev"": 89355.29, ""fcfMargin"": 0.2719, ""fcfPerShareTTM"": 39.9917, ""grossMargin"": 0.8702, ""inventoryTurnoverTTM"": 0.7396, ""longtermDebtTotalAsset"": 0.0617, ""longtermDebtTotalCapital"": 0.0718, ""longtermDebtTotalEquity"": 0.0796, ""netDebtToTotalCapital"": 0.02, ""netDebtToTotalEquity"": 0.0221, ""netMargin"": 0.2997, ""operatingMargin"": 0.3304, ""pb"": 3.5659, ""peTTM"": 22.2506, ""pfcfTTM"": 20.3722, ""pretaxMargin"": 0.3303, ""psTTM"": 6.7804, ""ptbv"": 3.7177, ""quickRatio"": 4.3062, ""receivablesTurnoverTTM"": 2.3529, ""roaTTM"": 0.1308, ""roeTTM"": 0.1679, ""roicTTM"": 0.1508, ""rotcTTM"": 0.1594, ""salesPerShare"": 29.6534, ""sgaToSale"": 0.1298, ""tangibleBookValue"": 23887, ""totalDebtToEquity"": 0.1085, ""totalDebtToTotalAsset"": 0.084, ""totalDebtToTotalCapital"": 0.0979, ""totalRatio"": 4.4308, ""period"": ""2023-09-30""}"
40,2023-10-15,839.6300048828125,2023-10-22,808.469970703125,-0.03711162535697676,D4,"[{""date"": ""2023-10-15"", ""headline"": ""Healthcare Portfolio Focus Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-15"", ""headline"": ""Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO"", ""summary"": ""Event-free survival of investigational use of Libtayo\u00ae (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presented Additional presentations on outcomes of Libtayo-based therapy in advanced non-small cell lung cancer, including PD-L1 expression and histology specific subgroups TARRYTOWN, N.Y., Oct. 15,""}, {""date"": ""2023-10-16"", ""headline"": ""Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation"", ""summary"": """"}, {""date"": ""2023-10-16"", ""headline"": ""Dow Jones Leader JPMorgan, Chip Giant Nvidia Eye Buy Points"", ""summary"": ""Dow Jones banking leader JPMorgan and chip giant Nvidia are approaching new buy points in today's stock market action.""}, {""date"": ""2023-10-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.48% higher to $843.66 Monday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-10-16"", ""headline"": ""2 Healthcare Stocks Near 52-Week Highs Still Worth Buying"", ""summary"": ""The three most prominent themes in stock investing this year have been artificial intelligence (AI), weight-loss care, and profitability.  Healthcare stocks Regeneron Pharmaceuticals(NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) are prime examples.  Read on to find out more about these two innovation-oriented healthcare stocks.""}, {""date"": ""2023-10-17"", ""headline"": ""Price Over Earnings Overview: Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Iovance Biotherapeutics (IOVA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.29% to $826.03 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-10-18"", ""headline"": ""Regeneron builds on Together for CHANGE\u2122 initiative with five-year,\u00a0$5 million commitment to fuel the STEM talent pipeline in Nashville, TN"", ""summary"": ""Commitment builds on Regeneron\u2019s longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search (STS) and Regeneron International Science and Engineering Fair (ISEF) Regeneron will adapt successful initiatives it co-created in its local New York-based community to Nashville\u2019s unique STEM ecosystem, helping to advance students to these premier competitions and inspire STEM careers Alongside this commitment, Reg""}, {""date"": ""2023-10-18"", ""headline"": ""Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry"", ""summary"": ""NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Me""}, {""date"": ""2023-10-18"", ""headline"": ""Incyte: One Of The Most Undervalued Pharmaceuticals"", ""summary"": ""Incyte stock declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Read more about INCY here.""}, {""date"": ""2023-10-18"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Regeneron's high dose EYLEA should return franchise to growth, says Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Meharry Medical College, partners launch Together for CHANGE initiative"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Intellia cleared to start Phase 3 trial for gene editing drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 2.11% to $808.64 Thursday, on what proved to be an all-around grim trading session for the stock market,...""}, {""date"": ""2023-10-19"", ""headline"": ""Baron Health Care Fund Q3 2023 Shareholder Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Roche slips after in-line Q3 sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Regeneron and Sanofi Provide Update on Dupixent\u00ae (dupilumab) sBLA for Chronic Spontaneous Urticaria"", ""summary"": ""TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Dupixent\u00ae (dupilumab) in chronic spontaneous urticaria (CSU). CSU is an inflammatory skin condition, which causes sudden and debilitating hives and swelling on the skin. The CRL states that additional efficacy""}, {""date"": ""2023-10-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.02% to $808.47 Friday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-10-20"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""FDA rejects Regeneron-Sanofi's Dupixent application for chronic hives, wants more data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Regeneron, Sanofi update on Dupixent sBLA in Chronic Spontaneous Urticaria"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-21"", ""headline"": ""Libtayo\u00ae (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)"", ""summary"": ""89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of patients who experienced a pathologic complete response in the primary analysis TARRYTOWN, N.Y., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo\u00ae (cemi""}, {""date"": ""2023-10-22"", ""headline"": ""Dupixent\u00ae (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)"", ""summary"": ""Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathways sBLA for Dupixent to treat children aged 1 to 11 years with EoE is under Priority Review in the U.S.; if approved, Dupixent would be the first and only FDA-approved treatment for these children with EoE""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 biopharma earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Regeneron presents secondary endpoints for PD-1 inhibitor Libtayo regimen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Regeneron, Sanofi announce results from Phase 3 trial evaluating Dupixent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
41,2023-10-22,808.469970703125,2023-10-29,775.1799926757812,-0.041176517661369094,D5,"[{""date"": ""2023-10-22"", ""headline"": ""Dupixent\u00ae (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)"", ""summary"": ""Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathways sBLA for Dupixent to treat children aged 1 to 11 years with EoE is under Priority Review in the U.S.; if approved, Dupixent would be the first and only FDA-approved treatment for these children with EoE""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Eli Lilly, Gilead favorites at BofA ahead of Q3 biopharma earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Regeneron presents secondary endpoints for PD-1 inhibitor Libtayo regimen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Regeneron, Sanofi announce results from Phase 3 trial evaluating Dupixent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Intellia (NTLA) Focuses on Developing Gene-Editing Therapies"", ""summary"": ""Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.""}, {""date"": ""2023-10-23"", ""headline"": ""Dupixent CRL 'unfortunate' for Regeneron, but TD Cowen sees path forward"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""US FDA asks Regeneron, Sanofi for more data on Dupixent for urticaria"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Regeneron\u2019s Growth Potential: Dupilumab\u2019s Expanded Applications and Future Prospects Despite CSU Approval Delay"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""These Gene-Editing Stocks Are Survivors. Take Another Look."", ""summary"": ""The market has nearly abandoned many of the biotech start-ups it funded in the excitement of the first Covid-19 vaccines in 2021.""}, {""date"": ""2023-10-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.10% to $804.28 Tuesday, on what proved to be an all-around great trading session for the stock market,...""}, {""date"": ""2023-10-25"", ""headline"": ""Regeneron data show gene therapy aids child with profound genetic hearing loss"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""Regeneron Announces Investor Conference Presentations"", ""summary"": ""TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BMO Biopharma Spotlight Series: Oncology at 9:30 a.m. ET on Wednesday, November 8, 2023Truist Securities BioPharma Symposium at 3:20 p.m. ET on Wednesday, November 8, 2023UBS Biopharma Conference at 11:00 a.m. ET on Thursday, November 9, 2023Jefferies London Healthcare Conference at 2:30 p.m. GMT (9:30 a.m. ET) on Wednesday, November 15, 2023 The ses""}, {""date"": ""2023-10-25"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 0.90% to $797.04 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-10-25"", ""headline"": ""Stock-Split Watch: Could These 2 Growth Stocks Be Next?"", ""summary"": ""Over the past few years, we have witnessed several high-profile stock splits.  Companies sometimes institute stock splits when their shares become \""too expensive.\""  With that in mind, let's look at two companies that could go that route based on their share prices: Regeneron (NASDAQ: REGN) and Booking Holdings (NASDAQ: BKNG).""}, {""date"": ""2023-10-25"", ""headline"": ""Alnylam reports added 'positive interim results' from Phase 1 Alzheimer's trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""Bronte Capital Amalthea Fund September 2023 Letter"", ""summary"": ""The Amalthea fund gained 9.96% in Q3 2023 whilst the globally diverse MSCI ACWI index (in $A) was up by 0.02%. Click here to read the full fund letter.""}, {""date"": ""2023-10-26"", ""headline"": ""Regeneron Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss"", ""summary"": ""Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron\u2019s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of genetic medicines for hearing loss and other therapeutic areas that are being advanced by the company TARRYTOWN, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced preliminary, positive safety and efficacy results from the first patient (<2 years of a""}, {""date"": ""2023-10-26"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.63% to $792.01 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-10-26"", ""headline"": ""Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for"", ""summary"": ""Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-10-26"", ""headline"": ""Regeneron\u2019s Growth Potential and R&D Conversion: Key Drivers for Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 2.12% to $775.18 Friday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-10-27"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 42% Discount?"", ""summary"": ""Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,372 based on 2 Stage Free Cash Flow to...""}, {""date"": ""2023-10-27"", ""headline"": ""Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?"", ""summary"": ""Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.""}, {""date"": ""2023-10-27"", ""headline"": ""SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Regeneron's hearing loss gene therapy shows positive outcomes in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-28"", ""headline"": ""Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Earnings week ahead: Apple, AMD, Pfizer, McDonald's, Starbucks and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,775.1799926757812,2023-11-05,816.9000244140625,0.053819799443315386,U5+,"[{""date"": ""2023-10-29"", ""headline"": ""Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Earnings week ahead: Apple, AMD, Pfizer, McDonald's, Starbucks and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.32% higher to $777.67 Monday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-10-30"", ""headline"": ""MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.29% higher to $779.89 Tuesday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-10-31"", ""headline"": ""Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?"", ""summary"": ""Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-10-31"", ""headline"": ""$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Green Wave Boosts Stocks, Bonds As Traders Embrace Fed's Stance, Await Apple Earnings: What's Driving Markets Thursday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""GLOBAL BRIEFING: Japan's Fumio Kishida announces stimulus package"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Glaukos (GKOS) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""EYLEA\u00ae HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema"", ""summary"": ""Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient characteristicsTARRYTOWN, N.Y., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced long-term outcomes and new analyses of pivotal clinical data for EYLEA\u00ae HD (aflibercept) Injection 8 mg will be presented at the American Academy of Ophthalmology (AAO) annual meeting""}, {""date"": ""2023-11-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.46% to $791.27 Wednesday, on what proved to be an all-around great trading session for the stock market,...""}, {""date"": ""2023-11-01"", ""headline"": ""Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics"", ""summary"": ""Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.""}, {""date"": ""2023-11-01"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Regeneron Pharmaceuticals Q3 2023 Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock Has Fared Decently: Is the Market Following Strong Financials?"", ""summary"": ""Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by 6.5% over the past...""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron upgraded to Outperform from Market Perform at Raymond James"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers"", ""summary"": ""Regeneron Pharmaceuticals topped third-quarter forecasts on Thursday, helped by a strong launch from its high dose of Eylea. REGN stock rose.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 3.48% to $818.79 Thursday, on what proved to be an all-around great trading session for the stock market,...""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline"", ""summary"": ""Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates"", ""summary"": ""While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharmaceuticals Inc (REGN) Reports 15% Revenue Growth in Q3 2023"", ""summary"": ""Strong performance of Dupixent and Libtayo drives revenue growth""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""UPDATE 3-Regeneron beats quarterly profit estimates on eczema treatment strength"", ""summary"": ""Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment, Dupixent.  Anti-inflammatory drug Dupixent, which was approved in 2017, has aided Regeneron's profits while sales of its eye drug Eylea has taken a backseat in recent quarters owing to increased competition from Roche's Vabysmo.  Quarterly sales of Dupixent, recorded by its partner Sanofi , rose 33% to $3.10 billion.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron beats quarterly profit estimates on eczema treatment strength"", ""summary"": ""Anti-inflammatory drug Dupixent, which was approved in 2017, has aided Regeneron's profits while sales of its eye drug Eylea has taken a backseat in recent quarters owing to increased competition from Roche's Vabysmo.  Quarterly sales of Dupixent, recorded by its partner Sanofi, rose 33% to $3.10 billion.  Regeneron has been leaning on the eczema treatment as Eylea sales have missed Wall Street expectations so far this year, partly due to competition from Vabysmo since the rival secured U.S. approval last year.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Reports Third Quarter 2023 Financial and Operating Results"", ""summary"": ""Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022Third quarter 2023 Dupixent\u00ae global net sales (recorded by Sanofi) increased 33% to $3.10 billion versus third quarter 2022Third quarter 2023 U.S. net sales for EYLEA\u00ae and EYLEA HD were $1.49 billion, including $43 million from EYLEA HDThird quarter 2023 Libtayo\u00ae global net sales increased 62% to $232 million versus third quarter 2022Third quarter 2023 GAAP diluted EPS of $8.89 and non-GAAP diluted EPS(a) of $11.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron third quarter profit suffers amid higher costs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Q3 sales drop as Eylea underperforms"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharma\u2019s adjusted earnings beat estimates"", ""summary"": ""Regeneron Pharmaceuticals Inc.\u2019s stock rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat...""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron: Q3 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharma adjusted earnings beat estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Regeneron reports Q3 adjusted EPS $11.59, consensus $10.77"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: United Therapeutics (UTHR), Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Earnings Scheduled For November 2, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.23% to $816.90 Friday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-11-03"", ""headline"": ""Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues"", ""summary"": ""Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.""}, {""date"": ""2023-11-03"", ""headline"": ""HRMY vs. REGN: Which Stock Should Value Investors Buy Now?"", ""summary"": ""HRMY vs. REGN: Which Stock Is the Better Value Option?""}, {""date"": ""2023-11-03"", ""headline"": ""Raymond James Upgrades Regeneron Pharmaceuticals (REGN)"", ""summary"": """"}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2023 Earnings Call Transcript"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2023 Earnings Call Transcript November 2, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.59, expectations were $10.8. Operator: Welcome to the Regeneron Pharmaceuticals Third Quarter 2023 Earnings Conference Call. My name is Shannon, and I will be your operator for today\u2019s call. At this time, all participants [\u2026]""}, {""date"": ""2023-11-03"", ""headline"": ""Morning Brew: Jobs Growth Moderates, Fortinet Plunges, Apple Dips, and Regeneron Upgraded"", ""summary"": ""The slower pace of job growth may give the Federal Reserve confidence that its tighter monetary policy is having its intended effect to tamp down the economy and thus, inflation.  Fortinet (NASDAQ:FTNT) shares plunged 22% in pre-market trading on Friday following a disappointing outlook for the fourth quarter.  Apple (NASDAQ:AAPL) shares dipped in pre-market trading on Friday as the tech giant suggested that sales growth would decline for a fifth straight quarter.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron: Analysis Of Vabysmo's Impact On Eylea Franchise"", ""summary"": ""Regeneron reported strong Q3 2023 results, driven by the growth of Dupixent and Libtayo, as by Eylea holding up against Vabysmo. Read more on REGN stock here.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron Is Pointed Higher, But Here's the Price Where I'd Be a Buyer"", ""summary"": ""Biotechnology firm Regeneron  was upgraded to an \""Outperform\"" (buy) rating at the sell-side firm Raymond James with a $950 price target.  In the daily bar chart of REGN, below, I can see that the shares have moved higher in the past year but the intermittent declines have been heart-stopping to buy-and-hold investors.  The trading volume has been choppy the past few months while the On-Balance-Volume (OBV) line has moved higher but with a host of dips.""}, {""date"": ""2023-11-03"", ""headline"": ""Q3 2023 Abcellera Biologics Inc Earnings Call"", ""summary"": ""Q3 2023 Abcellera Biologics Inc Earnings Call""}, {""date"": ""2023-11-03"", ""headline"": ""BioCryst, Clearside Biomedical in pact for diabetic eye disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH"", ""summary"": ""Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations include the first review of primary endpoint results with longer follow-up from the pivotal trial for linvoseltamab in heavily pre-treated patients with multiple myeloma TARRYTOWN, N.Y., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updat""}, {""date"": ""2023-11-03"", ""headline"": ""Uber upgraded, Fortinet downgraded: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron raised to Outperform at Raymond James on Q3 results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron price target raised to $1066 from $992 at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), Trupanion (TRUP) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron price target raised to $797 from $760 at Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron announces new, updated data from hematology pipeline at ASH meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Regeneron price target raised to $935 from $925 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Moderna (MRNA) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-05"", ""headline"": ""Positive Outlook for Regeneron: Eylea HD Success, Dupixent COPD Phase 3 Advancement & Future Obesity Research Developments Prompts Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
43,2023-11-05,816.9000244140625,2023-11-12,798.9400024414062,-0.021985581388051068,D3,"[{""date"": ""2023-11-05"", ""headline"": ""Positive Outlook for Regeneron: Eylea HD Success, Dupixent COPD Phase 3 Advancement & Future Obesity Research Developments Prompts Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi"", ""summary"": ""Celldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies.""}, {""date"": ""2023-11-06"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.90% to $832.41 Monday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-11-06"", ""headline"": ""Risk On For Biotech - Time To Trade The Small Caps"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Lantheus (LNTH), Cytokinetics (CYTK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Regeneron Pharmaceuticals (REGN): Bronte Capital\u2019s Biggest Winner of This Quarter"", ""summary"": ""Bronte Capital, an investment management company, released its \u201cAmalthea Fund\u201d third-quarter 2023 investor letter. A copy of the same can be downloaded here. The fund gained 9.96% last quarter (-0.44% in September) compared to 0.02% (-3.70% in September) for the MSCI ACWI (in $A). In addition, you can check the top 5 holdings of the fund [\u2026]""}, {""date"": ""2023-11-07"", ""headline"": ""Wall Street Analysts Are Neutral on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Regeneron initiated with a Hold at Deutsche Bank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.19% to $830.79 Tuesday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-11-07"", ""headline"": ""Notable Tuesday Option Activity: REGN, EBAY, NOC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) 19% CAGR outpaced the company's earnings growth over the same five-year period"", ""summary"": ""The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...""}, {""date"": ""2023-11-07"", ""headline"": ""Sanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source Says"", ""summary"": ""By Helena Smolak France's financial prosecutors have opened a preliminary investigation into Sanofi over possible dissemination of false or misleading...""}, {""date"": ""2023-11-07"", ""headline"": ""Sanofi said to be under scrutiny over possible market manipulation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Where Regeneron Pharmaceuticals Stands With Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""3 Biotech Stocks That Are Betting on the Future of Gene Editing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Intellia slides after Q3 pipeline updates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 0.96% to $822.79 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-11-08"", ""headline"": ""Alnylam price target lowered to $284 from $288 at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""7 Underappreciated Biotech Stocks to Pick Up on the Cheap"", ""summary"": ""Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an alternative upside pathway. By now, you\u2019ve likely heard about the impressive third-quarter U.S. GDP print, which came in hotter than expected. But looking ahead, circumstances don\u2019t seem so rosy to justify belief in a repeat performance.""}, {""date"": ""2023-11-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 2.74% to $800.26 Thursday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-11-09"", ""headline"": ""2 Soaring Stocks to Buy and Hold"", ""summary"": ""Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter earnings releases.  While a single quarterly update rarely fundamentally changes the investment thesis of a corporation, both Regeneron and Roku had some positive developments worth reviewing, further solidifying why they are excellent stocks to buy.  Regeneron has relied on two key medicines for growth for some time now.""}, {""date"": ""2023-11-09"", ""headline"": ""Deutsche Bank Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation"", ""summary"": """"}, {""date"": ""2023-11-09"", ""headline"": ""Eli Lilly declines a day after FDA nod for weight loss therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.16% to $798.94 Friday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-11-10"", ""headline"": ""Bayer Gets CHMP Backing for Higher-Dose Eylea in Two Major Retinal Eye Diseases"", ""summary"": ""By Colin Kellaher Bayer on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of a high-dose...""}, {""date"": ""2023-11-11"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ETCompany ParticipantsDr.""}, {""date"": ""2023-11-11"", ""headline"": ""Here's Why Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt Responsibly"", ""summary"": ""Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...""}, {""date"": ""2023-11-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. (REGN) UBS Biopharma Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) UBS Biopharma Conference Call November 9, 2023 11:00 AM ETCompany ParticipantsRyan Crowe - Vice...""}]",{}
44,2023-11-12,798.9400024414062,2023-11-19,802.4299926757812,0.004368275744999872,U1,"[{""date"": ""2023-11-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.28% to $796.70 Monday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-11-13"", ""headline"": ""Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)"", ""summary"": ""Regeneron has sponsored ISEF - the world\u2019s largest high school science and engineering competition, and a program of Society for Science (Society) - since 2019 Each year, over 175,000 students participate in the Society\u2019s affiliated high school science fairs around the world to earn the right to compete in Regeneron ISEF, where 1,600 finalists vie for almost $8 million in awards, prizes and scholarships Regeneron is also lead sponsor of the Society\u2019s Regeneron Science Talent Search (STS), the na""}, {""date"": ""2023-11-13"", ""headline"": ""Regeneron commits $34M over five years to sponsor science & engineering fair"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.38% to $793.70 Tuesday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-11-14"", ""headline"": ""Merck: Tracking Well Above The Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Regeneron Announces Investor Conference Presentation"", ""summary"": ""TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Piper Sandler 35th Annual Healthcare Conference at 8:30 a.m. ET on Tuesday, November 28, 2023 The session may be accessed from the \""Investors & Media\"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. About Rege""}, {""date"": ""2023-11-15"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.17% to $792.38 Wednesday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-11-15"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies London Healthcare Conference November 15, 2023 9:30 AM ETCompany ParticipantsBob Landry -...""}, {""date"": ""2023-11-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.53% higher to $796.54 Thursday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-11-16"", ""headline"": ""9 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""How Is The Market Feeling About Regeneron Pharmaceuticals?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.74% higher to $802.43 Friday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-11-17"", ""headline"": ""If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
45,2023-11-19,802.4299926757812,2023-11-26,798.2999877929688,-0.005146872525340962,D1,"[{""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 0.10% to $801.64 Monday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-11-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 0.35% to $798.83 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...""}, {""date"": ""2023-11-21"", ""headline"": ""HRMY vs. REGN: Which Stock Is the Better Value Option?"", ""summary"": ""HRMY vs. REGN: Which Stock Is the Better Value Option?""}, {""date"": ""2023-11-21"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.11% higher to $799.73 Wednesday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-11-22"", ""headline"": ""Jefferies U.S. quant portfolio - ROIC stars and high yield"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-24"", ""headline"": ""Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How"", ""summary"": ""Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.""}, {""date"": ""2023-11-24"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.18% to $798.30 Friday, on what proved to be an all-around great trading session for the stock market, with...""}, {""date"": ""2023-11-24"", ""headline"": ""Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?"", ""summary"": ""Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.""}]",{}
46,2023-11-26,798.2999877929688,2023-12-03,814.8599853515625,0.02074407843143855,U3,"[{""date"": ""2023-11-26"", ""headline"": ""Regeneron, Sanofi report Dupixent reduced COPD exacerbations in second trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-26"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-26"", ""headline"": ""Regeneron, Sanofi's Dupixent shows promising results for lung disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), Masimo (MASI) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""11 Analysts Have This to Say About Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales"", ""summary"": ""Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.""}, {""date"": ""2023-11-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.03% to $798.08 Monday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2023-11-27"", ""headline"": ""3 Biotech Stocks To Watch Before December 2023"", ""summary"": ""Biotech stocks to check out in the stock market today.""}, {""date"": ""2023-11-27"", ""headline"": ""Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study"", ""summary"": ""Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.""}, {""date"": ""2023-11-27"", ""headline"": ""Biotech And Healthcare Portfolio Playbook For December 2023/24"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Regeneron, Sanofi to seek new Dupixent approval in US after COPD success"", ""summary"": ""Results from the second of two Phase 3 trials testing the blockbuster drug in the respiratory condition showed treatment could reduce attacks and improve lung function.""}, {""date"": ""2023-11-27"", ""headline"": ""Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Dupixent\u00ae (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease"", ""summary"": ""NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils \u2265300 cells per \u03bcL), confirming results from the landmark BOREAS pivotal trial Dupixent rapidly and significantly improved lung function (139 mL in FEV1) compared to placebo (57 mL in FEV1) at 12 weeks Supplemental BLA submission planned by end of 2023""}, {""date"": ""2023-11-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $801.14 Tuesday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-11-28"", ""headline"": ""Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Piper Sandler 35th Annual Healthcare Conference Call November 28, 2023 8:30 AM ETCompany...""}, {""date"": ""2023-11-28"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Regeneron price target raised to $937 from $935 at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Merus (MRUS), Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""REGENERON PHARMACEUTICALS - DUPIXENT SIGNIFICANTLY REDUCED COPD EXACERBATIONS IN SECOND POSITIVE PHASE 3 TRIAL, ACCELERATING FDA SUBMISSION AND CONFIRMING POTENTIAL TO BECOME FIRST APPROVED BIOLOGIC FOR THIS SERIOUS DISEASE"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the second Dupixent investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent...""}, {""date"": ""2023-11-29"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.93% higher to $808.59 Wednesday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-11-29"", ""headline"": ""Biogen: LAQEMBI's $10 Billion Potential"", ""summary"": ""Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval. Click here to read why we still rate the BIIB stock as a 'Strong Buy'.""}, {""date"": ""2023-11-29"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Regeneron (REGN) and Outlook Therapeutics (OTLK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio"", ""summary"": ""TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET. This investor call follows Regeneron data updates presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, from December 9-12, 2023. The webcast may be accessed from the \""Investors & Media\"" page of Regeneron's w""}, {""date"": ""2023-11-30"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.88% to $823.81 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2023-11-30"", ""headline"": ""Regeneron Sues Samsung Bioepis For Proposed Biosimilar Of EYLEA In West Virginia District Court"", ""summary"": ""Regeneron Pharmaceuticals, Inc. filed a Complaint on November 22 against Samsung Bioepis Co., Ltd. in the U.S. District Court for the Northern District of West Virginia, alleging infringement of 37...""}, {""date"": ""2023-12-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slid 1.09% to $814.86 Friday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-12-02"", ""headline"": ""JP Morgan\u2019s Top 15 Stock Picks for 2023 and Now"", ""summary"": ""In this piece, we will take a look at JP Morgan\u2019s top 15 stock picks for 2023 and most recent stock picks. If you want to skip our introduction to the world\u2019s biggest bank in terms of assets, its latest performance, and other details, then check out JP Morgan\u2019s Top 5 Stock Picks for 2023. [\u2026]""}, {""date"": ""2023-12-02"", ""headline"": ""GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-03"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
47,2023-12-03,814.8599853515625,2023-12-10,840.1400146484375,0.031023770649344362,U4,"[{""date"": ""2023-12-03"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Regeneron (REGN), AbbVie (ABBV) and Taysha Gene Therapies (TSHA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.04% to $823.32 Monday, on what proved to be an all-around poor trading session for the stock market, with...""}, {""date"": ""2023-12-04"", ""headline"": ""EyePoint sees stock surge on AMD drug trial data"", ""summary"": ""The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was \""non-inferior\"" to Regeneron's Eylea.""}, {""date"": ""2023-12-04"", ""headline"": ""Morning Brew: Alaska Air's Hawaiian Holdings Takeover and Market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""EyePoint Pharma surges as wet AMD therapy succeeds in mid-stage trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Sanofi (SNYNF), Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.29% to $820.90 Tuesday, on what proved to be an all-around rough trading session for the stock market,...""}, {""date"": ""2023-12-05"", ""headline"": ""EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data"", ""summary"": ""EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.""}, {""date"": ""2023-12-05"", ""headline"": ""EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal"", ""summary"": ""There is no obvious compelling need to buy EyePoint Pharmaceuticals stock today. Read more to see an overview and analysis of EYPT stock.""}, {""date"": ""2023-12-05"", ""headline"": ""Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals"", ""summary"": ""Replimune Group Inc. shares dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet...""}, {""date"": ""2023-12-06"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Regeneron (REGN) and Arvinas Holding Company (ARVN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise"", ""summary"": ""Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating""}, {""date"": ""2023-12-06"", ""headline"": ""Regeneron price target raised to $1000 from $900 at TD Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Cooper Co (COO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Catalyst Watch: Intel's AI event, Oracle earnings and CAVA IPO lockup expiration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Why Regeneron could be the top biotech investment in 2024"", ""summary"": ""TD Cowen has named biotech company Regeneron (REGN) the best idea for 2024. TD Cowen Senior Biotech Equity Tyler Van Buren joins Yahoo Finance Live to break down the details of this call. Van Buren, who made the call, notes several factors that contributed to this decision. Van Buren views Regeneron's psoriasis drug Dupixent as being \""one of the largest drugs in biotech and pharmaceuticals\u201d which could bring in revenue of $21 billion by 2027. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-12-07"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.61% to $849.18 Thursday, on what proved to be an all-around great trading session for the stock market,...""}, {""date"": ""2023-12-07"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?"", ""summary"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 1.4% over the past week. Since the market usually pay for a...""}, {""date"": ""2023-12-07"", ""headline"": ""Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma"", ""summary"": ""71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up Data to be submitted to regulatory authorities, with Biologics License Application on track to be submitted to the FDA this year Regeneron to host virtual investor event to discuss results alongside updates across its hematology portfolio on Thursday, December 14 at 8:30 a.m. ET TARRYTOWN, N.Y., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today an""}, {""date"": ""2023-12-07"", ""headline"": ""Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO"", ""summary"": ""First dose-escalation results for REGN5668 (MUC16xCD28), a costimulatory bispecific, in combination with Libtayo\u00ae (cemiplimab) showed encouraging initial activity in patients with recurrent ovarian cancer Additional data include a late-breaking oral presentation of first results for neoadjuvant Libtayo in combination with low-dose stereotactic body radiotherapy in early-stage hepatocellular carcinoma TARRYTOWN, N.Y., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN""}, {""date"": ""2023-12-07"", ""headline"": ""Regeneron lifts complete remission in trial for multiple myeloma candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Regeneron announces results from Phase 1/2 trial of linvoseltamab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-08"", ""headline"": ""Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate"", ""summary"": ""Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.""}, {""date"": ""2023-12-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 1.06% to $840.14 Friday, on what proved to be an all-around positive trading session for the stock market,...""}, {""date"": ""2023-12-08"", ""headline"": ""Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?"", ""summary"": ""Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio.  Regeneron's business centers around its eye medication, Eylea, which treats wet age-related macular degeneration.  It recently obtained approval for a higher-dose (8 mg) version of the drug, which bolsters its growth prospects.""}, {""date"": ""2023-12-08"", ""headline"": ""REGENERON PHARMACEUTICALS - UPDATED LINVOSELTAMAB PIVOTAL DATA DEMONSTRATED STRONG RATES AND DEPTH OF RESPONSE IN PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the primary endpoint analysis from the pivotal trial investigating linvoseltamab demonstrated high rates of deep and durable...""}, {""date"": ""2023-12-08"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Regeneron (REGN) and PAVmed (PAVM)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-09"", ""headline"": ""Regeneron announces new, updated data for odronextamabn in R/R DLBCL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-09"", ""headline"": ""Regeneron to host conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes"", ""summary"": ""Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response , with a 23-month median duration of response and 24-month median duration of CR Oral...""}, {""date"": ""2023-12-10"", ""headline"": ""Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes"", ""summary"": ""Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the Phase 2 trial presented in an oral session showed an association between circulating tumor DNA (ctDNA) negativity and progression-free survival TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Reg""}]",{}
48,2023-12-10,840.1400146484375,2023-12-17,859.1400146484375,0.02261527801166663,U3,"[{""date"": ""2023-12-09"", ""headline"": ""Regeneron announces new, updated data for odronextamabn in R/R DLBCL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""Biotech Is Coming Back, Can The Run Last?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes"", ""summary"": ""Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR Oral presentation showcased overall maintenance of patient-reported outcomes from baseline to 50 weeks during investigational odronextamab treatment, complementing the overall efficacy and safety profile in this heavily pretreated and highly refractory patient population TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE""}, {""date"": ""2023-12-10"", ""headline"": ""Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes"", ""summary"": ""Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the Phase 2 trial presented in an oral session showed an association between circulating tumor DNA (ctDNA) negativity and progression-free survival TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Reg""}, {""date"": ""2023-12-11"", ""headline"": ""Leading pharmaceutical firms highlight positive trial data on lymphoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year"", ""summary"": ""TARRYTOWN, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America). These consistent rankings reflect the company's continued dedication to sustainability and highlight Regeneron\u2019s belief that advancing environmental, social and gover""}, {""date"": ""2023-12-11"", ""headline"": ""REGENERON PHARMACEUTICALS - LATEST ODRONEXTAMAB DATA IN RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA SHOWED COMPELLING RESPONSES AND OVERALL MAINTENANCE OF PATIENT-REPORTED OUTCOMES"", ""summary"": ""were presented at the 65th American Society of Hematology Annual Meeting and Exposition from December 9 to 12 in San Diego, CA. Odronextamab is an investigational CD20xCD3 bispecific antibody...""}, {""date"": ""2023-12-11"", ""headline"": ""REGENERON PHARMACEUTICALS - UPDATED ODRONEXTAMAB DATA FROM RELAPSED, REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PIVOTAL TRIAL SHOWED DEEP AND DURABLE RESPONSES AND THE POTENTIAL OF CTDNA TO PREDICT LONG-TERM OUTCOMES"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced new and updated data for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma .The data from the pivotal...""}, {""date"": ""2023-12-11"", ""headline"": ""(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Regeneron lymphoma therapy shows high response rate in ongoing trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""3 Gene-Editing Stocks With the Potential to Mint Millionaires"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""30 Largest Pharmaceutical Companies in the World"", ""summary"": ""In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world\u2019s leading pharmaceutical companies became the center of attention for people all over the world as a [\u2026]""}, {""date"": ""2023-12-12"", ""headline"": ""Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the splendid shareholder returns"", ""summary"": ""When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...""}, {""date"": ""2023-12-12"", ""headline"": ""Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve"", ""summary"": ""Corvus is a clinical-stage company with potential investment opportunities and a focus on ITK inhibitor soquelitinib. Read why I'm bullish on CRVS stock.""}, {""date"": ""2023-12-12"", ""headline"": ""Regeneron price target raised by $27 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Bluebird Bio (BLUE) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Regeneron Stock Assigned Sell Rating Amid Competitive Landscape and Commercial Execution Concerns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""3 Stocks to Buy Before 2024 That Can Set You Up For Life"", ""summary"": ""These stocks are still relatively cheap, but don't expect them to stay that way for long.""}, {""date"": ""2023-12-14"", ""headline"": ""Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) American Society of Hematology 2023 Investor Conference Call December 14, 2023 8:30 AM ETCompany...""}, {""date"": ""2023-12-14"", ""headline"": ""Biopharmaceutical Stocks: The Rally Has Just Begun"", ""summary"": ""With the recent rise in the XBI ETF, investors may begin to wonder if they 'missed the rally'. Read more to see my analysis.""}, {""date"": ""2023-12-14"", ""headline"": ""Regeneron to host conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-15"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Regeneron (REGN) and Teva Pharmaceutical (TEVA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-15"", ""headline"": ""RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-16"", ""headline"": ""AI Meets Biotech: 3 Top Stocks Transforming Medical Science"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-16"", ""headline"": ""Insider Sell Alert: Director Bonnie Bassler Sells Shares of Regeneron Pharmaceuticals Inc"", ""summary"": ""Regeneron Pharmaceuticals Inc (NASDAQ:REGN), a leader in the biotechnology industry, has recently witnessed an insider sell that has caught the attention of market watchers.""}, {""date"": ""2023-12-17"", ""headline"": ""It's Almost 2024: 3 Top Stocks to Buy Before the New Year"", ""summary"": ""You can pick these players up for a great price right now.""}]",{}
49,2023-12-17,859.1400146484375,2023-12-24,846.719970703125,-0.014456367685766303,D2,"[{""date"": ""2023-12-17"", ""headline"": ""Regeneron Sues Formycon AG For Proposed Biosimilar Of EYLEA In West Virginia District Court"", ""summary"": ""Regeneron Pharmaceuticals, Inc. filed a Complaint on November 29, 2023, against Formycon AG in the U.S. District Court for the Northern District of West Virginia, alleging infringement of 39...""}, {""date"": ""2023-12-17"", ""headline"": ""14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-17"", ""headline"": ""It's Almost 2024: 3 Top Stocks to Buy Before the New Year"", ""summary"": ""You can pick these players up for a great price right now.""}, {""date"": ""2023-12-18"", ""headline"": ""Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference"", ""summary"": ""TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the \""Investors & Media\"" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's""}, {""date"": ""2023-12-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slipped 0.96% to $850.87 Monday, on what proved to be an all-around mixed trading session for the stock market, with...""}, {""date"": ""2023-12-18"", ""headline"": ""5 Big Drug Stocks That May Continue to Outperform in 2024"", ""summary"": ""Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.""}, {""date"": ""2023-12-18"", ""headline"": ""Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings"", ""summary"": ""With a price-to-earnings (or \""P/E\"") ratio of 22.9x Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) may be sending...""}, {""date"": ""2023-12-18"", ""headline"": ""XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector"", ""summary"": ""XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.""}, {""date"": ""2023-12-18"", ""headline"": ""Price Over Earnings Overview: Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans"", ""summary"": ""Alnylam plans to significantly expand its clinical pipeline by the end of 2025. Read why I remain bullish on ALNY stock's long-term growth prospects.""}, {""date"": ""2023-12-19"", ""headline"": ""Regeneron's treatment of Hemophilia B granted FDA orphan designation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. dropped 0.29% to $848.39 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...""}, {""date"": ""2023-12-19"", ""headline"": ""The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK"", ""summary"": ""Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.""}, {""date"": ""2023-12-20"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.78% to $841.79 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...""}, {""date"": ""2023-12-20"", ""headline"": ""Lantheus Holdings Is Charting a Path to Sustainable Growth and Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""7 Undervalued Nasdaq-100 Stocks for Bargain Hunters"", ""summary"": ""Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks. Indeed, on a year-to-date basis, the index shot up about 52%. That\u2019s almost double the performance of the benchmark S&P 500. And that\u2019s not a bad run for the S&P given the circumstances. Typically, though, higher performance comes with an overvalued profile. Still, with so many securities available, a few tend to be overlooked, segueing into bargain Nasdaq-100 stocks. To be""}, {""date"": ""2023-12-21"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.01% higher to $841.88 Thursday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-12-21"", ""headline"": ""$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.57% higher to $846.72 Friday, on what proved to be an all-around mixed trading session for the stock...""}, {""date"": ""2023-12-22"", ""headline"": ""Where Will Regeneron Pharmaceuticals Be in 1 Year?"", ""summary"": ""Can the stock continue its market-beating ways?""}, {""date"": ""2023-12-22"", ""headline"": ""Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""2023-12-22"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Regeneron price target raised by $75 at Oppenheimer, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
50,2023-12-24,846.719970703125,2023-12-31,878.2899780273438,0.03728506285023925,U4,"[{""date"": ""2023-12-25"", ""headline"": ""Regeneron VP  Fenimore sells $1.6M in company shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Visualized: The Top S&P 500 Stocks Over 20 Years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Regeneron gains after mixed ruling in patent suit over Eylea vs Viatris  (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Regeneron rises after ruling in patent fight with Viatris"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Regeneron (NASDAQ:REGN) Gains after Patent Suit Mostly Wins"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Wednesday Sector Leaders: Healthcare, Financial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.33% higher to $849.53 Tuesday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-12-26"", ""headline"": ""JN.1 Omicron strain becomes dominant COVID variant in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Regeneron gets 'clear win' with West Virginia ruling, says JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Canopy Growth (CGC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Regeneron has path to Eylea protection until 2027, says Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Regeneron Gains After Eye-Drug Patent Victory Over Viatris"", ""summary"": ""(Bloomberg) -- Regeneron Pharmaceuticals Inc. rose the most since August after a court ruled that the drugmaker\u2019s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World\u2019s Most Popular EV MakerTesla Plans Revamp of Smash Hit Model Y From China PlantS&P 500 Rally Flashes Signs of Fatigue Near Record: Markets WrapApple\u2019s iPhone D""}, {""date"": ""2023-12-27"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 2.92% to $874.37 Wednesday, on what proved to be an all-around positive trading session for the stock...""}, {""date"": ""2023-12-27"", ""headline"": ""Regeneron gains after mixed ruling in patent suit over Eylea vs Viatris"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Regeneron gains after mixed win in patent suit over Eylea vs Viatris"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""FDA\u2019s new drug approvals for 2023 rise 51% from last year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""How Is The Market Feeling About Regeneron Pharmaceuticals?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Assessing Regeneron Pharmaceuticals (REGN)'s Market Valuation: Is It Justified?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.84% higher to $881.70 Thursday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2023-12-28"", ""headline"": ""Early notable gainers among liquid option names on December 28th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Eylea patent decision favorable for Regeneron, says Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Regeneron's Eylea in stronger position after IP win, says Goldman Sachs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Ruling in favor of Regeneron on Eylea IP removes key overhang, says Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-29"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.39% to $878.29 Friday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-12-29"", ""headline"": ""Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financial Metrics and Competitive Strengths"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-29"", ""headline"": ""Regeneron expands battle over Eylea patents in new lawsuit against Samsung Bioepis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
51,2023-12-31,878.2899780273438,2024-01-07,913.1699829101562,0.039713540807050585,U4,"[{""date"": ""2024-01-01"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financial Metrics and Competitive Strengths"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Anticompetitive Behavior At United Therapeutics"", ""summary"": ""United Therapeutics calls itself a Public Benefit company; in reality, it is a cynical monopolist about to lose its monopoly. Click here to read more.""}, {""date"": ""2024-01-03"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?"", ""summary"": ""Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.""}, {""date"": ""2024-01-03"", ""headline"": ""Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?"", ""summary"": ""Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.""}, {""date"": ""2024-01-03"", ""headline"": ""Top 5 Momentum Picks for January After a Fabulous 2023"", ""summary"": ""We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.""}, {""date"": ""2024-01-03"", ""headline"": ""Alvotech rises as biosimilar to Regeneron\u2019s Eylea succeeds in clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Alvotech rises as biosimilar to Regeneron\u2019s Eylea succeeds in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Eylea HD Launch Poised to Outperform and Drive Regeneron\u2019s Stock Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Powerful Inflows Send Regeneron Shares Surging"", ""summary"": ""Regeneron Pharmaceuticals (REGN) shares keep climbing, up 12% the past month. What\u2019s interesting is how the stock gains alongside increasing volumes.""}, {""date"": ""2024-01-04"", ""headline"": ""Intellia to lay off staff, cut some early research"", ""summary"": ""The CRISPR specialist joins some of its genetic medicine peers in trimming staff, announcing an \u201corganizational streamlining\u201d to focus resources on prioritiy drug programs.""}, {""date"": ""2024-01-04"", ""headline"": ""Are Medical Stocks Lagging  Aclaris Therapeutics (ACRS) This Year?"", ""summary"": ""Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.""}, {""date"": ""2024-01-04"", ""headline"": ""2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)"", ""summary"": ""These innovative biotechs likely aren't done rewarding their shareholders.""}, {""date"": ""2024-01-04"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Cigna (CI), Agios Pharma (AGIO) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""5 FDA decisions to watch in the first quarter"", ""summary"": ""The agency could soon clear important new drugs from Eli Lilly and Merck, as well as the first treatment for a common liver disease.""}, {""date"": ""2024-01-05"", ""headline"": ""Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024"", ""summary"": ""TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the \u2018Investors and Media\u2019 page of Re""}, {""date"": ""2024-01-05"", ""headline"": ""If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Latest Stock Performance Being Led By Its Strong Fundamentals?"", ""summary"": ""Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by 9.8% over the past...""}, {""date"": ""2024-01-07"", ""headline"": ""3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
52,2024-01-07,913.1699829101562,2024-01-14,933.2000122070312,0.0219346120347077,U3,"[{""date"": ""2024-01-07"", ""headline"": ""Regeneron to post over $1.3B U.S. Eylea sales in Q4"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Latest Stock Performance Being Led By Its Strong Fundamentals?"", ""summary"": ""Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by 9.8% over the past...""}, {""date"": ""2024-01-07"", ""headline"": ""3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron Sell Rating Justified by Underperforming Sales and Competitive Pressures"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)"", ""summary"": ""Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) 42nd Annual JPMorgan Healthcare Conference Call January 8, 2024 5:15 PM ETCompany ParticipantsChris...""}, {""date"": ""2024-01-08"", ""headline"": ""Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)"", ""summary"": ""Regeneron Pharmaceuticals, Inc.'s rising shares and market cap, driven by promising drugs and potential dividends, make it promising. Click for my REGN update.""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. shed 1.13% to $902.88 Monday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes"", ""summary"": ""Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.""}, {""date"": ""2024-01-08"", ""headline"": ""CORRECTED-UPDATE 2-Regeneron preliminary Q4 US sales of Eylea below expectations"", ""summary"": ""Regeneron Pharmaceuticals on Monday reported eye drug Eylea's fourth-quarter preliminary U.S. sales below Wall Street expectations, as the company's blockbuster product faced pressure from a rival.  Shares of Regeneron were down over 2% in premarket trading.  Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022.""}, {""date"": ""2024-01-08"", ""headline"": ""Medison Pharma Announces  Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae (cemiplimab) in Multiple Countries"", ""summary"": ""Medison Pharma (\""Medison\""), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo\u00ae (cemiplimab), a fully human""}, {""date"": ""2024-01-08"", ""headline"": ""CORRECTED-UPDATE 1-Regeneron preliminary Q4 US sales of Eylea below expectations"", ""summary"": ""Regeneron Pharmaceuticals on Monday reported eye drug Eylea's fourth-quarter U.S. preliminary sales, which came below Wall Street expectations, as the company's blockbuster product faced pressure from a rival.  The company garnered $1.34 billion in U.S. sales, while Wells Fargo analyst Mohit Bansal last week pegged consensus Wall Street estimates for U.S. sales of Eylea at $1.53 billion.  Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but its sales have come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022.""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron preliminary Q4 US sales of Eylea below expectations"", ""summary"": ""Shares of Regeneron were down over 2% in premarket trading.  Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022.  Regeneron has set its hopes on a higher-dose version of Eylea.""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financial Metrics and Competitive Strengths"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae (cemiplimab) in Multiple Countries"", ""summary"": ""Libtayo is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung...""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 bln"", ""summary"": ""Regeneron Pharmaceuticalssaid on Monday its franchise of eye drug Eylea recordedpreliminary sales of $1.34 billion in the United States in thefourth quarter. Wells Fargo analyst Mohit...""}, {""date"": ""2024-01-08"", ""headline"": ""Regeneron unit announces multi-national agreement with Medison Pharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Regeneron to test Wegovy drug combos to protect muscle mass, Bloomberg says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. sank 0.02% to $902.69 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...""}, {""date"": ""2024-01-09"", ""headline"": ""Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint"", ""summary"": ""Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.""}, {""date"": ""2024-01-09"", ""headline"": ""Xeris Biopharma: Speculative Buy, Size Your Position Accordingly"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo in Multiple Countries"", ""summary"": ""Switzerland - Medison Pharma , a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today their exclusive multi-national...""}, {""date"": ""2024-01-09"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Dexcom (DXCM)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Commit To Purchase Regeneron Pharmaceuticals At $730, Earn 5% Using Options"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $906.16 Wednesday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2024-01-10"", ""headline"": ""Corrections"", ""summary"": ""George Yancopoulos is chief scientific officer of Regeneron. Gallup has found that public confidence in U.S. higher education fell to 36% this year from 57% in 2015.""}, {""date"": ""2024-01-10"", ""headline"": ""Could Regeneron Stock Help You Retire a Millionaire?"", ""summary"": ""The blossoming biotech might give more than a nudge to investors in this project.""}, {""date"": ""2024-01-10"", ""headline"": ""GSK to Buy Private Biotech, Strengthen Respiratory Pipeline"", ""summary"": ""GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.""}, {""date"": ""2024-01-10"", ""headline"": ""Regeneron eyes Wegovy combo to improve quality of weight loss"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""RBC Capital gets more bullish on Regeneron, upgrades shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""What You Missed On Wall Street On Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""RBC ups Regeneron to outperform; cites Eylea patent win, Dupi sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. rallied 1.08% to $915.97 Thursday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2024-01-11"", ""headline"": ""Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results"", ""summary"": ""Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.""}, {""date"": ""2024-01-11"", ""headline"": ""Positive Outlook for Regeneron: Buy Rating Affirmed Amidst Eylea\u2019s Resilience and Promising Pipeline Developments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Top 25 tactical trades with recommended option trades for next 3 months of earnings - GS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation"", ""summary"": ""As we have previously reported, in November 2023 Regeneron Pharmaceuticals, Inc. filed complaints against Celltrion, Samsung Bioepis and ...""}, {""date"": ""2024-01-12"", ""headline"": ""Here's Why Regeneron Pharmaceuticals Just Hit A Record High \u2014 Again"", ""summary"": ""There's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as REGN stock touched another record high.""}, {""date"": ""2024-01-12"", ""headline"": ""Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know"", ""summary"": ""Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.""}, {""date"": ""2024-01-12"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. advanced 1.88% to $933.20 Friday, on what proved to be an all-around mixed trading session for the stock market,...""}, {""date"": ""2024-01-12"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""RBC downgrades Nevro to sector perform, cites salesforce turnaround"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""Twilio upgraded, Nutrien downgraded: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""Regeneron upgraded to Outperform at RBC Capital on increased visibility"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-13"", ""headline"": ""Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 123% gain"", ""summary"": ""When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...""}, {""date"": ""2024-01-14"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Regeneron (REGN) and Pediatrix Medical Group (MD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""First RSV shots, groundbreaking gene therapy among 2024 drugs to watch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""Vectoring In On Verve Therapeutics"", ""summary"": ""Verve's lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Find out my recommendation on VERV stock.""}]",{}
53,2024-01-14,933.2000122070312,2024-01-21,929.1300048828125,-0.004361345125353244,D1,"[{""date"": ""2024-01-14"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Regeneron (REGN) and Pediatrix Medical Group (MD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""First RSV shots, groundbreaking gene therapy among 2024 drugs to watch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""Vectoring In On Verve Therapeutics"", ""summary"": ""Verve's lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Find out my recommendation on VERV stock.""}, {""date"": ""2024-01-15"", ""headline"": ""Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use"", ""summary"": ""FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.""}, {""date"": ""2024-01-15"", ""headline"": ""GLOBAL BROKER RATINGS: BofA cuts Lloyds; UBS cuts L'Oreal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""10 Stocks That Show Why Healthcare Stocks Are Hot in 2024"", ""summary"": ""The sector has seen one of the best starts to the year in decades, Goldman says.""}, {""date"": ""2024-01-16"", ""headline"": ""Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market"", ""summary"": ""Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins. But 2024 might mark a renewal for biotech stocks. The FDA went on an approval spree throughout 2023, giving its stamp of approval to 50% more novel therapeutics than it did in 2022. The agency ultimately approved 55 treatment protocols containing a (previously) unapproved ing""}, {""date"": ""2024-01-16"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.44% higher to $937.32 Tuesday, on what proved to be an all-around poor trading session for the stock...""}, {""date"": ""2024-01-16"", ""headline"": ""Dupixent\u00ae (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement"", ""summary"": ""Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat population Phase 3 trial showed more than twice as many patients treated with Dupixent achieved clear or almost clear skin and nearly four times as many had improvement in itch, compared with placebo TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has up""}, {""date"": ""2024-01-16"", ""headline"": ""Top And Bottom S&P 500 Stocks To Consider In 2024"", ""summary"": ""Investors keep a close eye on the S&P 500 as it retreats at the start of the year. Check out the top and bottom S&P 500 stocks to consider in 2024.""}, {""date"": ""2024-01-16"", ""headline"": ""Regeneron, Sanofi announce U.S. FDA updated the label for Dupixent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. slumped 0.87% to $929.13 Wednesday, on what proved to be an all-around rough trading session for the stock market,...""}, {""date"": ""2024-01-17"", ""headline"": ""Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US"", ""summary"": ""The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.""}, {""date"": ""2024-01-17"", ""headline"": ""Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO"", ""summary"": ""Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.""}, {""date"": ""2024-01-17"", ""headline"": ""Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day"", ""summary"": ""Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day.""}, {""date"": ""2024-01-17"", ""headline"": ""REGENERON PHARMACEUTICALS - DUPIXENT U.S. LABEL UPDATED WITH DATA FURTHER SUPPORTING USE IN ATOPIC DERMATITIS WITH MODERATE-TO-SEVERE HAND AND FOOT INVOLVEMENT"", ""summary"": ""TARRYTOWN - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has updated the label for Dupixent in atopic dermatitis, adding efficacy and...""}, {""date"": ""2024-01-17"", ""headline"": ""Bull of the Day: Regeneron Pharmaceuticals (REGN)"", ""summary"": ""The Biotechnology company enjoys a litany of bullish catalysts on the horizon""}, {""date"": ""2024-01-18"", ""headline"": ""MAIA Soars 20% on Interim Results From Lung Cancer Study"", ""summary"": ""MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.""}, {""date"": ""2024-01-18"", ""headline"": ""Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why"", ""summary"": ""Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.""}, {""date"": ""2024-01-18"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.09% higher to $930.00 Thursday, on what proved to be an all-around favorable trading session for the stock...""}, {""date"": ""2024-01-18"", ""headline"": ""Regeneron\u2019s high-dose Eylea, argenx\u2019s Vyvgart injectable among latest approvals in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Regeneron Pharmaceuticals Inc. inched 0.37% higher to $933.40 Friday, on what proved to be an all-around great trading session for the stock...""}, {""date"": ""2024-01-19"", ""headline"": ""Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug"", ""summary"": ""Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.""}, {""date"": ""2024-01-19"", ""headline"": ""Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why"", ""summary"": ""Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.""}, {""date"": ""2024-01-19"", ""headline"": ""Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron"", ""summary"": ""Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.""}, {""date"": ""2024-01-19"", ""headline"": ""Regeneron price target raised by $163 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Regeneron price target raised by $61 at Piper Sandler, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-21"", ""headline"": ""2 Smart Growth Stocks to Buy Hand Over Fist in 2024"", ""summary"": ""These businesses are on paths to extremely bright futures.""}]",{}
